MASIMO CORP, 10-K filed on 2/28/2024
Annual Report
v3.24.0.1
Cover - USD ($)
$ in Billions
 12 Months Ended
Dec. 30, 2023
Jan. 27, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Current Fiscal Year End Date --12-30    
Document Period End Date Dec. 30, 2023    
Document Transition Report false    
Entity File Number 001-33642    
Entity Registrant Name MASIMO CORP    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 33-0368882    
Entity Address, Address Line One 52 Discovery    
Entity Address, City or Town Irvine,    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 92618    
City Area Code (949)    
Local Phone Number 297-7000    
Title of 12(b) Security Common Stock, par value $0.001    
Trading Symbol MASI    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction false    
Entity Shell Company false    
Entity Public Float     $ 6.5
Entity Common Stock, Shares Outstanding   52,913,166  
Documents Incorporated by Reference Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K incorporate information by reference from the registrant’s proxy statement for the registrant’s 2024 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days after the close of the fiscal year covered by this annual report on Form 10-K.    
Amendment Flag false    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Entity Central Index Key 0000937556    
v3.24.0.1
Audit Information
 12 Months Ended
Dec. 30, 2023
Audit Information [Abstract]  
Auditor Name GRANT THORNTON LLP
Auditor Location Newport Beach, California
Auditor Firm ID 248
v3.24.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Dec. 30, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 163.0 $ 202.9
Trade accounts receivable, net of allowance for credit losses of $4.8 and $7.7 at December 30, 2023 and December 31, 2022, respectively 355.5 445.9
Inventories 545.0 501.0
Other current assets 168.4 158.8
Total current assets 1,231.9 1,308.6
Lease receivable, non-current 71.4 73.1
Deferred costs and other contract assets 57.3 41.9
Property and equipment, net 424.4 402.5
Finite-lived intangible assets, net 419.9 460.6
Trademarks - (Note 9) 232.4 262.0
Goodwill 407.7 445.4
Deferred tax assets 107.2 102.5
Other non-current assets 89.3 114.0
Total assets 3,041.5 3,210.6
Current liabilities    
Accounts payable 251.5 276.8
Accrued compensation 62.6 89.3
Deferred revenue and other contract-related liabilities, current 87.3 80.6
Other current liabilities 162.4 183.3
Total current liabilities 563.8 630.0
Long-term debt 871.7 941.6
Deferred tax liabilities 111.7 163.6
Other non-current liabilities 129.5 136.5
Total liabilities 1,676.7 1,871.7
Commitments and contingencies - (Note 24)
Stockholders’ equity    
Preferred stock, $0.001 par value; 5.0 shares authorized; 0.0 shares issued and outstanding 0.0 0.0
Common stock, $0.001 par value; 100.0 shares authorized; 52.8 and 52.5 shares issued and outstanding at December 30, 2023 and December 31, 2022, respectively 0.1 0.1
Treasury stock, 19.5 and 19.5 shares at December 30, 2023 and December 31, 2022, respectively (1,169.2) (1,169.2)
Additional paid-in capital 783.4 782.2
Accumulated other comprehensive (loss) income (45.3) 11.5
Retained earnings 1,795.8 1,714.3
Total stockholders’ equity 1,364.8 1,338.9
Total liabilities and stockholders’ equity 3,041.5 3,210.6
Customer relationships    
Current assets    
Finite-lived intangible assets, net 177.7 201.6
Acquired technologies    
Current assets    
Finite-lived intangible assets, net 129.4 160.1
Other intangible assets, net    
Current assets    
Finite-lived intangible assets, net $ 112.8 $ 98.9
v3.24.0.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
shares in Millions, $ in Millions
Dec. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Allowance for credit losses $ 4.8 $ 7.7
Preferred stock, par value (in dollars per share) $ 1.000 $ 1.000
Preferred stock, shares authorized (in shares) 5.0 5.0
Preferred stock, shares issued (in shares) 0.0 0.0
Preferred stock, shares outstanding (in shares) 0.0 0.0
Common stock, par value (in dollars per share) $ 1.000 $ 1.000
Common stock, shares authorized (in shares) 100.0 100.0
Common stock, shares, issued (in shares) 52.8 52.5
Common stock, shares, outstanding (in shares) 52.8 52.5
Treasury stock, shares (in shares) 19.5 19.5
v3.24.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Income Statement [Abstract]      
Revenue $ 2,048.1 $ 2,035.8 $ 1,239.2
Cost of goods sold 1,044.6 977.0 430.8
Gross profit 1,003.5 1,058.8 808.4
Operating expenses:      
Selling, general and administrative 664.0 657.4 395.4
Research and development 175.2 191.4 137.2
Litigation settlements 17.8 0.0 0.0
Impairment charge 10.0 0.0 0.0
Total operating expenses 867.0 848.8 532.6
Operating income 136.5 210.0 275.8
Non-operating loss (48.4) (16.6) (1.4)
Income before provision for income taxes 88.1 193.4 274.4
Provision for income taxes 6.6 49.9 44.8
Net income $ 81.5 $ 143.5 $ 229.6
Net income per share:      
Basic (in dollars per share) $ 1.54 $ 2.68 $ 4.16
Diluted (in dollars per share) $ 1.51 $ 2.60 $ 3.98
Weighted-average shares used in per share calculations:      
Basic (in shares) 52.8 53.6 55.2
Diluted (in shares) 54.1 55.2 57.7
v3.24.0.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Income Statement [Abstract]      
Net income $ 81.5 $ 143.5 $ 229.6
Other comprehensive (loss) gain, net of tax:      
Unrealized (loss) gain from foreign currency translation adjustments (45.1) 4.9 (6.9)
Net change in retirement obligations (2.9) (2.6) 0.0
Unrealized gain on cash flow hedge [1] (8.8) 14.7 0.0
Total comprehensive income $ 24.7 $ 160.5 $ 222.7
[1] See Note 17, “Derivative Instruments and Hedging Activities”, for further details.
v3.24.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
$ in Millions
Total
Common Stock
Treasury Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Retained Earnings
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Beginning balance $ 1,407.7 $ 0.1 $ (638.7) $ 703.7 $ 1.4 $ 1,341.2
Beginning balance (in shares) at Jan. 02, 2021   55,300,000        
Beginning balance (in shares) at Jan. 02, 2021     16,000,000.0      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock options exercised (in shares) 400,000 400,000        
Stock options exercised $ 20.8     20.8    
Restricted/Performance stock units vested (in shares)   300,000        
Shares paid for tax withholding (in shares)   (100,000)        
Shares paid for tax withholding (16.7)     (16.7)    
Stock-based compensation $ 44.7     44.7    
Repurchases of common stock (in shares) 500,000 600,000 500,000      
Repurchases of common stock $ (129.0)   $ (129.0)      
Net change on pension obligations 0.0          
Unrealized gain on cash flow hedge [1] 0.0          
Net income 229.6         229.6
Foreign currency translation adjustment (6.9)       (6.9)  
Ending balance (in shares) at Jan. 01, 2022   55,300,000        
Ending Balance at Jan. 01, 2022 1,550.2 $ 0.1 $ (767.7) 752.5 (5.5) 1,570.8
Ending balance (in shares) at Jan. 01, 2022     16,500,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Beginning balance $ 1,550.2 $ 0.1 $ (767.7) 752.5 (5.5) 1,570.8
Stock options exercised (in shares) 100,000 100,000        
Stock options exercised $ 7.4     7.4    
Restricted/Performance stock units vested (in shares)   200,000        
Shares paid for tax withholding (in shares)   (100,000)        
Shares paid for tax withholding (25.4)     (25.4)    
Stock-based compensation $ 47.7     47.7    
Repurchases of common stock (in shares) 3,000,000.0 3,000,000.0 3,000,000.0      
Repurchases of common stock $ (401.5)   $ (401.5)      
Net change on pension obligations (2.6)       (2.6)  
Unrealized gain on cash flow hedge 14.7 [1]       14.7  
Net income 143.5         143.5
Foreign currency translation adjustment $ 4.9       4.9  
Ending balance (in shares) at Dec. 31, 2022 52,500,000 52,500,000        
Ending Balance at Dec. 31, 2022 $ 1,338.9 $ 0.1 $ (1,169.2) 782.2 11.5 1,714.3
Ending balance (in shares) at Dec. 31, 2022 19,500,000   19,500,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Beginning balance $ 1,338.9 $ 0.1 $ (1,169.2) 782.2 11.5 1,714.3
Stock options exercised (in shares) 200,000 200,000        
Stock options exercised $ 7.1     7.1    
Restricted/Performance stock units vested (in shares)   200,000        
Shares paid for tax withholding (in shares)   (100,000)        
Shares paid for tax withholding (12.9)     (12.9)    
Stock-based compensation $ 7.0     7.0    
Repurchases of common stock (in shares) 0          
Repurchases of common stock $ 0.0          
Net change on pension obligations (2.9)       (2.9)  
Unrealized gain on cash flow hedge (8.8) [1]       (8.8)  
Net income 81.5         81.5
Foreign currency translation adjustment $ (45.1)       (45.1)  
Ending balance (in shares) at Dec. 30, 2023 52,800,000 52,800,000        
Ending Balance at Dec. 30, 2023 $ 1,364.8 $ 0.1 $ (1,169.2) 783.4 (45.3) 1,795.8
Ending balance (in shares) at Dec. 30, 2023 19,500,000   19,500,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Beginning balance $ 1,364.8 $ 0.1 $ (1,169.2) $ 783.4 $ (45.3) $ 1,795.8
[1] See Note 17, “Derivative Instruments and Hedging Activities”, for further details.
v3.24.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Cash flows from operating activities:      
Net income $ 81.5 $ 143.5 $ 229.6
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 98.3 136.1 35.6
Stock-based compensation 7.0 47.7 44.7
Amortization of debt issuance costs 1.9 1.4 0.0
Loss on disposal of equipment, intangibles and other assets 0.8 0.5 0.5
Provision for credit losses 1.1 1.3 0.8
Benefit from deferred income taxes (35.6) (39.3) (15.1)
Impairment charge 10.0 0.0 0.0
Changes in operating assets and liabilities:      
(Increase) decrease in trade accounts receivable 90.2 (138.5) (60.8)
(Increase) decrease in inventories (69.2) (155.9) 13.5
(Increase) decrease in other current assets (8.6) (7.4) 6.9
(Increase) decrease in lease receivable, net 1.7 (12.8) (16.1)
(Increase) decrease in deferred costs and other contract assets (14.4) (13.4) (8.1)
(Increase) decrease in other non-current assets 3.0 (4.9) 0.0
Increase (decrease) in accounts payable (19.6) 60.5 11.0
Increase (decrease) in accrued compensation (26.8) (9.3) 0.0
Increase (decrease) in deferred revenue and other contract-related liabilities 7.1 28.1 7.1
Increase (decrease) in income taxes payable (15.1) 3.8 6.4
Increase (decrease) in accrued liabilities (22.8) (16.1) 7.8
Increase (decrease) in other non-current liabilities 3.6 4.1 0.8
Net cash provided by (used in) operating activities 94.1 29.4 264.6
Cash flows from investing activities:      
Purchases of property and equipment, net (44.0) (52.8) (25.5)
Increase in intangible assets (43.7) (3.5) (9.4)
Business combinations, net of cash acquired 7.5 (999.7) 0.0
Other strategic investing activities (1.0) (1.7) (2.6)
Net cash (used in) provided by investing activities (81.2) (1,057.7) (37.5)
Cash flows from financing activities:      
Borrowings under revolving line of credit 189.0 1,083.9 0.0
Repayments under revolving line of credit (240.2) (135.4) 0.0
Proceeds from issuance of common stock 7.0 8.1 23.2
Repurchases of common stock 0.0 (401.5) (128.9)
Payroll tax withholdings on behalf of employees for stock options (12.9) (25.4) (16.7)
Debt issuance costs 0.0 (9.3) 0.0
Net cash (used in) provided by financing activities (57.1) 520.4 (122.4)
Effect of foreign currency exchange rates on cash 2.8 (30.9) (1.3)
Net increase in cash, cash equivalents and restricted cash (41.4) (538.8) 103.4
Cash, cash equivalents and restricted cash at beginning of period 209.6 748.4 645.0
Cash, cash equivalents and restricted cash at end of period $ 168.2 $ 209.6 $ 748.4
v3.24.0.1
Description of the Company
 12 Months Ended
Dec. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of the Company
1. Description of the Company
Masimo Corporation (the “Company”) is a global technology company that develops, manufactures and markets a wide array of patient monitoring technologies, as well as automation and connectivity solutions. The Company’s mission is to improve patient outcomes, reduce the cost of care and take noninvasive monitoring to new sites and applications.
The Company’s patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. The Company primarily sells its products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities and consumers through its direct sales force, distributors and original equipment manufacturer (OEM) partners.
On April 11, 2022, the Company acquired Viper Holdings Corporation, the parent company of DEI Sales, Inc., d/b/a Sound United (Sound United), via the Company’s wholly-owned subsidiary, Sonic Boom Acquisition Corp (Sonic) (Sound United acquisition). For additional information on Masimo’s acquisition of Sound United, see Note 18, “Business Combinations”.
In addition, the Company updated its financial reporting segments to align with the way it manages its business units post-acquisition. See Note 25, “Segment and Enterprise Reporting”, for additional details.
The terms “the Company” and “Masimo” refer to Masimo Corporation and, where applicable, its consolidated subsidiaries.
v3.24.0.1
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 30, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
2. Summary of Significant Accounting Policies
Basis of Presentation
The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP), and include the accounts of the Company and its wholly-owned or controlled subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Fiscal Periods
The Company follows a conventional 52/53 week fiscal year. Under a conventional 52/53 week fiscal year, a 52 week fiscal year includes four quarters of 13 weeks while a 53 week fiscal year includes three 13 week fiscal quarters and one 14 week fiscal quarter. The Company’s last 53 week fiscal year was fiscal year 2020. Fiscal year 2023 was a 52 week fiscal year ended December 30, 2023. All references to years in these notes to consolidated financial statements are fiscal years unless otherwise noted.
Reclassifications
Certain amounts in the accompanying consolidated financial statements have been reclassified to conform to the current period presentation, including certain balance sheet asset accounts in the consolidated financial statements for the year ended December 31, 2022. There was no impact on previously reported total assets, liabilities, stockholders’ equity or net income.
Use of Estimates
The Company prepares its financial statements in conformity with GAAP, which requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates include the determination of standalone selling prices, variable consideration, total consideration allocated to each performance obligation within a contract, inventory valuation, valuation of the Company’s equity awards, valuation of identifiable assets and liabilities connected with business combinations, impairment of long-lived assets, intangible assets and goodwill; derivative and equity instruments, deferred taxes and any associated valuation allowances, deferred revenue, accounting for pensions, uncertain income tax positions, litigation costs, and related accruals. Actual results could differ from such estimates.
Business Combinations
The Company accounts for business combinations using the acquisition method of accounting in accordance with Accounting Standards Codification (ASC) Topic 805, Business Combinations, which requires that once control is obtained, assets acquired, liabilities assumed and noncontrolling interests in the acquired entity, if applicable, are recorded at their respective fair values at the date of acquisition, with the exception of acquired contract assets and contract liabilities (i.e., deferred revenue) from contracts with customers. These are recognized and measured in accordance with ASC Topic 606, Revenue from Contracts with Customers. The excess of the purchase price over fair values of identifiable assets, liabilities and noncontrolling interests in the acquired entity, if applicable, is recorded as goodwill.
Fair Value Measurements
The Company accounts for certain financial instruments at their fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its financial instruments using the framework prescribed by ASC Topic 820, Fair Value Measurements and Disclosures, and considers the estimated amount the Company would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and the Company’s creditworthiness for unrealized loss positions. In certain instances, the Company may utilize financial models to measure the fair value of its financial instruments. In doing so, the Company uses inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means.
Recurring Fair Value Measurement
On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. Authoritative guidance describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
●    Level 1—Quoted prices in active markets for identical assets or liabilities.
●    Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.
●    Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
The following tables represent the Company’s financial assets, measured at fair value on a recurring basis at December 30, 2023:
Fair Value Measurement Hierarchy
(in millions)Total Carrying
Value		Level 1Level 2Level 3
Assets
Cash and cash equivalents$87.0 $87.0 $— $— 
Money market funds76.0 76.0 — — 
Pension assets:
Cash and cash equivalents(1.2)
(1)
(1.2)— — 
Equity securities8.1 8.1 — — 
Debt securities10.7 9.9 0.8 — 
Real estate funds3.1 — 3.1 — 
Alternative investments1.9 — 1.9 — 
Other0.5 — 0.5 — 
Equity securities1.7 1.7 — — 
Derivative instruments - cash flow hedges(2)
11.6 11.6 — — 
Derivative instruments - warrants1.0 1.0 — — 
Total assets$200.4 $194.1 $6.3 $— 
Liabilities
Derivative instruments - cash flow hedge$3.6 $3.6 $— $— 
Pension benefit obligation32.6 32.6 — — 
Total liabilities$36.2 $36.2 $— $— 
______________
(1)     Due to the timing of a cash transfer, there was a payable as of December 30, 2023, resulting in a negative allocation as of year end.
(2)    Includes accrued interest.
The following tables represent the Company’s financial assets, measured at fair value on a recurring basis at December 31, 2022:
Fair Value Measurement Hierarchy
(in millions)Total Carrying
Value		Level 1Level 2Level 3
Assets
Cash and cash equivalents$148.5 $148.5 $— $— 
U.S. treasuries— — — — 
Money market funds54.4 54.4 — — 
Pension assets:
      Cash and cash equivalents1.0 1.0 — — 
      Equity securities 6.6 6.6 — — 
      Debt securities8.0 7.2 0.8 — 
      Real estate funds3.5 — 3.5 — 
      Alternative investments1.9 — 1.9 — 
      Other1.2 — 1.2 — 
Derivative instruments - cash flow hedges19.7 — 19.7 — 
Total assets$244.8 $217.7 $27.1 $— 
Liabilities
Pension benefit obligation$32.3 $32.3 $— $— 
Total liabilities$32.3 $32.3 $— $— 
The Company invests in checking, savings and money market fund accounts, which are classified within Level 1 of the fair value hierarchy as they are valued using quoted market prices. These investments are classified as cash and cash equivalents within the Company’s accompanying consolidated balance sheets, in accordance with GAAP and its accounting policies.
The Company has certain strategic investments in privately-held companies (non-marketable equity securities) and companies that have completed initial public offerings (marketable equity securities). The Company’s marketable equity securities, whose price is based on quoted market price in an active market, are classified within Level 1 of the fair value hierarchy. Equity securities are classified as current, short-term investments, or non-current, recorded in other non-current assets, based on the nature of the securities and their availability for use in current operations. The changes in the fair value of those equity securities are measured at each reporting date and changes in the value of these investments between reporting dates are recorded within non-operating income (loss).
The Company’s pension assets consist of Level 1 and Level 2 investments. The fair values of Level 2 assets are based on observable inputs such as prices or quotes for similar assets, adjusted for any differences in terms or conditions that may affect the value of the instrument being valued. The valuation techniques used for Level 2 assets may include the use of models or other valuation techniques, but these methods are all based on observable market inputs.
The Company also has investments in certain derivative instruments, which are measured at fair value and classified within Level 3 of the fair value hierarchy.
Non-Recurring Fair Value Measurements
For certain other financial assets and liabilities, including restricted cash, accounts receivable, accounts payable and other current assets and liabilities, the carrying amounts approximate their fair value primarily due to the relatively short maturity of these balances. The Company also measures certain non-financial assets at fair value on a non-recurring basis, primarily goodwill, intangible assets and operating lease right-of-use assets, in connection with periodic evaluations for potential impairment.
Furthermore, the Company did not elect to apply the fair value option to specific assets or liabilities on a contract-by-contract basis. The Company did not have any transfers between Level 2 and Level 3 during the years ended December 30, 2023 and December 31, 2022.
Cash and Cash Equivalents
The Company considers all highly liquid investments with an original maturity from the date of purchase of three months or less, or highly liquid investments that are readily convertible into known amounts of cash, to be cash equivalents. The Company carries cash and cash equivalents at cost, which approximates fair value, and they are Level 1 under the fair value hierarchy.
Accounts Receivable and Allowance for Credit Losses
Accounts receivable consist of trade receivables recorded at the time of invoicing of product sales, reduced by reserves for estimated bad debts and returns. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Credit is extended based on an evaluation of the customer’s financial condition. Collateral is generally not required. The Company records an allowance for credit losses that it does not expect to collect based on relevant information, including historical experience, current conditions, and reasonable and supportable forecasts. Accounts are charged off against the allowance when the Company believes they are uncollectible. The allowance for credit losses is measured on a collective (pool) basis when similar risk characteristics exist. Based on the risk characteristics, the Company has identified U.S. and international customers as separate portfolios for both segments, and measures expected credit losses on such receivables using an aging methodology.
Inventories
Inventories are stated at the lower of cost or net realizable value. Cost is determined using a standard cost method, which approximates the first in, first out method, and includes material, labor and overhead costs. Inventory valuation adjustments are recorded for inventory items that have become excess or obsolete or are no longer used in current production and for inventory items that have a market price less than the carrying value in inventory. The Company generally determines inventory valuation adjustments based on an evaluation of the expected future use of its inventory on an item by item basis and applies historical obsolescence rates to estimate the loss on inventory expected to have a recovery value below cost. The Company also records other specific inventory valuation adjustments when it becomes aware of unique events or circumstances that result in an expected recovery value below cost. For inventory items that have been written down, the reduced value becomes the new cost basis.
Property and Equipment
Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over estimated useful lives as follows:
Useful Lives
Buildings and building improvements
7 to 39 years
Computer equipment and software
2 to 12 years
Demonstration units
2 to 3 years
Furniture and office equipment
2 to 15 years
Leasehold improvementsLesser of useful life or term of lease
Machinery, equipment and tooling
3 to 20 years
Operating lease assetsLesser of useful life or term of lease
Transportation, vehicles and other
1 to 20 years
Land is not depreciated and construction-in-progress is not depreciated until placed in service. Normal repair and maintenance costs are expensed as incurred, whereas significant improvements that materially increase values or extend useful lives are capitalized and depreciated over the remaining estimated useful lives of the related assets. Upon sale or retirement of depreciable assets, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss on the sale or retirement is recognized in income.
Lessee Right-of-Use (ROU) Assets and Lease Liabilities
The Company determines if an arrangement contains a lease at inception. ROU assets represent the Company’s right to use an asset underlying an operating lease for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from an operating lease. ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company generally estimates the applicable discount rate used to determine the net present value of lease payments based on available information at the lease commencement date. Many of the Company’s lessee agreements include options to extend the lease, which the Company does not include in its lease terms unless they are reasonably certain to be exercised. The Company utilizes a portfolio approach to account for the ROU assets and liabilities associated with certain equipment leases.
The Company has also made an accounting policy election not to separate lease and non-lease components for its real estate leases and to exclude short-term leases with a term of twelve months or less from its ROU assets and lease liabilities. Rental expense for lease payments related to operating leases is recognized on a straight-line basis over the lease term.
Intangible Assets
Intangible assets consist primarily of patents, trademarks, software development costs, customer relationships and acquired technology. Costs related to patents and trademarks, which include legal and application fees, are capitalized and amortized over the estimated useful lives using the straight-line method. Patent and trademark amortization commences once final approval of the patent or trademark has been obtained. Patent costs are amortized over the lesser of 10 years or the patent’s remaining legal life, which assumes renewals, and trademark costs are amortized over 17 years, and their associated amortization cost is included in selling, general and administrative expense in the accompanying consolidated statements of operations. For intangibles purchased in an asset acquisition or business combination, which mainly include patents, trademarks, customer relationships and acquired technologies, the useful life is determined largely by valuation estimates of remaining economic life.
The Company’s policy is to renew its patents and trademarks. Costs to renew patents and trademarks are capitalized and amortized over the remaining useful life of the intangible asset. The Company periodically evaluates the amortization period and carrying basis of patents and trademarks to determine whether any events or circumstances warrant a revised estimated useful life or reduction in value. Capitalized application costs are charged to operations when it is determined that the patent or trademark will not be obtained or is abandoned.
Software development costs are accounted for in accordance with ASC Topic 985-20, Software - Costs of Software to be Sold, Leased, or Marketed. Once technological feasibility has been established, qualifying costs incurred in development are capitalized until available for general release to customers, and subsequently reported at the lower of unamortized cost or net realizable value.
Intangibles purchased as part of an asset acquisition or business combination historically have included patents, trademarks, customer relationships, developed technologies and contractual licenses. In certain circumstances, the Company has also acquired non-compete agreements tied to certain employment relationships. The useful life for all of these is largely determined by valuation estimates of remaining economic life. In connection with the Sound United acquisition, the Company acquired certain trademarks/tradenames, which are intangible assets with indefinite useful lives. These brands are expected to maintain brand value for an indefinite period of time.
Impairment of Goodwill, Intangible Assets and Other Long-Lived Assets
Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the acquired net tangible and intangible assets. Goodwill is not amortized, but instead is tested annually for impairment, or more frequently when events or changes in circumstances indicate that goodwill might be impaired. In assessing goodwill impairment, the Company has the option to first assess the qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. The Company has two reporting units, healthcare and non-healthcare. The Company’s qualitative assessment of the recoverability of goodwill considers various macro-economic, industry-specific and Company-specific factors, including: (i) severe adverse industry or economic trends; (ii) significant Company-specific actions; (iii) current, historical or projected deterioration of the Company’s financial performance; or (iv) a sustained decrease in the Company’s market capitalization below its net book value. If the qualitative assessment indicates that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying value, or if the Company elects to bypass the qualitative analysis, then the Company performs a quantitative analysis that compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, a goodwill impairment loss is recognized for the lesser of: (a) the amount that the carrying amount of such reporting unit exceeds its fair value; or (b) the amount of the goodwill allocated to such reporting unit. The annual impairment test is performed during the fourth fiscal quarter.
Similar to goodwill, indefinite-lived intangible assets are not amortized but instead are subject to annual impairment testing, unless circumstances dictate more frequent testing, if impairment indicators exist. Impairment for indefinite-lived assets exists if the carrying value of the indefinite-lived intangible asset exceeds its fair value. Determining whether impairment indicators exist and estimating the fair value of the Company’s indefinite-lived intangible assets if necessary for impairment testing require significant judgment. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors.
The Company reviews finite-lived intangible assets and long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.
Employee Defined Benefit Plans
The Company maintains noncontributory defined benefit plans that cover certain employees in certain international locations. The Company recognizes the funded status, or the difference between the fair value of plan assets and the projected benefit obligations of the pension plan on the consolidated balance sheet, with a corresponding adjustment to accumulated other comprehensive (loss) income. If the projected benefit obligation exceeds the fair value of plan assets, the difference or underfunded status represents the pension liability. The Company records a net periodic pension cost in the consolidated statement of operations. The liabilities and annual income or expense are determined using methodologies that involve several actuarial assumptions, the most significant of which are the discount rate and the expected long-term rate of asset return. The Company’s accounting policy includes an annual re-measurement of pension assets and obligations. In addition, the Company re-measures pension assets and obligations for significant events, as of the nearest month-end date on the calendar. The fair values of plan assets are determined based on prevailing market prices. See Note 21, “Employee Benefits”, for further details.
Income Taxes
The Company accounts for income taxes using the asset and liability method, under which the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for net operating loss and tax credit carryforwards. Tax positions that meet a more-likely-than-not recognition threshold are recognized in the first reporting period that it becomes more-likely-than-not such tax position will be sustained upon examination. A tax position that meets this more-likely-than-not recognition threshold is recorded at the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Previously recognized income tax positions that fail to meet the recognition threshold in a subsequent period are derecognized in that period. Differences between actual results and the Company’s assumptions, or changes in the Company’s assumptions in future periods, are recorded in the period they become known. The Company records potential accrued interest and penalties related to unrecognized tax benefits in income tax expense.
As a multinational corporation, the Company is subject to complex tax laws and regulations in various jurisdictions. The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws themselves are subject to change as a result of changes in fiscal policy, changes in legislation, evolution of regulations and court rulings. Therefore, the actual liability for U.S. or foreign taxes may be materially different from the Company’s estimates, which could result in the need to record additional liabilities or potentially to reverse previously recorded tax liabilities.
Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance is recorded against any deferred tax assets when, in the judgment of management, it is more-likely-than-not that all or part of a deferred tax asset will not be realized. In assessing the need for a valuation allowance, the Company considers all positive and negative evidence, including recent financial performance, scheduled reversals of temporary differences, projected future taxable income, availability of taxable income in carryback periods and tax planning strategies.
Income taxes are highly susceptible to changes from period to period, requiring management to make assumptions about the Company’s future income over the lives of its deferred tax assets and the impact of changes in valuation allowances. Any difference in the assumptions, judgments and estimates mentioned above could result in changes to the Company’s results of operations.
Revenue Recognition, Deferred Revenue and Other Contract Liabilities
The Company generally recognizes revenue following a single, principles-based five-step model to be applied to all contracts with customers and generally provides for the recognition of revenue in an amount that reflects the consideration to which the Company expects to be entitled, net of allowances for estimated returns, discounts or sales incentives, as well as taxes collected from customers that are remitted to government authorities when control over the promised goods or services are transferred to the customer.
Healthcare segment
While the majority of the Company’s healthcare segment revenue contracts and transactions contain standard business terms and conditions, there are some transactions that contain non-standard business terms and conditions. As a result, contract interpretation, judgment and analysis are required to determine the appropriate accounting, including: (i) the amount of the total consideration, as well as variable consideration, (ii) whether the arrangement contains an embedded lease, and if so, whether such embedded lease is a sales-type lease or an operating lease, (iii) the identification of the distinct performance obligations contained within the arrangement, (iv) how the arrangement consideration should be allocated to each performance obligation when multiple performance obligations exist, including the determination of standalone selling price, and (v) when to recognize revenue on the performance obligations. Changes in judgments on these assumptions and estimates could materially impact the timing of revenue recognition. Revenue from fixed lease payments related to equipment supplied under sales-type lease arrangements is recognized once control over the equipment is transferred to the customer, while revenue from fixed lease payments related to equipment supplied under operating-type lease arrangements is generally recognized on a straight-line basis over the term of the lease and variable lease payments are recognized as they occur.
The Company derives the majority of its healthcare segment revenue from four primary sources: (i) direct sales under deferred equipment agreements with end-user hospitals where the Company provides up-front monitoring equipment at no up-front charge in exchange for a multi-year sensor purchase commitment; (ii) other direct sales of noninvasive monitoring solutions to end-user hospitals, emergency medical response organizations and other direct customers; (iii) sales of noninvasive monitoring solutions to distributors who then typically resell to end-user hospitals, emergency medical response organizations and other customers; and (iv) sales of integrated circuit boards to OEM customers who incorporate the Company’s embedded software technology into their multiparameter monitoring devices. Subject to customer credit considerations, the majority of such sales are made on open accounts using industry standard payment terms based on the geography within which the specific customer is located.
The Company enters into agreements to sell its monitoring solutions and services, sometimes as a part of arrangements with multiple performance obligations that include various combinations of product sales, equipment leases, software and services. In the case of contracts with multiple performance obligations, the authoritative guidance provides that the total consideration be allocated to each performance obligation on the basis of relative standalone selling prices. When a standalone selling price is not readily observable, the Company estimates the standalone selling price by considering multiple factors including, but not limited to, features and functionality of the product, geographies, type of customer, contractual prices pursuant to Group Purchasing Organization (GPO) contracts, the Company’s pricing and discount practices, and other market conditions.
Sales under deferred equipment agreements are generally structured such that the Company agrees to provide certain monitoring-related equipment, software, installation, training and/or warranty support at no up-front charge in exchange for the customer’s commitment to purchase sensors over the term of the agreement, which generally ranges from three years to six years. The Company allocates contract consideration under deferred equipment agreements containing fixed annual sensor purchase commitments to the underlying lease and non-lease components at contract inception. In determining whether any underlying lease components are related to a sales-type lease or an operating lease, the Company evaluates the customer’s rights and ability to control the use of the underlying equipment throughout the contract term, including any equipment substitution rights retained by the Company, as well as the Company’s expectations surrounding potential contract/lease extensions or renewals and the customer’s likelihood to exercise any purchase options.
Beginning in 2022, for contracts that contain variable lease payments that are not dependent on an index or rate, the Company classifies as operating leases any lease components that would have otherwise been classified as sales-type leases that would result in a selling loss upon lease commencement. Revenue allocable to non-lease performance obligations is generally recognized as such non-lease performance obligations are satisfied. Revenue allocable to lease components under sales-type lease arrangements is generally recognized when control over the equipment is transferred to the customer. Revenue allocable to lease components under operating lease arrangements is generally recognized over the term of the operating lease. The Company generally does not expect to derive any significant value in excess of such asset’s unamortized book value from equipment underlying its operating lease arrangements after the end of the agreement.
Revenue from the sale of products and software, to end-user hospitals, emergency medical response organizations, other direct customers, distributors and OEM customers, is recognized by the Company when control of such performance obligations transfers to the customer based upon the terms of the contract or underlying purchase order.
Revenue related to OEM rainbow® parameter software licenses is recognized by the Company upon the OEM’s shipment of its product to its customer, as reported to the Company by the OEM.
The Company provides certain customers with various sales incentives that may take the form of discounts or rebates. The Company records estimates related to these programs as a reduction to revenue at the time of sale. In general, customers do not have a right of return for credit or refund. However, the Company allows returns under certain circumstances. At the end of each period, the Company estimates and accrues for these returns as a reduction to revenue. The Company estimates the revenue constraints related to these forms of variable consideration based on various factors, including expected purchasing volumes, prior sales and returns history, and specific contractual terms and limitations.
Non-healthcare segment
Non-healthcare segment revenue is related to hardware and embedded software that is integrated into final products that are manufactured and sold by the Company. Products and related software are accounted for as a single performance obligation and all intended functionality is available to the customer upon purchase. Non-healthcare segment revenue is recognized upon transfer of control of promised products or service to customers, which is either upon shipment or upon delivery to the customers, depending on delivery terms. The Company offers sales incentives and has customer programs consisting primarily of discounts and market development fund programs, and records them as contra revenue. Estimates for sales incentives are developed using the most likely amount and are included in the transaction price to the extent that a significant reversal of revenue would not result once the uncertainty is resolved. In developing these estimates, the Company also considers the susceptibility of the incentive to outside influences, the length of time until the uncertainty is resolved and the Company’s experience with similar contracts. Reductions in revenue related to discounts are allocated to products on a relative basis based on their respective standard selling price if there are undelivered products in a contract. Judgment is required to determine the timing and amount of recognition of marketing funds, which the Company estimates based on past practice of providing similar funds.
Payment terms and conditions vary among the Company’s distribution channels although terms generally include a requirement of payment within 30 to 60 days of product shipment. Sales made directly to customers from the Company’s website are paid at the time of product shipment. Prior to determining payment terms for each customer, an evaluation of such customer’s credit risk is performed. Contractual allowances are an offset to accounts receivable.
Shipping and Handling Costs and Fees
All shipping and handling costs are expensed as incurred and are recorded as a component of cost of goods sold in the accompanying consolidated statements of operations. Charges for shipping and handling billed to customers are included as a component of revenue.
Taxes Collected From Customers and Remitted to Governmental Authorities
The Company’s policy is to present revenue net of taxes collected from customers and remitted to governmental authorities.
Deferred Costs and Other Contract Assets
The costs of monitoring-related equipment provided to customers under operating lease arrangements within the Company’s deferred equipment agreements are generally deferred and amortized to cost of goods sold over the life of the underlying contracts. Some of the Company’s deferred equipment agreements also contain provisions for certain allowances to be made directly to the end-user hospital customer at the inception of the arrangement. These allowances are generally allocated to the lease and non-lease components and recognized as a reduction to revenue as the underlying performance obligations are satisfied.
The Company generally invoices its customers under deferred equipment agreements as sensors are provided to the customer. However, the Company may recognize revenue for certain non-lease performance obligations under deferred equipment agreements with fixed annual commitments at the time such performance obligations are satisfied and prior to the customer being invoiced. When this occurs, the Company records an unbilled contract receivable related to such revenue until the customer has been invoiced pursuant to the terms of the underlying deferred equipment agreement.
The incremental costs of obtaining a contract with a customer are capitalized and deferred if the Company expects such costs to be recoverable over the life of the contract and the contract term is greater than one year. Such deferred costs generally relate to certain incentive sales commissions earned by the Company’s internal sales team in connection with the execution of deferred equipment agreements and are amortized to expense over the expected term of the underlying contract.
The Company recognizes non-healthcare royalty revenue associated with certain prepaid license arrangements. The Company recognizes non-healthcare revenue from the prepaid license arrangements based upon sales-based royalties when a subsequent sale occurs.
Warranty
The Company generally provides a warranty against defects in material and workmanship for a period ranging from six months to forty-eight months, depending on the product type. In traditional sales activities, including direct and OEM sales, the Company establishes an accrued liability for the estimated warranty costs at the time of revenue recognition, with a corresponding provision to cost of goods sold. Customers may also purchase extended warranty coverage or service level upgrades separately or as part of a deferred equipment agreement. Revenue related to extended warranty coverage and service level upgrades is generally recognized over the life of the contract, which reasonably approximates the period over which such services will be provided. The related extended warranty and service level upgrade costs are expensed as incurred.
Changes in the product warranty accrual were as follows:
Year Ended
(in millions)December 30,
2023		December 31,
2022		January 1,
2022
Product warranty accrual, beginning of period$10.6 $2.5 $2.7 
Increase related to acquisition, net of reserve— 8.4 — 
Accrual for warranties issued7.8 1.8 2.2 
Changes in pre-existing warranties (including changes in estimates)(7.5)4.7 (1.4)
Settlements made(2.3)(6.8)(1.0)
Product warranty accrual, end of period$8.6 $10.6 $2.5 
Advertising Costs
Advertising costs are expensed as incurred. These costs are included in selling, general and administrative expense in the accompanying consolidated statements of operations. Advertising costs for the years ended December 30, 2023, December 31, 2022 and January 1, 2022, were $61.4 million, $49.3 million, and $9.0 million, respectively. Advertising costs for the year ended December 31, 2022 has been adjusted due to an immaterial correction of an error from the previously reported amount of $12.3 million.
Research and Development
Costs related to research and development activities are expensed as incurred. These costs include personnel costs, materials, depreciation and amortization on associated tangible and intangible assets and an allocation of facility costs, all of which are directly related to research and development activities.
Litigation Costs and Contingencies
The Company records a charge equal to at least the minimum estimated liability for a loss contingency or litigation settlement when both of the following conditions are met: (i) information available prior to issuance of the financial statements indicates that it is probable that a liability had been incurred at the date of the financial statements, and (ii) the range of loss can be reasonably estimated. The determination of whether a loss contingency or litigation settlement is probable or reasonably possible involves a significant amount of management judgment, as does the estimation of the range of loss given the nature of contingencies. Liabilities related to litigation settlements with multiple elements are recorded based on the fair value of each element. Legal and other litigation related expenses are recognized as the services are provided. The Company records insurance and other indemnity recoveries for litigation expenses when both of the following conditions are met: (a) the recovery is probable, and (b) collectability is reasonably assured. Insurance recoveries are only recorded to the extent the litigation costs to which they relate have been incurred and recognized in the financial statements.
Foreign Currency Translation
The Company’s international headquarters is in Switzerland, and its functional currency is the U.S. Dollar. The Company has many other foreign subsidiaries, and the largest transactions in foreign currency translations occur in the Japanese Yen, the British Pound, the Chinese Yuan and the European Euro.
The Company records certain revenues and expenses in foreign currencies. These revenues and expenses are translated into U.S. Dollars based on the average exchange rate for the reporting period. Assets and liabilities denominated in foreign currencies are translated into U.S. Dollars at the exchange rate in effect as of the balance sheet date. Translation gains and losses related to foreign currency assets and liabilities of a subsidiary that are denominated in the functional currency of such subsidiary are included as a component of accumulated other comprehensive (loss) income within the accompanying consolidated balance sheets. Realized and unrealized foreign currency gains and losses related to foreign currency assets and liabilities of the Company, or a subsidiary that are not denominated in the underlying functional currency are included as a component of non-operating income (loss) within the accompanying consolidated statements of operations.
Derivatives Instruments and Hedging Activities
The Company addresses market risk from changes in interest rates risks through risk management programs, which include the use of derivative instruments. The Company’s exposure to a counterparty’s credit risk is generally limited to the amounts of the net obligation to the counterparty. The Company established policies to enter into contracts only with major investment-grade financial institutions to mitigate such counterparty credit risk. The Company also established a policy to further monitor the counterparty risks throughout the life of the instruments. None of the derivative instruments currently held by the Company were entered into for speculative trading purposes.
All derivative financial instruments are recognized as either assets or liabilities at fair value in the consolidated balance sheets and are classified as short-term or long-term based on the tenor of the instrument. The Company has elected not to separate a derivative instrument into current and long-term portions. A derivative instrument whose fair value is a net liability is classified as current in total. A derivative instrument whose fair value is a net asset and whose current portion is an asset is classified as non-current in total. For a derivative instrument that meets the criteria to qualify for hedge accounting, the Company marks the fair value of the derivative instrument to market periodically through other comprehensive (loss) income. When the hedged items are recorded to income (loss), the associated deferred gains (losses) of the derivatives in accumulated other comprehensive (loss) income will be reclassified into earnings. Any fluctuation in the fair value of a derivative instrument that does not meet the criteria for hedge accounting is recorded to earnings (expense) in the period it occurs.
Comprehensive (Loss) Income
Comprehensive (loss) income includes foreign currency translation adjustments, changes to pension benefits, unrealized gains (losses) on cash flow hedges and any related tax benefits (expenses) that have been excluded from net income and reflected in stockholders’ equity.
Net Income Per Share
A computation of basic and diluted net income per share is as follows:
Year Ended
(in millions, except per share amounts)December 30,
2023		December 31,
2022		January 1,
2022
Net income$81.5 $143.5 $229.6 
Basic net income per share:
Weighted-average shares outstanding - basic52.8 53.6 55.2 
Net income per basic share$1.54 $2.68 $4.16 
Diluted net income per share:
Weighted-average shares outstanding - basic52.8 53.6 55.2 
Diluted share equivalents: stock options, RSUs and PSUs1.3 1.6 2.5 
Weighted-average shares outstanding - diluted54.1 55.2 57.7 
Net income per diluted share$1.51 $2.60 $3.98 
Basic net income per share is computed by dividing net income by the weighted-average number of shares outstanding during the period. Net income per diluted share is computed by dividing the net income by the weighted-average number of shares and potential shares outstanding during the period, if the effect of potential shares is dilutive. Potential shares include incremental shares of stock issuable upon the exercise of stock options and the vesting of both restricted share units (RSUs) and performance stock units (PSUs). For the years ended December 30, 2023, December 31, 2022 and January 1, 2022, weighted options to purchase 1.2 million, 0.8 million and 0.2 million shares of common stock, respectively, were outstanding but not included in the computation of diluted net income per share because the effect of including such shares would have been antidilutive in the applicable period. Certain RSUs were considered contingently issuable shares as their vesting is contingent upon the occurrence of certain future events. Since such events had not occurred and were not considered probable of occurring as of December 30, 2023, December 31, 2022 and January 1, 2022, 2.7 million weighted-average shares related to such RSUs have been excluded from the calculation of potential shares. For additional information with respect to these RSUs, please see “Employment and Severance Agreements” in Note 24, “Commitments and Contingencies”.
Supplemental Cash Flow Information
Supplemental cash flow information includes the following:
Year Ended
(in millions)December 30,
2023		December 31,
2022		January 1,
2022
Cash paid during the year for:
Interest expense
$51.0 $23.0 $0.3 
Income taxes
54.4 87.3 43.9 
Operating lease liabilities
22.4 17.2 7.3 
Non-cash operating activities:
ROU assets obtained in exchange for lease liabilities$16.3 $— $6.0 
Non-cash investing activities:
Unpaid purchases of property and equipment$0.2 $3.8 $— 
Non-cash financing activities:
       Unsettled common stock proceeds from option exercises$— $— $0.7 
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents
$163.0 $202.9 $745.3 
Restricted cash
5.2 6.7 3.1 
Total cash, cash equivalents and restricted cash shown in the statement of cash flows
$168.2 $209.6 $748.4 
Recently Adopted Accounting Pronouncements
There were no recently adopted accounting pronouncements during for the fiscal year ended December 30, 2023.
Recently Announced Accounting Pronouncements
In July 2023, the Financial Accounting Standard Board (FASB) issued Accounting Standard Update (ASU) No. 2023-03, Presentation of Financial Statements (Topic 205), Income Statement—Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation—Stock Compensation (Topic 718): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 120, SEC Staff Announcement at the March 24, 2022 EITF Meeting, and Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280—General Revision of Regulation S-X: Income or Loss Applicable to Common Stock. The new standard amends the FASB Codification for SEC paragraphs to SEC SAB 120, 2022 EITF Meeting and SAB Topic 6B. ASU No. 2023-03 is effective upon addition to the FASB Codification. ASU No. 2023-03 does not provide new guidance, and the Company does not expect it to have a material impact on its consolidated financial statements upon adoption.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The new standard is intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. ASU No. 2023-07 is effective for annual reporting periods beginning after December 15, 2023 and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted with retrospective application to all prior periods presented. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company is currently evaluating the expected impact of this standard on its consolidated financial statements upon adoption.
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The new standard requires companies to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate). ASU No. 2023-09 is effective for annual reporting periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the expected impact of this standard, but does not expect it to have a material impact on its consolidated financial statements upon adoption.
v3.24.0.1
Related Party Transactions
 12 Months Ended
Dec. 30, 2023
Related Party Transactions [Abstract]  
Related Party Transactions
3. Related Party Transactions
Willow Laboratories, Inc., (Willow), formerly known as Cercacor Laboratories, Inc., is an independent entity that was spun off from the Company to its stockholders in 1998. Joe Kiani, the Company’s Chairman and Chief Executive Officer (CEO), is also the Chairman and CEO of Willow. Effective as of January 3, 2016, in connection with changes in the capital structure of Willow, the Company determined that Willow was no longer required to be consolidated. Although the Company believes that Willow continues to be considered a variable interest entity, the Company has determined that it is no longer the primary beneficiary of Willow as it does not have the power to direct the activities of Willow that most significantly impact Willow’s economic performance and has no obligation to absorb Willow’s losses.
The Company is a party to the following agreements with Willow:
•Cross-Licensing Agreement - The Company and Willow are parties to a cross-licensing agreement (Cross-Licensing Agreement), which governs each party’s rights to certain intellectual property held by the two companies. The Company is subject to certain annual minimum aggregate royalty obligations for use of the rainbow® licensed technology. The current annual minimum royalty obligation is $5.0 million. Aggregate liabilities payable to Willow arising under the Cross-Licensing Agreement were $19.2 million, $16.9 million and $13.5 million for the years ended December 30, 2023, December 31, 2022 and January 1, 2022, respectively. The Company had sales to Willow in the amount of $0.1 million, $0.2 million and $0.1 million for the years ended December 30, 2023, December 31, 2022 and January 1, 2022, respectively.
•Administrative Services Agreement - The Company is a party to an administrative services agreement with Willow (G&A Services Agreement), which governs certain general and administrative services that the Company provides to Willow. Amounts charged by the Company pursuant to the G&A Services Agreement were $0.5 million, $0.4 million and $0.3 million for the years ended December 30, 2023, December 31, 2022 and January 1, 2022, respectively.
•Lease Agreement - Effective December 2019, the Company entered into a lease agreement with Willow for approximately 34,000 square feet of office, research and development space at one of the Company’s owned facilities in Irvine (Willow Lease). The term of the Willow Lease expires on December 31, 2024. The Company recognized approximately $1.2 million of lease income for each year ended December 30, 2023, December 31, 2022 and January 1, 2022, respectively.
Net amounts due to Willow were approximately $4.1 million and $3.8 million as of December 30, 2023 and December 31, 2022, respectively.
The Company’s CEO is also the Chairman of the Masimo Foundation for Ethics, Innovation and Competition in Healthcare (Masimo Foundation), a non-profit organization that was founded in 2010 to provide a platform for encouraging ethics, innovation and competition in healthcare. In addition, the Company’s Executive Vice President (EVP), Chief Financial Officer (CFO) serves as the Treasurer of the Masimo Foundation and the Company’s EVP, General Counsel and Corporate Secretary serves as the Secretary for the Masimo Foundation. For each of the fiscal years ended December 30, 2023 and December 31, 2022, the Company made cash contributions of approximately $1.0 million to the Masimo Foundation. For the fiscal year ended January 1, 2022, the Company made no contributions to the Masimo Foundation. In addition, for each of the years ended December 30, 2023, December 31, 2022 and January 1, 2022, the Company made various in-kind contributions to the Masimo Foundation, mainly in the form of donated administrative services.
The Company’s CEO is also a co-founder and a member of the board of directors of Like Minded Media Ventures (LMMV), a team of storytellers that create content focused in the areas of true stories, social causes and science. LMMV creates stories with a multi-platform strategy, bridging the gap between film, television, digital and social media. The Company entered into a marketing service agreement with LMMV for audiovisual production services promoting brand awareness, including television commercials and digital advertising, during the second quarter of 2020. During the fiscal years ended December 30, 2023 and December 31, 2022, the Company incurred $1.5 million and $1.4 million in marketing expenses to LMMV under the marketing service agreement, respectively. During the fiscal year ended January 1, 2022, the Company incurred no marketing expenses to LMMV under the marketing service agreement. At December 30, 2023 and December 31, 2022, there were no amounts due to LMMV for services rendered.
During the second quarter of 2021, the Company entered into a software license and professional services agreement with Like Minded Labs (LML), a subsidiary of LMMV. Pursuant to the software license agreement, LML granted the Company a perpetual, non-exclusive and fully paid-up right and license to integrate LML’s software into the Company’s products in exchange for a $3.0 million one-time license fee. Pursuant to the professional services agreement, LML will provide professional services to the Company, including the development of custom software intended to support the integration of the licensed software into the Company’s products, as well as future support services upon the Company’s acceptance of deliverables.
In July 2021, the Company entered into a patent purchase and option agreement with Vantrix Corporation (Vantrix), an acquiree of LML, for certain patents for $0.5 million, and the right to purchase two pools of additional patents from Vantrix for an exercise fee of up to $1.1 million. The agreements with LML and Vantrix include sublicensing provisions whereby the software and patents are licensed back to LML or Vantrix, respectively, for further advancement of the technologies.
The Company maintains an aircraft time share agreement, pursuant to which the Company has agreed from time to time to make its aircraft available to the Company’s CEO for lease on a time-sharing basis. The Company charges the Company’s CEO for personal use based on agreed upon reimbursement rates. During each of the fiscal years ended December 30, 2023, December 31, 2022 and January 1, 2022, the Company charged the Company’s CEO $0.1 million related to such reimbursements.
v3.24.0.1
Inventories
 12 Months Ended
Dec. 30, 2023
Inventory Disclosure [Abstract]  
Inventories
4. Inventories
Inventories consist of the following:
(in millions)December 30,
2023		December 31,
2022
Raw materials$229.7 $209.9 
Work-in-process30.0 30.4 
Finished goods285.3 260.7 
Total inventories$545.0 $501.0 
v3.24.0.1
Other Current Assets
 12 Months Ended
Dec. 30, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Other Current Assets
5. Other Current Assets
Other current assets consist of the following:
(in millions)December 30,
2023		December 31,
2022
Prepaid expenses$58.3 $77.5 
Lease receivable, current30.2 28.5 
Prepaid income taxes29.3 12.4 
Indirect taxes receivable28.6 26.8 
Contract assets, current6.7 3.9 
Prepaid rebates and royalties4.8 3.7 
Restricted cash(1)
3.0 2.4 
Other current assets7.5 3.6 
Total other current assets
$168.4 $158.8 
______________
(1)     Restricted cash includes funds received from the Bill and Melinda Gates Foundation. As the Company incurs costs associated with research and development related to this project, on a quarterly basis, the Company reclasses amounts from the grant to offset costs incurred.
v3.24.0.1
Lease Receivable
 12 Months Ended
Dec. 30, 2023
Leases [Abstract]  
Lease Receivable
6. Lease Receivable
For deferred equipment agreements that contain embedded operating leases, upon lease commencement, the Company defers and records the equipment cost of operating lease assets within property, plant and equipment, net of accumulated depreciation. These operating lease assets are subsequently amortized to cost of goods sold over the lease term on a straight-line basis.

For deferred equipment agreements that contain embedded sales-type leases, the Company recognizes lease revenue and costs, as well as a lease receivable, at the time the lease commences. Lease revenue related to both operating-type and sales-type leases for the years ended December 30, 2023 and December 31, 2022 was approximately $58.0 million and $52.0 million, respectively. Lease revenue for the year ended December 31, 2022 has been adjusted from the previously reported amount of $57 million to reflect the recategorization of certain system related revenue as non-lease revenue. Costs related to embedded sales-type leases within the Company’s deferred equipment agreements are included in cost of goods sold.
Lease receivable from sales-type leases consists of the following:
(in millions)December 30,
2023		December 31,
2022
Lease receivable$101.9 $101.8 
Allowance for credit loss(0.3)(0.2)
     Lease receivable, net101.6 101.6 
Less: current portion of lease receivable(30.2)(28.5)
     Lease receivable, non-current$71.4 $73.1 
As of December 30, 2023, estimated future maturities of customer sales-type lease receivables and operating lease payments for each of the following fiscal years are as follows:
Future Lease Receivables/Payments
(in millions)
Fiscal year
Sales-Type LeasesOperating Leases
2024$30.2 $10.4 
202525.0 9.3 
202618.9 8.5 
202713.6 6.9 
20287.0 5.4 
Thereafter6.9 6.0 
     Total$101.6 $46.5 
Less: imputed interest(1)
— 
     Present value of total lease payments$101.6 
______________
(1) The calculation of the rates implicit in the leases resulted in negative discount rates. Therefore, the Company as a lessor used a 0% discount rate to measure the net investment in the lease.
v3.24.0.1
Deferred Costs and Other Contract Assets
 12 Months Ended
Dec. 30, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Deferred Costs and Other Contract Assets
7. Deferred Costs and Other Contract Assets
Deferred costs and other contract assets consist of the following:
(in millions)December 30,
2023		December 31,
2022
Deferred commissions$21.8 $17.1 
Prepaid contract allowances17.0 13.7 
Unbilled contract receivables17.0 9.4 
Deferred equipment agreements, net1.5 1.7 
     Deferred costs and other contract assets$57.3 $41.9 
For the years ended December 30, 2023, December 31, 2022 and January 1, 2022, deferred commission amortization expense was $5.8 million, $4.3 million and $3.2 million, respectively.
v3.24.0.1
Property and Equipment, net
 12 Months Ended
Dec. 30, 2023
Property, Plant and Equipment [Abstract]  
Property and Equipment, net
8. Property and Equipment, net
Property and equipment, net, consists of the following:
(in millions)December 30,
2023		December 31,
2022
Building and building improvements$151.0 $151.0 
Machinery, equipment and tooling169.7 149.4 
Operating lease assets92.2 50.2 
Land66.2 65.1 
Computer equipment and software45.5 42.1 
Leasehold improvements37.5 32.3 
Transportation, vehicles and other34.0 32.7 
Furniture and office equipment20.4 19.4 
Demonstration units11.1 11.2 
Construction-in-progress (CIP)59.2 50.6 
Total property and equipment
686.8 604.0 
Accumulated depreciation(262.4)(201.5)
Property and equipment, net
$424.4 $402.5 
For the years ended December 30, 2023, December 31, 2022 and January 1, 2022, depreciation expense of property and equipment was $43.9 million, $43.0 million and $25.3 million, respectively.
For the years ended December 30, 2023, December 31, 2022 and January 1, 2022, depreciation expense of operating lease assets was $19.3 million, $4.4 million and $0.5 million, respectively.
For the years ended December 30, 2023 and December 31, 2022, $19.3 million and $4.3 million of equipment leased to customers was amortized to cost of goods sold, respectively. As of December 30, 2023 and December 31, 2022, accumulated amortization of equipment leased to customers was $1.5 million and $2.1 million, respectively.
The balance in CIP at December 30, 2023 and December 31, 2022, related primarily to the capitalized implementation costs related to a new enterprise resource planning software system, costs related to facility improvements, the expansion of certain key manufacturing facilities globally, machinery and equipment at the Company’s corporate headquarters, as well as on-going development costs associated with a new research and development facility, the underlying assets for which have not been completed or placed into service.
On February 14, 2022, the Company’s wholly owned subsidiary, Masimo Canada ULC, entered into a Purchase and Sale Agreement (Purchase Agreement) with Keltic (Prior) Development Limited Partnership (Vendor) for the purchase of a property in Vancouver, British Columbia, Canada for a purchase price of CAD123.0 million, plus GST (Purchase Price), subject to certain adjustments. The Company paid CAD21.0 million as a deposit towards the purchase during the year ended December 31, 2022. The balance of the Purchase Price will be due and payable upon the closing of the transaction, which is currently expected to occur in mid-2025.
v3.24.0.1
Intangible Assets, net
 12 Months Ended
Dec. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets, net
9. Intangible Assets, net
Intangible assets, net, consist of the following:
December 30,
2023
As Adjusted,
December 31,
2022(1)
(in millions)Gross Carrying
Amount		Accumulated
Amortization		Net Carrying
Amount		Gross Carrying
Amount		Accumulated
Amortization		Net Carrying
Amount
Intangible assets subject to amortization:
Customer relationships$209.2 $(31.5)$177.7 $220.9 $(19.3)$201.6 
Acquired technologies174.7 (45.3)129.4 185.3 (25.2)160.1 
Capitalized software development costs53.9 (15.2)38.7 25.0 (2.9)22.1 
Licenses39.7 (7.4)32.3 39.0 (4.4)34.6 
Patents39.2 (15.2)24.0 35.2 (13.9)21.3 
Trademarks20.1 (7.4)12.7 19.8 (5.8)14.0 
Licenses-related party7.5 (6.7)0.8 7.5 (6.3)1.2 
Non-compete agreements6.3 (2.6)3.7 6.3 (1.1)5.2 
Other1.7 (1.1)0.6 1.6 (1.1)0.5 
     Total intangible assets subject to amortization, net$552.3 $(132.4)$419.9 $540.6 $(80.0)$460.6 
Intangible assets not subject to amortization:
Trademarks$242.4 $262.0 
Impairment charge(10.0)— 
     Total trademarks232.4 262.0 
     Intangible assets, net$652.3 $722.6 
The following intangible assets reclassification adjustments were made as of September 30, 2023(1):
As Adjusted,
 December 31,
2022
As Previously Filed,
 December 31,
2022
(in millions)Gross Carrying
Amount		Accumulated
Amortization		Net Carrying
Amount		Gross Carrying
Amount		Accumulated
Amortization		Net Carrying
Amount
Intangible assets subject to amortization:
Capitalized software development costs$25.0 $(2.9)$22.1 $5.5 $(2.9)$2.6 
Trademarks19.8 (5.8)14.0 39.3 (5.8)33.5 
__________________
(1)    The Company recorded an immaterial reclassification adjustment between the intangible assets balances in Trademarks and Capitalized Software Development Costs in the amount of $19.5 million, for the year ended December 31, 2022. There was no impact on total intangible assets, net as for December 30, 2022. The adjusted balances were reflected in the Form 10-Q for the quarter ended September 30, 2023, filed with the SEC November 8, 2023.
Finite lived intangible assets have a weighted-average amortization period ranging from twelve years to fourteen years.
Total amortization expense for the years ended December 30, 2023, December 31, 2022 and January 1, 2022, was $54.4 million, $39.8 million and $10.3 million, respectively.
Total unamortized capitalized software development costs for the years ended December 30, 2023 was $11.9 million. There was no unamortized capitalized software development costs for the year ended December 31, 2022.
The total costs of patents not yet amortizing for the years ended December 30, 2023 and December 31, 2022, was $12.1 million and $10.6 million, respectively.
The total costs of trademarks not yet amortizing for the years ended December 30, 2023 and December 31, 2022, was $1.0 million and $1.1 million, respectively.
Total renewal costs capitalized for patents and trademarks for the years ended December 30, 2023 and December 31, 2022 were $1.0 million and $1.2 million, respectively. As of December 30, 2023, the weighted-average number of years until the next renewal was two years for patents and six years for trademarks.
Estimated amortization expense for each of the next fiscal years is as follows:
Fiscal year
Amount
(in millions)
2024$53.7 
202551.0 
202640.1 
202739.2 
202839.0 
Thereafter196.9 
Total$419.9 
Indefinite-lived intangible assets are subject to annual impairment testing, unless circumstances dictate more frequent testing, if impairment indicators exist.
In the third quarter of 2023, declines in the Company’s stock price and certain worsening macro-economic market conditions, including continued slowing in demand for consumer audio products, contributed to a significant decline in the Company’s market capitalization, which led the Company to conclude a trigger event had occurred. As a result, the Company performed a quantitative impairment assessment, which resulted in recording a $7.0 million impairment charge for indefinite-lived trademarks in the non-healthcare reporting unit. In conjunction with this third quarter interim impairment quantitative assessment, the Company concluded that both the healthcare reporting unit’s and non-healthcare reporting unit’s respective estimated fair values exceeded their carrying values. Furthermore, recoverability tests performed for other long-lived assets with finite lives indicated no recoverability issues.
During the fourth quarter of 2023, the Company performed its annual impairment analysis by first electing to complete a qualitative assessment of its indefinite-lived intangible assets. Based on this assessment, the Company determined it was not more likely than not that the fair value of the indefinite lived intangibles within the non-healthcare reporting unit exceeded their carrying values. Accordingly, the Company proceeded to perform a quantitative impairment assessment, which resulted in recording a $3.0 million impairment charge for indefinite-lived trademarks. For purposes of the impairment test, the fair value of indefinite-lived assets were determined using the same methodology as described in Note 18, “Business Combinations.” The estimates and assumptions applied represent a Level 3 measurement because they are supported by limited or no market activity and reflect the Company’s assumptions in measuring fair value.
During the fourth quarter of 2023, the Company performed its annual goodwill impairment analysis by first electing to complete a qualitative assessment for its healthcare and non-healthcare reporting units. Based on this assessment, the Company concluded that it was more likely than not that the fair value of the healthcare reporting unit was greater than its carrying value. Accordingly, no further testing was required for the healthcare reporting unit. However, the Company concluded that it was not more likely than not that the fair value of the non-healthcare reporting unit was greater than its carrying value. Therefore, the Company proceeded to perform a quantitative assessment for its non-healthcare reporting unit.
When a quantitative assessment is required for the impairment test for goodwill, the Company uses a combination of both an income and a market approach to determine the fair value of the reporting unit. The income approach utilized the estimated discounted cash flows for the reporting unit, while the market approach utilized comparable company information. Estimates and assumptions used in the income approach to calculate projected future discounted cash flows included revenue growth rates, operating margins and a discount rate for the reporting unit. Discount rates were determined using a weighted average cost of capital for risk factors specific to the reporting unit and other market and industry data. The assumptions used are inherently subject to uncertainty and the Company noted that slight changes in these assumptions could have a significant impact on the concluded value.
The estimates and assumptions applied represent a Level 3 measurement because they are supported by limited or no market activity and reflect the Company’s assumptions in measuring fair value.
v3.24.0.1
Goodwill
 12 Months Ended
Dec. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill
10. Goodwill
Changes in goodwill were as follows:
December 30,
2023
(in millions)HealthcareNon-healthcareTotal
Goodwill, beginning of period$97.6 $347.8 $445.4 
Adjustments to goodwill from purchase price allocation(1)
— (18.2)(18.2)
Foreign currency translation adjustment1.0 (20.5)(19.5)
Goodwill, end of period$98.6 $309.1 $407.7 
December 31,
2022
(in millions)HealthcareNon-healthcareTotal
Goodwill, beginning of period$100.3 $— $100.3 
Increase from business combinations— 347.8 347.8 
Foreign currency translation adjustment(2.7)— (2.7)
Goodwill, end of period$97.6 $347.8 $445.4 
______________
(1)     Includes an immaterial correction of an error to the final purchase price allocation from the Sound United acquisition, which resulted in a reduction of goodwill of $7.8 million. See Note 18 “Business Combinations” for further details.
v3.24.0.1
Lessee ROU Assets and Lease Liabilities
 12 Months Ended
Dec. 30, 2023
Leases [Abstract]  
Lessee ROU Assets and Lease Liabilities
11. Lessee ROU Assets and Lease Liabilities
The Company leases certain facilities in North and South America, Europe, the Middle East and Asia-Pacific regions under operating lease agreements expiring at various dates through January 2032. In addition, the Company leases equipment in the U.S. and Europe pursuant to leases that are classified as operating leases and expire at various dates through November 2028. The majority of these leases are non-cancellable and generally do not contain any material restrictive covenants, material residual value guarantees, or other material guarantees. The Company recognizes lease costs under these agreements using a straight-line method based on total lease payments. Certain facility leases contain predetermined price escalations and in some cases renewal options, the longest of which is for five years.
The Company generally estimates the applicable discount rate used to determine the net present value of lease payments based on available information at the lease commencement date. As of December 30, 2023, the weighted-average discount rate used by the Company for all operating leases was approximately 4.1%.The balance sheet classifications for amounts related to the Company’s operating leases for which it is the lessee are as follows:
(in millions)Balance Sheet ClassificationDecember 30,
2023		December 31,
2022
Lessee ROU assetsOther non-current assets$59.1 $69.6 
Lessee current lease liabilitiesOther current liabilities18.2 18.7 
Lessee non-current lease liabilitiesOther non-current liabilities45.8 53.4 
     Total operating lease liabilities$64.0 $72.1 
For the years ended December 30, 2023 and December 31, 2022, accumulated amortization for lessee ROU assets was $48.9 million and $36.6 million, respectively. The weighted-average remaining lease term for the Company’s operating leases was 5.6 years as of December 30, 2023.
As of December 30, 2023, estimated future operating lease payments for each of the following fiscal years were as follows:
Fiscal year
Amount
(in millions)
2024$19.2 
202515.3 
202610.9 
20276.6 
20285.7 
Thereafter(1)
17.8 
Total75.5 
Imputed interest(11.5)
Present value$64.0 
______________
(1)     Includes optional renewal period for certain leases.
For the years ended December 30, 2023, December 31, 2022 and January 1, 2022, the Company’s operating lease costs were approximately $22.7 million, $18.0 million and $8.2 million, respectively.
v3.24.0.1
Other Non-Current Assets
 12 Months Ended
Dec. 30, 2023
Other Assets, Noncurrent [Abstract]  
Other Non-Current Assets
12. Other Non-Current Assets
Other non-current assets consist of the following:
(in millions)December 30,
2023		December 31,
2022
Lessee ROU assets, net$59.1 $69.6 
Derivative assets - non-current(1)
11.4 19.3 
Prepaid deposits and other6.4 5.8 
Strategic investments7.2 13.8 
Equity investments - fair value2.7 — 
Restricted cash(2)
2.2 5.2 
Other non-current assets0.3 0.3 
Total non-current assets$89.3 $114.0 
______________
(1)    Excludes accrued interest.
(2)    Restricted cash includes cash held in certain subsidiaries such as China, that may be subject to transfer restrictions depending on jurisdictions.
v3.24.0.1
Deferred Revenue and Other Contract Liabilities, Current
 12 Months Ended
Dec. 30, 2023
Revenue Recognition and Deferred Revenue [Abstract]  
Deferred Revenue and Other Contract Liabilities, Current
13. Deferred Revenue and Other Contract Liabilities, Current
Deferred revenue and other contract liabilities consist of the following:
(in millions)December 30,
2023		December 31,
2022
Deferred revenue$63.8 $61.0 
Accrued rebates and allowances37.5 38.5 
Accrued customer reimbursements12.4 6.1 
     Total deferred revenue and other contract liabilities113.7 105.6 
Less: Non-current portion of deferred revenue(26.4)(25.0)
     Deferred revenue and other contract liabilities, current$87.3 $80.6 
Deferred revenue relates to contracted amounts that have been invoiced to customers for which remaining performance obligations must be completed before the Company can recognize revenue. Generally, both healthcare and non-healthcare segments record deferred revenue when revenue is to be recognized subsequent to invoicing.
Healthcare Deferred Revenue
Healthcare deferred revenue primarily relates to undelivered equipment, sensors and services under deferred equipment agreements, extended warranty agreements and maintenance agreements. Expected revenue from remaining contractual performance obligations (Unrecognized Contract Revenue) includes deferred revenue, as well as other amounts that will be invoiced and recognized as revenue in future periods when the Company completes its performance obligations. Unrecognized Contract Revenue excludes revenue allocable to monitoring-related equipment that is effectively leased to customers under deferred equipment agreements and other contractual obligations for which neither party has performed. The estimated timing of this revenue is based, in part, on management’s estimates and assumptions about when its performance obligations will be completed. As a result, the actual timing of this revenue in future periods may vary, possibly materially. As of December 30, 2023, the Company had approximately $1,497.2 million of Unrecognized Contract Revenue related to executed contracts with an original duration of one year or more. The Company expects to recognize approximately $380.9 million of this amount as revenue within the next twelve months and the remaining balance thereafter.
Non-Healthcare Deferred Revenue
In October 2020, the Company’s subsidiary, B&W Group Ltd. (B&W), entered into an amendment to a licensing agreement, whereby B&W received a $20.0 million royalty prepayment in relation to sound system units manufactured under the Bowers & Wilkins brand for various high-end car manufacturers with a total commitment of $35.0 million to be received by September 30, 2028. As of December 30, 2023, deferred revenue was $15.3 million.
Changes in deferred revenue for the year ended December 30, 2023 were as follows:
(in millions)December 30,
2023
Deferred revenue, beginning of the period$61.0 
  Revenue deferred during the period28.3 
  Recognition of revenue deferred in prior periods(25.5)
     Deferred revenue, end of the period$63.8 
v3.24.0.1
Other Current Liabilities
 12 Months Ended
Dec. 30, 2023
Other Liabilities Disclosure [Abstract]  
Other Current Liabilities
14. Other Current Liabilities
Other current liabilities consist of the following:
(in millions)December 30,
2023		December 31,
2022
Current portion of long-term debt$34.3 $15.1 
Accrued expenses26.3 39.9 
Accrued indirect taxes payable23.9 28.2 
Lessee lease liabilities, current18.2 18.7 
Income tax payable16.1 32.1 
Accrued property taxes10.2 12.1 
Accrued legal fees9.9 11.4 
Accrued warranty8.6 10.6 
Other current liabilities6.7 6.1 
Related party payables4.2 4.0 
Accrued donations4.0 5.1 
Total other current liabilities
$162.4 $183.3 
v3.24.0.1
Debt
 12 Months Ended
Dec. 30, 2023
Debt Disclosure [Abstract]  
Debt
15. Debt
(in millions)December 30,
2023		December 31,
2022
Japanese loans - current portion$23.0 $7.6 
Term loan - current portion11.3 7.5 
Short-term debt34.3 15.1 
Revolver - long-term591.5 651.0 
Term loan - long-term271.4 278.9 
Japanese loans - long-term8.8 11.7 
Long-term debt871.7 941.6 
Total debt$906.0 $956.7 
Prior Credit Facility
Until April 11, 2022, the Company maintained a credit agreement (Prior Credit Facility) with JPMorgan Chase Bank, N.A., as the Administrative Agent and a Lender, and Bank of the West, a Lender (collectively, the Lenders). The Prior Credit Facility provided for up to $150.0 million of unsecured borrowings, with an option, subject to certain conditions, for the Company to increase the aggregate borrowing capacity up to $550.0 million in the future with the Lenders and additional lenders, as required. The Prior Credit Facility also provided for a sublimit of up to $25.0 million for the issuance of letters of credit and a sublimit of $75.0 million for borrowings in specified foreign currencies.
On April 11, 2022, the Company paid off all obligations owing under the Prior Credit Facility, and terminated it. As a result of the repayment, the Company expensed $0.1 million of previously capitalized debt issuance costs.
Credit Facility
On April 11, 2022, the Company entered into a credit agreement (Credit Facility) with financial institutions party thereto as initial lenders (collectively, the Initial Lenders), Citibank, N.A., as Administrative Agent, Citibank, N.A., JPMorgan Chase Bank, N.A., Bank of the West and BofA Securities, Inc., as joint lead arrangers and joint bookrunners, and JPMorgan Chase Bank, N.A., Bank of the West and BofA Securities, Inc., as co-syndication agents.
The Credit Facility provides for an unsecured term loan of $300.0 million (Term Loan) and $500.0 million of ongoing unsecured revolving commitments (Revolver), with an option, subject to certain conditions, for the Company to increase the aggregate borrowing capacity by an additional $400.0 million (plus additional unlimited amounts if certain incurrence tests are met) in the future with the Initial Lenders and additional lenders, as required. Debt issuance costs of $8.4 million were recorded as a reduction to the carrying amount of the Credit Facility and are being amortized to interest expense using the effective interest method.
The Credit Facility also provides for a sublimit of up to $50.0 million for the issuance of letters of credit.
Borrowings under the Credit Facility will be deemed, at the Company’s election, either: (a) an Alternate Base Rate (ABR) Loan, which bears interest at the ABR, plus a spread of 0.000% to 0.750% based upon a Company leverage ratio, or (b) a Term SOFR Loan, which bears interest at the Adjusted Term SOFR Rate (as defined below), plus a spread of 1.000% to 1.750% based upon a Company net leverage ratio. Pursuant to the terms of the Credit Facility, the ABR is equal to the greatest of (i) the prime rate, (ii) the Federal Reserve Bank of New York effective rate plus 0.50%, and (iii) the one-month Adjusted Term SOFR plus 1.0%. The Adjusted Term SOFR Rate is equal to the Term SOFR Rate (as defined in the Credit Facility) for the applicable interest period plus a spread adjustment of 0.10%, 0.15% and 0.25% for the interest periods ending one, three and six months, respectively.
The Company is also obligated under the Credit Facility to pay an unused fee ranging from 0.150% to 0.275% per annum, based upon a Company leverage ratio, with respect to any non-utilized portion of the Credit Facility.
The Company is subject to certain covenants, including financial covenants related to a net leverage ratio and an interest charge coverage ratio, and other customary negative covenants. The Credit Facility also includes customary events of default which, upon the occurrence of any such event of default, provide the Initial Lenders (and any additional lenders) with the right to take either or both of the following actions: (a) immediately terminate the commitments, and (b) declare the loans then outstanding immediately due and payable in full. All unpaid principal under the Credit Facility will become due and payable on April 12, 2027.
On May 16, 2022, the Company entered into the First Amendment to the Credit Agreement (First Amendment) with the Initial Lenders and Citibank, N.A., as the administrative agent, which amended the Credit Facility. The First Amendment provides for an additional $205 million of unsecured revolving commitments, increasing the aggregate amount of the Revolver from $500 million to $705 million.
Borrowing rates, financial covenants, affirmative and negative covenants and other restricted terms remain unchanged from the Credit Facility. All unpaid principal under the First Amendment will become due and payable on April 12, 2027. The Company was in full compliance with all covenants contained in its debt agreements and Credit Facility at December 30, 2023.
For the years ended December 30, 2023 and December 31, 2022, the Company incurred total interest expense of $47.0 million and $23.7 million, under the Credit Facility, respectively. For the year ended January 1, 2022, the Company did not incur any interest expense under the Credit Facility.
Furthermore, in connection with the Sound United acquisition, the Company assumed three outstanding loans as follows:
Japanese Revolving Loan
In March 2020, the Company entered into a secured revolving loan (Japanese Revolving Loan) with Mizuho bank, which allows the Company to borrow up to ¥800 million (approximately $5.7 million). The Japanese Revolving Loan is an evergreen agreement that terminates upon request by either the financial institution or the borrower and is collateralized with land and buildings in Shirakawa-Shi owned by the borrower. The carrying value collateralized assets was approximately $11.4 million as of December 30, 2023. Interest accrues at a rate equal to the Mizuho Tokyo Interbank Offered Rate (TIBOR) plus a fixed spread of 0.50% per annum. In connection with the execution of the Japanese Revolving Loan, the Company incurred debt issuance costs of ¥7.2 million (approximately $0.1 million).
On February 28, 2023, the Company and Mizuho Bank executed an amendment to the Japanese Revolving Loan, to increase the maximum aggregate revolving loan to ¥3.00 billion (approximately $21.3 million). Under the amendment, the facility accrues interest at a rate equal to the TIBOR plus a fixed spread of 0.75% per annum. The Company also paid an upfront fee of ¥22.0 million (approximately $0.2 million) on the incremental amount of the revolving Credit Facility.
The Japanese Revolving Loan agreement contains customary affirmative and negative covenants, such as financial reporting requirements and customary covenants that restrict the borrower’s ability to, among other things, provide collateral for obligations borne by the borrower, and determine the eligibility to declare, and amount of potential dividends to be paid during a given fiscal year. As of December 30, 2023, the Company was in compliance with all covenants under the Japanese Revolving Loan agreements.
Japanese Government Loans
In May and June 2020, the Company received ¥1.48 billion (approximately $10.5 million) in non-collateralized Japanese Government Loan facilities (Japanese Government Loans) as part of its local Japanese stimulus program. Interest accrues at a weighted-average rate of 1.33% and is repayable in installments with various maturities through June 2035. The non-current portion of the Japanese Government Loans is presented under long-term debt and the current portion is presented under short-term debt on the accompanying consolidated balance sheets. The Company incurred no debt issuance costs in connection with the Japanese Government Loans.
Japanese Equipment Loans
In April and May 2021, the Company entered into collateralized Japanese Equipment Loans of ¥150 million (approximately $1.1 million), payable in installments through March 2031 with an interest of 0.58%, and ¥80 million (approximately $0.6 million) payable in installments through April 2028 with interest of 1.2%. The non-current portion of the Japanese Equipment Loans is presented under long-term debt and the current portion is presented under short-term debt on the accompanying consolidated balance sheets. The Company incurred no debt issuance costs in connection with these Japanese Equipment Loans.
As of December 30, 2023, the aggregate maturities of principal on all debt for each of the next five years and thereafter are as follows:
Fiscal year
Amount
(in millions)
2024$34.3 
202516.7
202616.7
2027834.6
20281.1 
Thereafter2.6
Total$906.0 
v3.24.0.1
Other Non-Current Liabilities
 12 Months Ended
Dec. 30, 2023
Other Liabilities Disclosure [Abstract]  
Other Non-Current Liabilities
16. Other Non-Current Liabilities
Other non-current liabilities consist of the following:
(in millions)December 30,
2023		December 31,
2022
Lessee non-current lease liabilities$45.8 $53.4 
Deferred revenue, non-current26.4 25.0 
Unrecognized tax benefits24.4 18.0 
Projected benefit obligation9.5 10.1 
Indirect tax payable, non-current8.4 8.2 
Income tax payable, non-current7.1 12.7 
Other7.9 9.1 
Total other non-current liabilities
$129.5 $136.5 
Unrecognized tax benefits relate to the Company’s long-term portion of tax liability associated with uncertain tax positions. Authoritative guidance prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. See Note 23, “Income Taxes”, for further details.
v3.24.0.1
Derivative Instruments and Hedging Activities
 12 Months Ended
Dec. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Instruments and Hedging Activities
17. Derivative Instruments and Hedging Activities
Derivative Instruments - Cash Flow Hedges
The Company’s cash flow hedges are designed to mitigate the risk of exposure to variability in expected future cash flows of recognized assets, liabilities or any unrecognized forecasted transactions. Since July 2022, the Company has entered into various interest rate swaps that are designated as cash flow hedges on a substantial portion of the Company’s outstanding debt. The interest rate swaps reduce the variability of cash flow payments for the Company by converting the variable interest rate on the Company’s long-term debt to an average fixed interest rate of 3.14%. These contracts, carried at fair value, have maturities of approximately three years. All hedging relationships were highly effective at achieving offsetting changes in cash flows attributable to the risk being hedged. The Company used a regression analysis at hedge inception to assess the effectiveness of cash flow hedge and periodically thereafter.
The Company records gains and losses from the changes in the fair value of these instruments as a component of other comprehensive (loss) income. Deferred gains or losses from these designated cash flow hedges are reclassified into earnings in the period that the hedged items affect earnings. The Company does not offset fair value amounts recognized for derivative instruments in its consolidated balance sheets for presentation purposes. The following table summarizes the fair value of the hedging instruments, presented on a gross basis, as of December 30, 2023 and December 31, 2022.
Consolidated
Balance Sheets
(in millions)Balance Sheet ClassificationDecember 30,
2023		December 31,
2022
Interest rate contracts, inclusive of accrued interestOther non-current assets$11.6 $19.7 
Interest rate contracts, inclusive of accrued interest
Other non-current liabilities
(3.6)— 
Total$8.0 $19.7 
The following table summarizes the gains (losses) reclassified from accumulated other comprehensive (loss) income to the consolidated financial statements for the year ended December 30, 2023.
Consolidated
Statement of Operations
(in millions)Location of Gain (Loss) December 30,
2023		December 31,
2022		January 1,
2022
Cash flow hedges - interest rate contracts
Non-operating (loss) income
$14.9 $0.7 $— 
Total$14.9 $0.7 $— 
The following tables summarize the changes in accumulated other comprehensive (loss) income related to the hedging instruments:
(in millions)December 30,
2023		December 31,
2022
Beginning balance$19.3 $— 
Amount recognized in other comprehensive income3.4 20.0 
Amount reclassified into earnings(14.9)(0.7)
Ending balance$7.8 $19.3 
For the year ended December 30, 2023 and December 31, 2022, the unrealized (loss) gain, net of tax was $(8.8) million and $14.7 million, respectively.
The Company expects to reclassify a net amount of gains of $10.6 million from accumulated other comprehensive (loss) income gain to non-operating income (loss) within the next 12 months.
v3.24.0.1
Business Combinations
 12 Months Ended
Dec. 30, 2023
Business Combination and Asset Acquisition [Abstract]  
Business Combinations
18. Business Combinations
Sound United Acquisition
On April 11, 2022, the Company completed the previously announced acquisition of Sound United, pursuant to a Merger Agreement dated as of February 15, 2022, by and among the Company, Sonic Boom Acquisition Corp., a wholly-owned subsidiary of the Company (Merger Sub), Viper Holdings Corporation (Sound United), and, solely in its capacity as the Seller Representative, Viper Holdings, LLC, pursuant to which Merger Sub merged with and into Sound United, with Sound United continuing as a wholly-owned subsidiary of the Company (Merger).
Sound United is a leading innovator of premium, high-performance audio products for consumers around the world, which operates iconic consumer brands: Bowers & Wilkins®, Denon™, Marantz™, HEOS™, Classé™, Polk Audio™, Boston Acoustics™ and Definitive Technology™. The brands are linked by a commitment to the highest production standards and a focus on unparalleled audio quality and audio performance. Sound United delivers significant competitive benefits through its platform advantages, including global distribution across online, retail, and custom installation channels; a cloud-connected home ecosystem; and a state-of-the-art research and development function focused on creating the highest-quality consumer products with world-class industrial design.
The Company acquired 100% of the equity interests of Sound United for $1.0575 billion in cash, subject to adjustments based on Sound United’s net working capital, transaction expenses, cash and debt as of the closing of the Merger, payable by the Company in cash. The transaction was primarily funded with the proceeds from the Credit Facility. See Note 15, “Debt”, for additional information about the Credit Facility. There was no contingent consideration resulting from the transaction.
The results of operations of Sound United subsequent to the acquisition date and the acquired assets and assumed liabilities, including the allocation of goodwill and intangible assets, are included in the non-healthcare segment. For the period of April 11, 2022 to December 30, 2022, the Company recorded revenue of $694.9 million and a net loss of $38.6 million from Sound United. For the period of January 1, 2023 to December 30, 2023, the Company recorded revenue of $771.1 million and a net loss of $20.9 million from Sound United.
Acquisition Costs
The Company recognized transaction costs related to the Sound United acquisition of $16.6 million for the year ended December 31, 2022. The Company recognized no transaction costs related to the Sound United acquisition for the year ended December 30, 2023.
Purchase Price Allocations
The purchase price allocation for the Sound United acquisition is final. Goodwill was calculated as the excess of the consideration transferred over the fair value of the identifiable net assets acquired in a business combination and represents the future economic benefits expected to arise from intangible assets acquired that do not qualify for separate recognition, including the assembled workforce. Goodwill is not expected to be deductible for tax purposes.
The measurement period adjustments resulted primarily from valuation inputs pertaining to certain acquired assets based on facts and circumstances that existed as of the acquisition date and did not result from events subsequent to the acquisition date.
The table below summarizes the final allocation of fair value of assets acquired and liabilities assumed.
(in millions)Sound United
Cash consideration
$1,057.5 
Purchase price$1,057.5 
Assets acquired:
Cash and cash equivalents$82.6 
Accounts receivables108.5 
Inventories238.6 
Prepaid expenses and other current assets30.0 
Property, plant and equipment113.2 
Intangible assets
649.0 
Goodwill(1)
318.0 
Long-term other assets7.4 
Total assets acquired$1,547.3 
Liabilities assumed:
Accounts payable$(118.8)
Accrued liabilities and other current liabilities(148.9)
Deferred tax liabilities(1)
(145.1)
Other long-term liabilities(77.0)
Total liabilities assumed$(489.8)
______________
(1)    Includes an immaterial correction of an error to the final purchase price allocation from the Sound United acquisition, which resulted in a reduction to both goodwill and deferred tax liabilities of $7.8 million.
Identifiable Intangible Assets
The following table sets forth the components of identifiable intangible assets acquired and the weighted average amortization period as of the acquisition date:
Weighted average
amortization period
(in years)
April 11,
 2022
(in millions)
Trademarks/tradenames10$6.0 
Customer relationships17196.0 
Developed technology8156.0 
Contractual license agreements1529.0 
Subtotal14 years$387.0 
Indefinite trademarks/tradenamesN/A262.0 
Total$649.0 
In determining the fair value of the identifiable intangible assets, the Company utilized various forms of the income approach, depending on the asset being valued. The estimation of fair value requires significant judgment related to cash flow forecasts, discount rates reflecting the risk inherent in each cash flow stream, competitive trends, market comparables and other factors. Other inputs included historical data, current and anticipated market conditions, and growth rates. Contractual license agreements have a weighted-average amortization period of five years until the next renewal term.
The intangible assets were valued using the following valuation approaches:
Customer relationships
The fair value of customer relationships was determined using the multi-period excess earnings method. The multi-period excess earnings method involves forecasting the net earnings expected to be generated by the asset, reducing them by appropriate returns on contributory assets and then discounting the resulting net cash flows to a present value using an appropriate discount rate.
Trademarks/tradenames
The fair values of the trademark/tradenames were determined using the relief-from-royalty method under the income approach. This involves forecasting avoided royalties, reducing them by taxes, and discounting the resulting net cash flows to a present value using an appropriate discount rate. Judgment was applied for a number of assumptions in valuing the identified intangible assets, including revenue and cash flow forecasts, survival rates, technology life, royalty rate, obsolescence and discount rate.
Developed technology
The fair values of the developed technology were determined using the relief-from-royalty method under the income approach. This involves forecasting avoided royalties, reducing them by taxes, and discounting the resulting net cash flows to a present value using an appropriate discount rate. Judgment was applied for a number of assumptions in valuing the identified intangible assets, including revenue and cash flow forecasts, survival rates, technology life, royalty rate, obsolescence and discount rate.
Contractual licensing agreements
The fair value of the contractual license agreements was determined using a variation of the multi-period excess earnings method. This method involves forecasting the net earnings expected to be generated by the asset and then discounting the resulting net cash flows to a present value using an appropriate discount rate.
Unaudited pro forma financial information
The supplemental pro forma financial information has been prepared using the acquisition method of accounting and is based on the historical financial information of Masimo and Sound United, assuming the transaction occurred on January 1, 2021. The supplemental pro forma financial information does not necessarily represent what the combined companies’ revenue or results of operations would have been had the acquisition of Sound United been completed on January 1, 2021, nor is it intended to be a projection of future operating results of the combined company. It also does not reflect any operating efficiencies or potential cost savings that might be achieved from synergies of combining Masimo and Sound United.
The unaudited supplemental pro forma financial information has been calculated after applying Masimo’s accounting policies and adjusting the results of the combined Company to reflect incremental amortization and depreciation expense resulting from the fair value adjustments for acquired intangible assets, inventory, property, plant and equipment as well as the net decrease to interest expense resulting from the elimination of the historical interest expense on Sound United’s debt that was paid off at closing partially offset by incremental interest expense resulting from the external debt borrowed by Masimo to fund the acquisition, and the corresponding income tax impact of these adjustments.
Also, during the year ended December 31, 2022, Masimo and Sound United incurred $22.4 million and $41.1 million of acquisition-related costs, respectively. The acquisition related integration expenses incurred by Masimo are included in selling, general and administrative, in the Company’s consolidated statements of comprehensive income for the twelve months ended December 30, 2023.
There are no other material non-recurring pro forma adjustments directly attributable to the Sound United Acquisition included in the reported pro forma revenue and pro forma net income.
Twelve Months Ended
December 30,
2023		December 31,
2022		January 1,
2022
(in millions)ActualPro formaPro forma
Net revenue$2,048.1 $2,293.4 $2,187.4 
Net income $81.5 $181.8 $126.2 
v3.24.0.1
Equity
 12 Months Ended
Dec. 30, 2023
Equity [Abstract]  
Equity
19. Equity
Series A Junior Participating Preferred Stock and Stockholder Rights Plan
In September 2022, the Company authorized and declared a dividend of one preferred stock purchase right (Right) for each outstanding share of its common stock to stockholders of record at the close of business on September 20, 2022 (the Record Date) pursuant to a Rights Agreement, dated as of September 9, 2022 (Rights Agreement),with Broadridge Corporate Issuer Solutions, Inc. as Rights Agent. In addition, one Right was issued with each share of common stock that became outstanding after the Record Date. Each Right entitled the registered holder to purchase from the Company one thousandth of one share of the Company’s Series A junior participating preferred stock, par value $0.001 per share, at a purchase price equal to $1,000.00 per Right, subject to adjustment. Generally, the Rights were to become exercisable in the event any person or group of affiliated or associated persons acquires beneficial ownership of 10% (20% in the case of a passive institutional investor), subject to certain exceptions.
On March 22, 2023, the Company and the Rights Agent entered into an amendment (Rights Agreement Amendment) to the Rights Agreement. The Rights Agreement Amendment accelerated the expiration of the Rights to 5:00 P.M., New York time, on March 22, 2023, and the Rights Agreement terminated at such time. At the time of the termination of the Rights Agreement, all Rights distributed to holders of the Company’s common stock pursuant to the Rights Agreement expired.
Stock Repurchase Programs
In October 2021, the Board approved a stock repurchase program, authorizing the Company to purchase up to 3.0 million shares of its common stock over a period of up to three years (2021 Repurchase Program). The 2021 Repurchase Program became effective in October 2021 upon the expiration of the Company’s prior repurchase program approved in 2018. The 2021 Repurchase Program was completed in May 2022.
In June 2022, the Board approved a stock repurchase program, authorizing the Company to purchase up to 5.0 million shares of its common stock on or before December 31, 2027 (2022 Repurchase Program). The 2022 Repurchase Program became effective in July 2022. The Company expects to fund the 2022 Repurchase Program through its available cash, cash expected to be generated from future operations, the Credit Facility and other potential sources of capital. The 2022 Repurchase Program can be carried out at the discretion of a committee comprised of the Company’s CEO and CFO through open market purchases, one or more Rule 10b5-1 trading plans, block trades and privately negotiated transactions. No shares were repurchased pursuant to the 2022 Repurchase Program during the year ended December 30, 2023. As of December 30, 2023, 5.0 million shares remained available for repurchase pursuant to the 2022 Repurchase Program.
The following table provides a summary of the Company’s stock repurchase activities during the years ended December 30, 2023, December 31, 2022 and January 1, 2022:
Years Ended
(in millions, except per share amounts)December 30,
2023		December 31,
2022		January 1,
2022
Shares repurchased
— (1)3.0 (1)0.5 (1)
Average cost per share$— $133.82 $235.88 
Value of shares repurchased$— $401.5 $129.0 
______________
(1)     Excludes shares withheld from the shares of its common stock actually issued in connection with the vesting of PSU or RSU awards to satisfy certain U.S. federal and state tax withholding obligations.
v3.24.0.1
Stock-Based Compensation
 12 Months Ended
Dec. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation
20. Stock-Based Compensation
Equity Incentive Plans
2007 Stock Incentive Plan
Effective June 1, 2017, upon the approval and ratification of the Masimo Corporation 2017 Equity Incentive Plan (2017 Equity Plan), the Company’s 2007 Stock Incentive Plan (2007 Equity Plan) terminated, provided that awards outstanding under the 2007 Equity Plan will continue to be governed by the terms of that plan. In addition, upon the effectiveness of the 2017 Equity Plan, an aggregate of 5.0 million shares of the Company’s common stock registered under prior registration statements for issuance pursuant to the 2007 Equity Plan were deregistered and concurrently registered under the 2017 Equity Plan.
2017 Equity Incentive Plan
The 2017 Equity Plan permits the grant of stock options, restricted stock, RSUs, stock appreciation rights, PSUs, performance shares, performance bonus awards and other stock or cash awards to employees, directors and consultants of the Company and employees and consultants of any parent or subsidiary of the Company. Upon effectiveness, an aggregate of 5.0 million shares were available for issuance under the 2017 Equity Plan. In May 2020, the Company’s stockholders approved an increase of 2.5 million shares to the 2017 Equity Plan. The aggregate number of shares that may be awarded under the 2017 Equity Plan is 7.5 million shares. The 2017 Equity Plan provides that at least 95% of the equity awards issued under the 2017 Equity Plan must vest over a period of not less than one year following the date of grant. The exercise price per share of each option granted under the 2017 Equity Plan may not be less than the fair market value of a share of the Company’s common stock on the date of grant, which is generally equal to the closing price of the Company’s common stock on the Nasdaq Global Select Market on the grant date.
Total stock-based compensation expense under both the 2007 Equity Plan and the 2017 Equity Incentive Plan for the years ended December 30, 2023, December 31, 2022 and January 1, 2022 was $7.0 million, $47.7 million and $44.6 million, respectively.
Additional information related to the Company’s current equity incentive plans, stock-based award activity and valuation of stock-based awards is included below.
Stock-Based Award Activity
Stock Options
The number and weighted-average exercise price of options issued and outstanding under all of the Company’s equity plans are as follows:
Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
(in millions, except for weighted-average exercise prices)SharesWeighted-Average
Exercise
Price		SharesWeighted-Average
Exercise
Price		SharesWeighted-Average
Exercise
Price
Options outstanding, beginning of period2.8 $83.85 2.9 $81.38 3.4 $77.44 
Granted0.1 177.29 0.1 150.91 0.1 250.15 
Canceled— 45.96 (0.1)162.77 (0.2)149.11 
Exercised(0.2)43.22 (0.1)54.53 (0.4)53.55 
Options outstanding, end of period2.7 $87.79 2.8 $83.85 2.9 $81.38 
Options exercisable, end of period2.4 $73.79 2.4 $65.83 2.2 $57.09 
Total stock option expense for the years ended December 30, 2023, December 31, 2022 and January 1, 2022 was $8.8 million, $11.4 million and $13.0 million, respectively. As of December 30, 2023, the Company had $15.2 million of unrecognized compensation cost related to non-vested stock options that are expected to vest over a weighted-average period of approximately 2.3 years.
The number and weighted-average exercise price of outstanding and exercisable stock options segregated by exercise price ranges were as follows:
Year Ended
December 30,
2023
Year Ended
December 31,
2022
(in millions, except range of exercise prices and average remaining contractual life)
Options OutstandingOptions
Exercisable		Options OutstandingOptions
Exercisable
Range of Exercise PricesNumber of
Options		Average
Remaining
Contractual
Life		Number of
Options		Number of
Options		Average
Remaining
Contractual
Life
Number of
Options
$15.00 to $50.00
1.2 1.51.2 1.3 2.41.3 
$50.01 to $80.00
— 2.5— 0.1 3.70.1 
$80.01 to $120.00
0.7 3.70.7 0.8 4.80.7 
$120.01 to $160.00
0.4 6.00.3 0.4 7.10.2 
$160.01 to $200.00
0.3 7.00.1 0.2 7.20.1 
$200.01 to $230.00
— 6.5— — 7.2— 
$230.01 to $280.00
0.1 7.00.1 — 8.0— 
Total
2.7 4.92.4 2.8 4.32.4 
As of December 30, 2023 and December 31, 2022, the weighted-average remaining contractual term of options outstanding was 4.9 years and 4.3 years, respectively. As of December 30, 2023 and December 31, 2022, the weighted-average remaining contractual term of options exercisable with an exercise price less than the closing price of the Company’s common stock was 2.9 years and 3.6 years respectively.
RSUs
The number of RSUs issued and outstanding under all of the Company’s equity plans are as follows:
Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
(in millions, except for weighted-average grant date fair value)
UnitsWeighted-Average
Grant Date
Fair Value		UnitsWeighted-Average
Grant Date
Fair Value		UnitsWeighted-Average
Grant Date
Fair Value
RSUs outstanding, beginning of period3.2 $105.65 3.0 $104.13 2.9 $99.66 
Granted
0.5 125.44 0.3 148.52 0.1 257.43 
Canceled(0.1)172.19 (0.1)168.90 — 204.33 
Vested(0.1)173.18 — 184.04 — 163.71 
RSUs outstanding, end of period3.5 $105.87 3.2 $105.65 3.0 $104.13 
Total RSU expense for the years ended December 30, 2023, December 31, 2022 and January 1, 2022 was $20.1 million, $14.4 million and $9.0 million, respectively. As of December 30, 2023, the Company had $90.7 million of unrecognized compensation cost related to non-vested RSU awards expected to be recognized and vest over a weighted-average period of approximately 4.0 years, excluding any contingent compensation expense related to certain RSUs that were granted to the Company’s Chairman and CEO in connection with the amendment and restatement of his employment agreement. See “Employment and Severance Agreements” in Note 24, “Commitments and Contingencies” for further details on the CEO’s employment agreement.
PSUs
The number of PSUs outstanding under all of the Company’s equity plans are as follows:
Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
(in millions, except for weighted-average grant date fair value)
UnitsWeighted-Average
Grant Date
Fair Value		UnitsWeighted-Average
Grant Date
Fair Value		UnitsWeighted-Average
Grant Date
Fair Value
PSUs outstanding, beginning of period0.3 $180.04 0.3 $168.68 0.4 $120.28 
Granted(1)
0.1 
(1)
204.67 0.3 
(1)
145.49 0.2 250.73 
Canceled— 155.98 (0.1)139.73 — 166.84 
Vested(0.1)179.42 (0.2)127.46 (0.3)86.95 
PSUs outstanding, end of period0.3 $190.04 0.3 $180.04 0.3 $168.68 
(1) On February 27, 2023, the Audit Committee approved the weighted payout percentage for the 2019 PSU awards (three-year performance period), which were based upon the Company’s actual fiscal year 2022 performance against pre-established performance objectives. Included in the granted amount are those additional PSUs earned based on actual performance achieved. These PSUs were originally awarded at target.
During the year ended January 1, 2022, the Company awarded 69,000 PSUs that will vest three years from the award date, based on the achievement of certain fiscal year 2023 performance criteria approved by the Compensation Committee. If earned, the PSUs granted will vest upon achievement of the performance criteria after the year in which the performance achievement level has been determined. The number of shares that may be earned can range from 0% to 200% of the target amount; therefore, the maximum number of shares that can be issued under these awards is twice the original award of 69,000 PSUs, or 138,000 shares.
During the year ended December 31, 2022, the Company awarded 162,562 PSUs that will vest three years from the award date, based on the achievement of certain fiscal year 2024 performance criteria approved by the Compensation Committee. If earned, the PSUs granted will vest upon achievement of the performance criteria after the year in which the performance achievement level has been determined. The number of shares that may be earned can range from 0% to 200% of the target amount; therefore, the maximum number of shares that can be issued under these awards is twice the original award of 162,562 PSUs, or 325,124 shares.
During the year ended December 30, 2023, the Company awarded 103,000 PSUs that will vest three years from the award date, based on the achievement of certain pre-established multi-year performance criteria approved by the Board. Estimates of stock-based compensation expense for an award with performance conditions are based on the probable outcome of the performance conditions and the cumulative effect of any changes in the probability outcomes is recorded in the period in which the changes occur. If earned, the PSUs granted will vest upon achievement of the performance criteria, which include a relative total shareholder return (TSR) component, in the year following the evaluation and confirmation of the performance achievement criteria. The Company’s TSR is based on the Company’s common stock percentile ranking relative to the constituents of the Nasdaq Composite Index for the performance period beginning on January 1, 2023 and ending on December 31, 2025. The number of shares that may be earned can range from 0% to 200% of the target amount. The fair value of market-based RSUs is determined using a Monte Carlo simulation model, which uses multiple input variables to determine the probability of satisfying the market condition requirements. The fair value of performance-based PSUs is determined using the closing price of the Company’s common stock on the grant date. Based on management’s estimate of the number of units expected to vest, total PSU (benefit) expense for the years ended December 30, 2023, December 31, 2022 and January 1, 2022 was $(21.9) million, $21.9 million and $22.6 million, respectively. The PSU benefit amounts for the years ended December 30, 2023, December 31, 2022 and January 1, 2022 relate to adjustments for the expected life-to-date performance of the PSU. As of December 30, 2023, the Company had $7.2 million of unrecognized compensation cost related to non-vested PSU awards expected to be recognized and vest over a weighted-average period of approximately 1.3 years.
Valuation of Stock-Based Award Activity
The fair value of each RSU and PSU is determined based on the closing price of the Company’s common stock on the grant date.
The Black-Scholes option pricing model is used to estimate the fair value of options granted under the Company’s stock-based compensation plans. The range of assumptions used and the resulting weighted-average fair value of options granted at the date of grant were as follows:
Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
Risk-free interest rate
3.6% to 4.2%
1.0% to 1.9%
0.3% to 0.9%
Expected term (in years)
5.1 years to 5.9 years
5.1 years to 5.7 years
5.1 years to 5.6 years
Estimated volatility
31.6% to 36.7%
31.2% to 38.9%
30.9% to 34.7%
Expected dividends0%0%0%
Weighted-average fair value of options granted$75.08 per share$49.69 per share$75.72 per share
Risk-free interest rate. The risk-free interest rate is based on the implied yield available on U.S. Treasury zero-coupon issues with a remaining term approximately equal to the expected term of the Company’s stock options.
Expected term. The expected term represents the average period that the Company’s stock options are expected to be outstanding. The expected term is based on both the Company’s specific historical option exercise experience, as well as expected term information available from a peer group of companies with a similar vesting schedule.
Estimated volatility. The estimated volatility is the amount by which the Company’s share price is expected to fluctuate during a period. The Company’s estimated volatilities for the years ended December 30, 2023, December 31, 2022 and January 1, 2022 are based on historical and implied volatilities of the Company’s share price over the expected term of the option.
Expected dividends. The Board may from time to time declare, and the Company may pay, dividends on its outstanding shares in the manner and upon the terms and conditions provided by law. Any determination to declare and pay dividends will be made by the Board and will depend upon the Company’s results of operations, earnings, capital requirements, financial condition, business prospects, contractual restrictions and other factors deemed relevant by the Board. In the event a dividend is declared, there is no assurance with respect to the amount, timing or frequency of any such dividends. The dividend declared in 2012 was deemed to be a special dividend and there is no assurance that special dividends will be declared again during the expected term. Based on this uncertainty and unknown frequency, for the years ended December 30, 2023, December 31, 2022 and January 1, 2022, no dividend rate was used in the assumptions to calculate the stock-based compensation expense.
The Company has elected to recognize stock-based compensation expense on a straight-line basis over the requisite service period for the entire award, net of forfeitures. Forfeitures of stock-based awards are recognized as they occur. The total fair value of all options that vested during the years ended December 30, 2023, December 31, 2022 and January 1, 2022 was $9.5 million, $12.4 million and $15.2 million, respectively.
The aggregate intrinsic value of options is calculated as the positive difference, if any, between the market value of the Company’s common stock on the date of exercise or the respective period end, as appropriate, and the exercise price of the options. The aggregate intrinsic value of options outstanding, with an exercise price less than the closing price of the Company’s common stock as of December 30, 2023 was $123.3 million. The aggregate intrinsic value of options exercisable with an exercise price less than the closing price of the Company’s common stock, as of December 30, 2023 was $123.3 million. The aggregate intrinsic value of options exercised during the years ended December 30, 2023, December 31, 2022 and January 1, 2022 was $19.0 million, $14.6 million and $84.7 million, respectively.
The total income tax benefit recognized in the consolidated statements of operations for stock-based compensation expense was $2.9 million, $2.5 million and $16.4 million for the years ended December 30, 2023, December 31, 2022 and January 1, 2022, respectively.
The following table presents the total stock-based compensation expense that is included in each functional line item of the consolidated statements of operations:
(in millions)
Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
Cost of goods sold$1.1 $1.0 $0.8 
Selling, general and administrative(1.5)32.9 31.3 
Research and development7.4 13.8 12.5 
Total
$7.0 $47.7 $44.6 
v3.24.0.1
Employee Benefits
 12 Months Ended
Dec. 30, 2023
Postemployment Benefits [Abstract]  
Employee Benefits
21. Employee Benefits
Defined Contribution Plans
In the U.S., the Company sponsors one qualified defined contribution plan or 401(k) plan, the Masimo Retirement Savings Plan (MRSP), covering the Company’s full-time U.S. employees who meet certain eligibility requirements. On April 11, 2022, in connection with the Sound United acquisition, the MRSP was amended to allow for participation by eligible Sound United employees.
The MRSP matches 100% of a participant’s salary deferral, up to 3% of each participant’s compensation for the pay period, subject to a maximum amount. The Company may also contribute to the MRSP on a discretionary basis. The Company contributed $4.9 million, $4.5 million and $3.4 million to the MRSP for the years ended December 30, 2023, December 31, 2022 and January 1, 2022, respectively, all in the form of matching contributions.
In addition, some of the Company’s international subsidiaries also have defined contribution plans to which both the employee and employers are eligible to make contributions. The Company contributed $5.5 million and $4.3 million for the year ended December 30, 2023 and December 31, 2022, respectively. The Company contributed immaterial amounts to these plans for the year ended January 1, 2022.
Defined Benefit Plans
The Company sponsors several international noncontributory defined benefit plans. In connection with the Sound United acquisition, the Company assumed sponsorship of several international defined benefit plans and post-retirement benefit plans. All defined benefit plans and post-retirement benefit plans assumed by the Company were closed to new participants prior to the Sound United acquisition.
The service cost component for the defined benefit plans are recorded in operating expenses in the consolidated statement of operations. All other cost components are recorded in non-operating loss, net in the consolidated statement of operations.
The following table sets forth the funded status and amounts recognized in the consolidated balance sheet for the Company’s defined benefit plans.
(in millions)December 30,
2023		December 31,
2022
Plan Assets
Fair value of plan assets at beginning of year$22.2 $21.7 
Realized net gains (losses) on plan assets1.1 (2.5)
Employer contributions0.4 1.5 
Participant contributions0.6 0.5 
Benefits paid0.8 2.8 
Foreign currency revaluation and translation gains and (losses)
(2.0)(1.8)
Fair value of plan assets at end of year$23.1 $22.2 
Projected Benefit Obligation
Projected benefit obligation at beginning of year$32.3 $32.3 
Service cost1.2 1.1 
Interest cost0.5 0.1 
Participant contributions0.6 0.5 
Actuarial gains (losses)2.3 (1.9)
Benefits paid(0.5)
(1)
2.0 
Foreign currency revaluation and translation gains and (losses)
(3.8)(1.8)
Projected benefit obligation at end of year$32.6 $32.3 
Funded status$(9.5)$(10.1)
______________
(1)     Due to the timing of a cash transfer, there was a payable as of December 30, 2023, resulting in a negative allocation as of year end.
The net decrease in the fair value of the Company’s plan assets for the year ended December 30, 2023 was principally driven by $4.3 million of foreign currency revaluation on the plan assets, partially offset by $1.1 million of realized gains on assets, and $0.8 million of benefits paid.
The net decrease in the Company’s projected benefit obligation for the year ended December 30, 2023 was primarily driven by $6.1 million of foreign currency revaluation on the project benefit obligation, offset by change in the discount rate from the prior year and $2.3 million of actuarial gains.
The underfunded balance of $9.5 million and $10.1 million was included in the long-term other liabilities on the consolidated balance sheets as of December 30, 2023 and December 31, 2022, respectively.
The Company’s consolidated statement of operations reflect the following components of net periodic defined benefit costs:
(in millions)Year Ended
December 30,
2023		Year Ended
December 31,
2022
Components of net periodic benefit cost $— $— 
Service cost1.2 1.1 
Interest cost0.5 0.1 
Expected (gains) on plan assets(0.7)(0.6)
Amortization of net losses— 0.1 
Recognized net actuarial loss— 0.3 
Net periodic defined benefit plan cost$1.0 $1.0
The amounts provided above for amortization of prior service costs (credits) and amortization of net losses represent the reclassifications of prior service cost (credits) and net actuarial gain (losses) that were recognized in accumulated other comprehensive (loss) income in prior periods.
Classification of amounts recognized in the consolidated balance sheets are as follows:
(in millions)December 30,
2023		December 31,
2022
Non-current assets$— $— 
Current liability— — 
Non-current liability9.5 10.1 
International defined benefit plans with accumulated benefit obligations in excess of fair value of plan assets consist of the following:
(in millions)December 30,
2023		December 31,
2022
Projected benefit obligation$32.6 $32.3 
Accumulated benefit obligation28.3 31.0 
Fair value of plan assets$23.1 $22.2 
Plan Assumptions
The Company determines actuarial assumptions on an annual basis. The actuarial assumptions used for the Company’s defined benefit plans for international participants will vary depending on the applicable country. On a weighted-average basis, the following assumptions were used to determine benefit obligations and to determine net periodic benefit cost:
Year Ended
December 30,
2023		Year Ended
December 31,
2022
Assumptions - benefit obligations:
Discount rate1.35 %1.61 %
Rate of compensation increase1.04 0.96 
Assumptions - net periodic benefit costs:
Discount rate 1.91 %0.49 %
Rate of compensation increase1.43 0.09 
Expected long-term return on plan assets(1)
3.53 1.70 
Interest credit rate1.98 2.34 
______________
(1)     The pension expected return on assets assumption is derived primarily from underlying investment allocations and historical risk premiums per each plan, adjusted for current and future expectations, such as easing of global inflationary pressure.
Plan Assets
The weighted-average asset allocations at year end by asset category were as follows:
Actual Allocation
Asset category
December 30,
2023		December 31,
2022
Cash and cash equivalents(5.0)%
(1)
3.0 %
Equity securities35.0 30.0 
Debt securities47.0 36.0 
Other24.0 31.0 
______________
(1)     Due to the timing of a cash transfer , there was a payable as of December 30, 2023, resulting in a negative allocation as of year end.
The Plan invests in a diversified portfolio of assets intended to minimize risk of poor returns while maximizing expected portfolio returns. The actual portfolio investment mix may, from time to time, deviate from the established target mix due to various factors such as normal market fluctuations, the reliance on estimates in connection with the determination of allocations and normal portfolio activity such as additions and withdrawals. The target allocations are subject to periodic review, including a review of the asset portfolio’s performance, by the named fiduciary of the plans. Such plans have local independent fiduciary advisors with responsibility for the development and oversight of the investment policy, including asset allocation decisions. In making such decisions, consideration is given to local regulations, investment practices and funding rules. The fair value of investments is included in the fair value hierarchy, see Note 2, “Summary of Significant Accounting Policies”. While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.
Plan Contributions
The Company determines expected funding needs of its defined benefit pension plans based on legal funding requirements, plus any additional amounts that may be appropriate considering the funded status of the plans, tax consequences, the cash flow generated by the Company and other factors. The Company made $0.4 million and $1.5 million contributions to its defined benefit plans for the years ended December 30, 2023 and December 31, 2022, respectively. The Company expects to contribute $1.8 million for the fiscal year 2024.
Estimated Future Benefit Payments
The estimated future benefit payments, based upon the same assumptions used to measure the benefit obligations and expected future employee service, were as follows:
(in millions)Year Ended
December 30,
2023
2024$0.4 
20252.5 
20262.4 
20272.5 
2028
2.2 
Thereafter
4.2 
Total $14.2 
v3.24.0.1
Non-operating Loss
 12 Months Ended
Dec. 30, 2023
Nonoperating Income (Expense) [Abstract]  
Non-operating Loss
22. Non-operating Loss
Non-operating loss consists of the following:
(in millions)
Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
Interest income$3.0 $1.8 $0.9 
Realized and unrealized foreign currency (loss) gain(1.1)7.3 (2.0)
Interest expense(50.3)(25.7)(0.3)
Total non-operating loss$(48.4)$(16.6)$(1.4)
v3.24.0.1
Income Taxes
 12 Months Ended
Dec. 30, 2023
Income Tax Disclosure [Abstract]  
Income Taxes 23. Income Taxes
The components of income before provision for income taxes are as follows:
(in millions)
Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
United States$9.1 $77.6 $221.2 
Foreign79.0 115.8 53.2 
Total
$88.1 $193.4 $274.4 
The following table presents the current and deferred provision (benefit) for income taxes:
(in millions)Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
Current:
Federal$15.0 $48.7 $38.1 
State3.5 6.1 7.1 
Foreign23.7 34.4 14.7 
Subtotal$42.2 $89.2 $59.9 
Deferred:
Federal$(12.5)$(20.5)$(4.9)
State(9.0)(8.7)(6.1)
Foreign(14.1)(10.1)(4.1)
Subtotal
(35.6)(39.3)(15.1)
Total
$6.6 $49.9 $44.8 
Included in the fiscal year 2023, 2022 and 2021 tax provisions are increases of $7.4 million, $4.5 million and $3.6 million, respectively, for tax and accrued interest related to uncertain tax positions for each fiscal year.
The reconciliation of the U.S. federal statutory tax rate to the Company’s effective tax rate is as follows:
Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
Statutory regular federal income tax rate21.0 %21.0 %21.0 %
U.S. tax on foreign income, net10.0 4.8 0.9 
Foreign income taxed at different rates1.1 — (0.3)
Transaction-related costs— 0.9 — 
Nondeductible executive compensation(1.6)2.9 2.1 
Derecognition of uncertain tax position(2.3)(0.8)(1.0)
State provision, net of federal benefit(4.9)(1.0)0.3 
Excess stock-based compensation(3.2)(1.2)(5.5)
Research and development tax credits(5.1)(1.7)(1.8)
Tax Credit(9.2)— — 
Other1.6 0.9 0.6 
Total
7.4 %25.8 %16.3 %
As of December 30, 2023, the Company has accumulated undistributed earnings generated by its foreign subsidiaries of approximately $875.5 million. Because such earnings have previously been subject to U.S. tax are eligible for a dividends received deduction when repatriated, any additional taxes due with respect to such earnings or the excess of the amount for financial reporting over the tax basis of its foreign investments would generally be limited to foreign withholding and state taxes. The Company considers $86.5 million of these accumulated undistributed earnings as no longer permanently reinvested and has accrued foreign withholding and state taxes, net of estimated foreign tax credits, of $1.9 million. The Company intends, however, to indefinitely reinvest the remaining $789.0 million of earnings. If the Company decides to distribute such permanently reinvested earnings, the Company would accrue estimated additional income tax expense of up to approximately $23.1 million.
The components of the deferred tax assets are as follows:
(in millions)December 30,
2023		December 31,
2022
Deferred tax assets:
Net operating losses$53.7 $34.7 
Tax credits33.2 18.0 
Capitalized R&D33.0 18.5 
Deferred revenue28.0 27.8 
Accrued liabilities24.6 32.1 
Interest15.6 22.4 
Stock-based compensation12.3 10.9 
Operating lease liabilities9.7 8.7 
Other7.3 5.8 
Total217.4 178.9 
Valuation allowance(18.9)(7.3)
Total deferred tax assets$198.5 $171.6 
Deferred tax liabilities:
Inventory$(0.8)$(4.0)
Interest rate hedge(1.9)(4.1)
Withholding taxes on undistributed foreign earnings(3.1)(2.8)
State taxes and other(10.4)(7.5)
Operating lease liabilities(11.8)(8.6)
Property and equipment(14.4)(18.2)
Intangible assets(160.5)(186.7)
Other(0.2)(0.9)
Total deferred tax liabilities(203.1)(232.8)
Net deferred tax assets$(4.6)$(61.2)
As of December 30, 2023, the Company has $39.0 million and $208.1 million of net operating losses from federal and various state jurisdictions, which will begin to expire in 2037 and 2024, respectively. Additionally, the Company has $114.7 million of net operating losses from foreign jurisdictions that will begin to expire in 2024. The Company also has federal research and development tax credits of $2.8 million that will begin to expire in 2031, state research and development tax credits of $29.5 million that will carry forward indefinitely, $2.3 million of foreign tax credits on research and development expenditures that will begin to expire in 2042 and $8.2 million of Swiss tax credits that will begin to expire in 2026. In assessing the realizability of deferred tax assets, the Company considers whether it is more-likely-than-not that all or some portion of the deferred tax assets will not be realized. In making this determination, the Company considered all available positive and negative evidence, including scheduled reversals of liabilities, projected future taxable income, tax planning strategies and recent financial performance.
During the year ended December 31, 2022, the Company established a valuation allowance to reduce the deferred tax assets relating to certain acquired operating losses in certain foreign jurisdictions that the Company believes are not likely to be realized. During the year ended December 30, 2023, there was an increase in the valuation allowance of $11.6 million, primarily due to the losses of certain foreign operations, and additional valuation allowance established, within the Purchase Price Allocation measurement period, to reduce the deferred tax assets relating to certain acquired operating losses in certain state jurisdictions that the Company believes are not likely to be realized.
As a result of certain business and employment actions undertaken by the Company, income earned in a certain European country is subject to a reduced tax rate through 2023. For the year ended December 30, 2023 and December 31, 2022, the estimated income tax benefit related to such business arrangement was $1.4 million and $1.7 million, respectively, and impacted net income per diluted share by $0.03 for each year.
The following is a tabular reconciliation of the total amounts of unrecognized tax benefits:
(in millions)Year Ended
December 30,
2023		Year Ended
December 31,
2022
Unrecognized tax benefits (gross), beginning of period$26.1 $21.6 
Increase from tax positions in current period7.9 6.0 
Increase from tax positions in prior period1.3 0.7 
Decrease from tax position in prior period— (0.6)
Lapse of statute of limitations(2.3)(1.6)
Unrecognized tax benefits (gross), end of period$33.0 $26.1 
The amount of unrecognized benefits which, if ultimately recognized, could favorably affect the tax rate in a future period was $30.6 million and $24.0 million as of December 30, 2023 and December 31, 2022, respectively. It is reasonably possible that the amount of unrecognized tax benefits in various jurisdictions may change in the next twelve months due to the expiration of statutes of limitation and audit settlements. However, due to the uncertainty surrounding the timing of these events, an estimate of the change within the next twelve months cannot currently be made.
For the year ended December 30, 2023 the Company recorded an expense of $1.0 million for interest and penalties related to unrecognized tax benefits as part of income tax expense. For the year ended December 31, 2022, the Company recorded a benefit of $0.3 million for interest and penalties related to unrecognized tax benefits as part of income tax expense.
Total accrued interest and penalties related to unrecognized tax benefits as of December 30, 2023 and December 31, 2022 were $2.1 million and $1.1 million, respectively.
The Company conducts business in multiple jurisdictions and, as a result, one or more of the Company’s subsidiaries files income tax returns in U.S. federal, various state, local and foreign jurisdictions. The Company has concluded all U.S. federal income tax matters through fiscal year 2019. All material state, local and foreign income tax matters have been concluded through fiscal year 2016.
The Company does not believe that the results of any tax authority examination would have a significant impact on its consolidated financial statements.
v3.24.0.1
Commitments and Contingencies
 12 Months Ended
Dec. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
24. Commitments and Contingencies

Employment and Severance Agreements
In July 2017, the Company entered into the First Amendment to that certain Amended and Restated Employment Agreement entered into between the Company and Mr. Kiani on November 4, 2015 (as amended, the Amended Employment Agreement). Pursuant to the terms of the Amended Employment Agreement, upon a “Qualifying Termination” (as defined in the Amended Employment Agreement), Mr. Kiani will be entitled to receive a cash severance benefit equal to two times the sum of his then-current base salary and the average annual bonus paid to Mr. Kiani during the immediately preceding three years, the full amount of the “Award Shares” (as defined in the Amended Employment Agreement) and the full amount of the “Cash Payment” (as defined in the Amended Employment Agreement). In addition, in the event of a “Change in Control” (as defined in the Amended Employment Agreement) prior to a Qualifying Termination, on each of the first and second anniversaries of the Change in Control, 50% of the Cash Payment and 50% of the Award Shares will vest, subject in each case to Mr. Kiani’s continuous employment through each such anniversary date; however, in the event of a Qualifying Termination or a termination of Mr. Kiani’s employment due to death or disability prior to either of such anniversaries, any unvested amount of the Cash Payment and all of the unvested Award Shares shall vest and be paid in full. Additionally, in the event of a Change in Control prior to a Qualifying Termination, Mr. Kiani’s stock options and any other equity awards will vest in accordance with their terms, but in no event later than in two equal installments on each of the one year and two year anniversaries of the Change in Control, subject in each case to Mr. Kiani’s continuous employment through each such anniversary date.
On January 14, 2022, the Company entered into the Second Amendment to the Amended Employment Agreement (Second Amendment) with Mr. Kiani. The Second Amendment provides that the RSUs granted to Mr. Kiani pursuant to the Amended Employment Agreement will vest in full upon the termination of Mr. Kiani’s employment with the Company pursuant to Mr. Kiani’s death or disability.
On February 8, 2023, Mr. Kiani agreed that the valid election to the Company’s Board of Directors (Board) at the Company’s 2023 Annual Meeting of Stockholders (2023 Annual Meeting) of any two individuals nominated by the Company’s stockholders in lieu of two of the Company’s then-current Board members would not be deemed to constitute a “Change in Control” for purposes of Section 9(iii) of the Amended Employment Agreement.
On March 22, 2023, in connection with the Board’s unanimous selection of H Michael Cohen as Lead Independent Director, Mr. Kiani voluntarily irrevocably and permanently waived his right to treat the appointment of any lead independent director as “Good Reason”, to terminate his employment under the Amended Employment Agreement, and waived his right to receive contractual separation payments on this basis.
On June 5, 2023, Mr. Kiani, pursuant to a Limited Waiver (Waiver), unconditionally, irrevocably and permanently waived his right, pursuant to the Amended Employment Agreement, to assert that a “Change in Control” has occurred pursuant to Section 9(iii) of the Amended Employment Agreement unless the individuals who constituted the Board at the beginning of the twelve (12) month period immediately preceding such change, as defined in Section 9(iii) of the Amended Employment Agreement, cease for any reason to constitute one-half or more of the directors then in office. In addition, Mr. Kiani agreed that, for purposes of determining whether such a “Change in Control” has occurred, any individual elected to the Board at the Company’s 2023 Annual Meeting will be treated as a member of the Board at the beginning of the twelve (12) month period.
As a result of Mr. Kiani’s execution of the Waiver on June 5, 2023, which waived certain of the “Change in Control” provisions in the Amended Employment Agreement, the Company remeasured the expense related to the Award Shares and Cash Payment that would be recognized in the Company’s consolidated financial statements upon the occurrence of a Qualifying Termination under the Amended Employment Agreement, as amended by the Second Amendment, and the expense was determined to be approximately $479.7 million.
As of December 30, 2023, the Company had severance plan participation agreements with six executive officers. The participation agreements (the Agreements) are governed by the terms and conditions of the Company’s 2007 Severance Protection Plan (the Severance Plan), which became effective on July 19, 2007 and which was amended effective December 31, 2008.
Under each of the Agreements, the applicable executive officer may be entitled to receive certain salary, equity, medical and life insurance benefits if he is terminated by the Company without cause or if he terminates his employment for good reason under certain circumstances. Each executive officer is also required to give the Company six months’ advance notice of his resignation under certain circumstances.
Willow Cross-Licensing Agreement Provisions
The Company’s Cross-Licensing Agreement with Willow contains annual minimum aggregate royalty obligations for use of the rainbow® licensed technology. The current annual minimum royalty obligation is $5.0 million. Upon a change in control (as defined in the Cross-Licensing Agreement) of the Company or Willow: (i) all rights to the “Masimo” trademark will be assigned to Willow if the surviving or acquiring entity ceases to use “Masimo” as a company name and trademark; (ii) the option to license technology developed by Willow for use in blood glucose monitoring will be deemed automatically exercised and a $2.5 million license fee for this technology will become immediately payable to Willow; and (iii) the minimum aggregate annual royalties payable to Willow for carbon monoxide, methemoglobin, fractional arterial oxygen saturation, hemoglobin and/or glucose measurements will increase to $15.0 million per year until the exclusivity period of the agreement ends, plus up to $2.0 million for each additional vital sign measurement with no maximum ceiling for non-vital sign measurements.
Purchase Commitments
Pursuant to contractual obligations with vendors, the Company had $274.5 million of purchase commitments as of December 30, 2023 that are expected to be purchased within one year. These purchase commitments have been made for certain inventory items in order to secure sufficient levels of those items, other critical inventory and manufacturing supplies, and to achieve better pricing.
Other Contractual Commitments
In the normal course of business, the Company may provide bank guarantees to support government hospital tenders in certain foreign jurisdictions. As of December 30, 2023, the Company had approximately $4.3 million in outstanding unsecured bank guarantees.
In certain circumstances, the Company also provides limited indemnification within its various customer contracts whereby the Company indemnifies the parties to whom it sells its products with respect to potential infringement of intellectual property, and against bodily injury caused by a defective Company product. It is not possible to predict the maximum potential amount of future payments under these or similar agreements, due to the conditional nature of the Company’s obligations and the unique facts and circumstances involved. As of December 30, 2023, the Company had not incurred any significant costs related to contractual indemnification of its customers.
Concentrations of Risk
The Company is exposed to credit loss for the amount of its cash deposits with financial institutions in excess of federally insured limits. The Company invests a portion of its excess cash with major financial institutions. As of December 30, 2023, the Company had $163.0 million of bank balances, of which $7.6 million was covered by either the U.S. Federal Deposit Insurance Corporation limit or foreign countries’ deposit insurance organizations.
The Company’s ability to sell its healthcare products to U.S. hospitals depends in part on its relationships with GPOs. Many existing and potential healthcare customers for the Company’s products become members of GPOs. GPOs negotiate pricing arrangements and contracts, sometimes exclusively, with medical supply manufacturers and distributors, and these negotiated prices are made available to a GPO’s affiliated hospitals and other members. During the years ended December 30, 2023, December 31, 2022 and January 1, 2022, revenue from the sale of the Company’s healthcare products to customers that are members of GPOs approximated 53.2%, 53.8% and 51.9% of healthcare revenue, respectively.
For the years ended December 30, 2023, December 31, 2022 and January 1, 2022, the Company had sales through one just-in-time healthcare distributor that represented 18.1%, 10.1%, and 14.6% of consolidated revenue, respectively.
As of December 30, 2023 and December 31, 2022, one healthcare customer represented 6.4% and 9.1%, respectively, of the Company’s consolidated accounts receivable balance. The receivable balance related to such healthcare customer is fully secured by a letter of credit.
As of December 30, 2023, there were no customer concentration risks associated with the Company’s non-healthcare business.
Litigation
On January 9, 2020, the Company filed a complaint against Apple Inc. (Apple) in the United States District Court for the Central District of California for infringement of a number of patents, for trade secret misappropriation, and for ownership and correction of inventorship of a number of Apple patents listing one of its former employees as an inventor. The Company is seeking damages, injunctive relief, and declaratory judgment regarding ownership of the Apple patents. Apple filed petitions for Inter Partes review (IPR) of the asserted patents in the U.S. Patent and Trademark Office (PTO). The PTO instituted IPR of the asserted patents. On October 13, 2020, the District Court stayed the patent infringement claims pending completion of the IPR proceedings. In the IPR proceedings, one or more of the challenged claims of three of the asserted patents were found valid. The challenged claims of nine of the asserted patents were found invalid. On appeal, the U.S. Court of Appeals for the Federal Circuit affirmed all the IPR decisions except it reversed a finding of invalidity for certain dependent claims of one Masimo patent. From April 4, 2023 through May 1, 2023, the District Court held a jury trial on the trade secret, ownership, and inventorship claims. The District Court granted Apple’s motion for judgment as a matter of law on certain trade secrets and denied the remainder of Apple’s motion. On May 1, 2023, the District Court declared a mistrial because the jury was unable to reach a unanimous verdict. The District Court has not yet scheduled a new trial, but has indicated it is prepared to start trial on October 31, 2024.
On June 30, 2021, the Company filed a complaint with the U.S. International Trade Commission (ITC) against Apple for infringement of a number of other patents. The Company filed an amended complaint on July 12, 2021. On August 13, 2021, the ITC issued a Notice of Institution of Investigation on the asserted patents. From June 6, 2022 to June 10, 2022, the ITC conducted an evidentiary hearing. In July and August 2022, Apple filed petitions for IPR of the asserted patents in the PTO. On January 10, 2023, a United States Administrative Law Judge in Washington, D.C. ruled that Apple violated Section 337 of the Tariff Act of 1930 (Section 337), as amended, by importing and selling within the United States certain Apple Watches with light-based pulse oximetry functionality and components, which infringe one of the Company’s pulse oximeter patents. On January 24, 2023, the United States Administrative Law Judge further recommended that the ITC issue an exclusion order and a cease and desist order on certain Apple Watches. On October 26, 2023, the ITC issued a Notice of Final Determination finding a violation of Section 337 by Apple. The ITC determined that that appropriate form of relief is a Limited Exclusion Order (LEO) prohibiting the unlicensed entry of infringing wearable electronic devices with light-based pulse oximetry functionality manufactured by or on behalf of Apple, and a Cease and Desist Order (CDO). The LEO and CDO went into effect after the 60-day Presidential review period expired. The LEO and CDO are currently in effect. Apple’s appeal to the Federal Circuit is pending. On January 30, 2023, the PTO denied institution of IPR proceedings for the Company’s pulse oximeter patents that the ITC ruled were infringed. With respect to the other patents asserted at the ITC, the PTO denied institution of IPR proceedings for two patents and instituted IPR proceedings for two patents in January and February 2023. In the IPR proceedings, one or more of the challenged claims were found valid, while others were found invalid. The time period for the appeal is pending.
On October 20, 2022, Apple filed two complaints against the Company in the U.S. District Court for the District of Delaware alleging that the Masimo W1™ watch infringes six utility and four design patents. Apple is seeking damages and injunctive relief. On December 12, 2022, the Company counterclaimed for monopolization, attempted monopolization, false advertising (and related causes of action) and infringement of ten patents. The Company is seeking damages and injunctive relief. On May 5, 2023, the Court ordered that the two cases be coordinated through the pre-trial stage. The Court is scheduled to hold a case management conference in March 2024 to address the scope of claims and counterclaims for trial and set a trial date. The Company intends to vigorously pursue all of its claims against Apple and believes the Company has good and substantial defenses to Apple’s claims, but there is no guarantee that the Company will be successful in these efforts.
On October 21, 2022, a complaint was filed in the Delaware Court of Chancery against the Company and members of the Company’s Board (Director Defendants) by Politan Capital Management LP and Politan Capital NY LLC (Activist Plaintiffs). The Activist Plaintiffs are managed by Quentin Koffey, who is a member of the Board. The complaint sought to (i) declare certain amendments to the Company’s bylaws that became effective on September 9, 2022 (Bylaw Amendments) unenforceable, (ii) find that the Director Defendants breached their fiduciary duties by approving and implementing the Bylaw Amendments and the shareholder rights plan adopted by the Company on September 9, 2022, and refusing to invalidate certain change of control provisions in the Company’s employment agreement with Joe Kiani, the Company’s Chief Executive Officer (CEO), (iii) invalidate certain change of control provisions in Mr. Kiani’s employment agreement, (iv) permanently enjoin the Company and its Board from taking any actions to prevent the Activist Plaintiffs from exercising their rights in accordance with the Company’s prior bylaws to nominate directors, and (v) award the Activist Plaintiffs their fees, costs and expenses in connection with the action covered by the complaint.
On February 5, 2023 the Board approved and adopted amended and restated bylaws (the Amended and Restated Bylaws) which reverted mostly to the Second Amended and Restated Bylaws of the Corporation, dated as of October 24, 2019 (included as Exhibit 3.1 to the Current Report on Form 8-K, filed by the Corporation with the U.S. Securities and Exchange Commission on October 30, 2019). In addition, effective February 8, 2023, Mr. Kiani agreed that the valid election to the Board at the 2023 Annual Meeting of any two individuals nominated by the Company stockholders in lieu of two of the Company’s then-current Board members would not be deemed to constitute a “Change in Control” for purposes of Section 9(iii) of his employment agreement. On February 8, 2023, the Court informed the parties that the Amended and Restated Bylaws mooted the Bylaw Amendments dispute and continued trial on the change in control provisions. On May 1, 2023, Politan filed a motion for an interim fee award of attorneys’ fees and expenses.
On March 3, 2023, Politan filed a motion for leave to file a second amended and supplemented verified complaint (the Second Amended Complaint), which the Court granted on March 15, 2023. The Second Amended Complaint added the California State Teachers’ Retirement System (CalSTRS) as a co-plaintiff and added several former members of the Company’s Board as additional co-defendants. On July 18, 2023, the Court granted a stipulation to dismiss some of the former Board members. On August 7, 2023, Politan filed a third amended and supplemented complaint. On September 7, 2023, the Court granted the plaintiffs’ motion to dismiss the case without prejudice. On November 17, 2023, the Court granted Politan’s motion for an award of attorneys’ fees and expenses amounting to approximately $18 million.
On August 22, 2023, a putative class action complaint was filed by Sergio Vazquez against the Company and members of its management alleging violations of the federal securities laws. On November 14, 2023, the court appointed Boston Retirement System, Central Pennsylvania Teamsters Pension Fund-Defined Benefit Plan, and Central Pennsylvania Teamsters Pension Fund-Retirement Income Plan 1987 as lead plaintiffs. The lead plaintiffs filed an amended complaint on February 12, 2024. The amended complaint alleges that the Company and members of its management, from May 4, 2022 through August 8, 2023, disseminated materially false and misleading statements and/or concealed material adverse facts relating to the performance of its healthcare business and the success of the Company’s legacy Sound United business. The Company believes it has good and substantial defenses to the claims in the amended complaint, but there is no guarantee that the Company will be successful in these efforts. The Company is unable to determine whether any loss ultimately will occur or to estimate the range of such loss; therefore, no amount of loss has been accrued by the Company in the accompanying consolidated financial statements.
In August 2023, the Company determined to initiate a voluntary recall of select Rad-G® products in connection with an issue that can result in an unintentional change in the power state of the device. On February 14, 2024, we initiated the voluntary recall. On February 21, 2024, we received a subpoena from the Department of Justice seeking documents and information related to the Company’s Rad-G® and Rad-97® products, including information relating to complaints surrounding the products and the Company’s decision to recall the Rad-G®. We are investigating the reasons for the delay between August 2023 and February 2024 when the recall was initiated. We are cooperating with the government and may expend significant financial and managerial resources in connection with responding to the subpoena and any related investigation or any other future requests for information.
From time to time, the Company may be involved in other litigation and investigations relating to claims and matters arising out of its operations in the normal course of business. The Company believes that it currently is not a party to any other legal proceedings which, individually or in the aggregate, would have a material adverse effect on its consolidated financial position, results of operations or cash flows.
v3.24.0.1
Segment and Enterprise Reporting
 12 Months Ended
Dec. 30, 2023
Segment Reporting [Abstract]  
Segment and Enterprise Reporting
25. Segment and Enterprise Reporting
The Company’s reportable segments are determined based upon the Company’s organizational structure and the way in which the Company’s Chief Operating Decision Maker (CODM), the CEO, makes operating decisions and assesses financial performance. The CODM considered several factors including, but not limited to, customer base, technology, and homogeneity of products. The two segments are:
•Healthcare - develops, manufactures, and markets a variety of noninvasive monitoring technologies and hospital automation solutions and therapeutics. This segment includes the Company’s core legacy hospital business and new Masimo-technology-enabled consumer products that are distributed through many channels including e-commerce sites, leading national retailers and specialty chains globally.
•Non-healthcare - designs, develops, manufactures, markets and sells a broad portfolio of premium, high-performance audio products and services.
Income from operations for each segment includes all geographic revenues, related cost of net revenues and operating expenses directly attributable to the segment. The Company uses gross profit, as presented in the Company’s financial reports, as the primary measure of segment profitability. The Company uses the same accounting policies to generate segment results as the Company does for consolidated results. Segment information presented herein reflects the impact of these changes for all periods presented. For the year ended December 30, 2023, intercompany revenues between healthcare and non-healthcare were $7.7 million. For the year ended December 31, 2022, there was no intercompany revenue between healthcare and non-healthcare. All inter-segment transactions and balances are eliminated in consolidation for all periods presented below.
Selected information by reportable segment is presented below for the years ended December 30, 2023, December 31, 2022 and January 1, 2022:
(in millions)Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
Revenues by segment:
Healthcare$1,275.5 $1,340.3 $1,239.2 
Non-healthcare772.6 695.5 — 
Total revenue by segment$2,048.1 $2,035.8 $1,239.2 
Gross profit:
Healthcare$777.1 $870.2 $808.4 
Non-healthcare258.0 252.5 — 
Other(1)
(31.6)(63.9)— 
Gross profit$1,003.5 $1,058.8 $808.4 
__________________
(1)     Management excludes certain corporate expenses from segment gross profit. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment gross profit because management evaluates the operating results of the segments excluding such items.
The Company’s depreciation and amortization by segment are as follows:
(in millions)Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
Total depreciation and amortization by segment:
Healthcare$38.1 $36.0 $35.6 
Non-healthcare60.1 100.1 — 
Total depreciation and amortization by segment
$98.2 $136.1 $35.6 
The Company’s total assets by segment are as follows:
(in millions)December 30,
2023		December 31,
2022
Total assets by segment:
Healthcare$1,631.8 $1,594.1 
Non-healthcare1,390.6 1,597.5 
Corporate overhead19.1 19.0 
Total assets by segment$3,041.5 $3,210.6 
The Company’s consolidated long-lived assets (tangible non-current assets) by geographic area are as follows:
(in millions, except percentages)
Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
Total long-lived assets by geographic area:
United States$317.9 74.6 %$319.7 79.1 %$239.4 86.9 %
International108.0 25.4 84.5 20.9 36.0 13.1 
Total long-lived assets by geographic area$425.9 100.0 %$404.2 100.0 %$275.4 100.0 %
The following schedule presents an analysis of the Company’s revenues based upon the geographic area:
(in millions, except percentages)
Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
Total revenue by geographic area:
United States (U.S.)$1,058.8 51.7 %$1,141.7 56.1 %$822.4 66.4 %
Europe, Middle East and Africa571.9 27.9 523.6 25.7 251.8 20.3 
Asia and Australia351.0 17.1 326.8 16.1 123.6 10.0 
North and South America (excluding U.S.)66.4 3.3 43.7 2.1 41.4 3.3 
     Total revenue by geographic area$2,048.1 100.0 %$2,035.8 100.0 %$1,239.2 100.0 %
v3.24.0.1
Schedule II - Valuation and Qualifying Accounts
 12 Months Ended
Dec. 30, 2023
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
Schedule II - Valuation and Qualifying Accounts
VALUATION AND QUALIFYING ACCOUNTS
Years ended December 30, 2023, December 31, 2022 and January 1, 2022
(in millions)
DescriptionBalance at
Beginning of Period		Additions Charged to
 Expense and Other Accounts		Amounts Charged
 Against Reserve		Balance at
End of Period
Year ended December 30, 2023
Allowance for credit losses$7.9 $(2.7)$(0.2)$5.0 
Allowance for sales returns
5.33.8 (0.4)8.7 
Year ended December 31, 2022
Allowance for credit losses
2.5 5.6 
(1)
(0.2)7.9 
Allowance for sales returns, as adjusted
1.5 11.1 
(1)
(7.3)5.3 
Year ended January 1, 2022
Allowance for credit losses1.8 0.7 — 2.5 
Allowance for sales returns, as adjusted
2.2 (0.6)(0.1)1.5 

DescriptionBalance at
Beginning of Period		Additions Charged to
 Expense and Other Accounts		Amounts Charged
 Against Reserve		Balance at
End of Period
Year ended December 31, 2022
Allowance for sales returns. as previously filed
0.1 0.2 — 0.3 
Year ended January 1, 2022
Allowance for sales returns. as previously filed
1.2 (1.0)(0.1)0.1 
______________
(1)     Additions charged to expense and other accounts include amounts from immaterial business combinations.
(2)     Includes an immaterial correction of an error to the allowance for sales return for the years ended December 31, 2022 and January 1, 2022.
v3.24.0.1
Pay vs Performance Disclosure - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Pay vs Performance Disclosure      
Net income $ 81.5 $ 143.5 $ 229.6
v3.24.0.1
Insider Trading Arrangements
 3 Months Ended
Dec. 30, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.24.0.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP), and include the accounts of the Company and its wholly-owned or controlled subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Fiscal Periods
Fiscal Periods
The Company follows a conventional 52/53 week fiscal year. Under a conventional 52/53 week fiscal year, a 52 week fiscal year includes four quarters of 13 weeks while a 53 week fiscal year includes three 13 week fiscal quarters and one 14 week fiscal quarter. The Company’s last 53 week fiscal year was fiscal year 2020. Fiscal year 2023 was a 52 week fiscal year ended December 30, 2023. All references to years in these notes to consolidated financial statements are fiscal years unless otherwise noted.
Reclassifications
Reclassifications
Certain amounts in the accompanying consolidated financial statements have been reclassified to conform to the current period presentation, including certain balance sheet asset accounts in the consolidated financial statements for the year ended December 31, 2022. There was no impact on previously reported total assets, liabilities, stockholders’ equity or net income.
Use of Estimates
Use of Estimates
The Company prepares its financial statements in conformity with GAAP, which requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates include the determination of standalone selling prices, variable consideration, total consideration allocated to each performance obligation within a contract, inventory valuation, valuation of the Company’s equity awards, valuation of identifiable assets and liabilities connected with business combinations, impairment of long-lived assets, intangible assets and goodwill; derivative and equity instruments, deferred taxes and any associated valuation allowances, deferred revenue, accounting for pensions, uncertain income tax positions, litigation costs, and related accruals. Actual results could differ from such estimates.
Business Combinations
Business Combinations
The Company accounts for business combinations using the acquisition method of accounting in accordance with Accounting Standards Codification (ASC) Topic 805, Business Combinations, which requires that once control is obtained, assets acquired, liabilities assumed and noncontrolling interests in the acquired entity, if applicable, are recorded at their respective fair values at the date of acquisition, with the exception of acquired contract assets and contract liabilities (i.e., deferred revenue) from contracts with customers. These are recognized and measured in accordance with ASC Topic 606, Revenue from Contracts with Customers. The excess of the purchase price over fair values of identifiable assets, liabilities and noncontrolling interests in the acquired entity, if applicable, is recorded as goodwill.
Fair Value Measurements
Fair Value Measurements
The Company accounts for certain financial instruments at their fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its financial instruments using the framework prescribed by ASC Topic 820, Fair Value Measurements and Disclosures, and considers the estimated amount the Company would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and the Company’s creditworthiness for unrealized loss positions. In certain instances, the Company may utilize financial models to measure the fair value of its financial instruments. In doing so, the Company uses inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means.
Recurring Fair Value Measurement
On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. Authoritative guidance describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
●    Level 1—Quoted prices in active markets for identical assets or liabilities.
●    Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.
●    Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
The following tables represent the Company’s financial assets, measured at fair value on a recurring basis at December 30, 2023:
Fair Value Measurement Hierarchy
(in millions)Total Carrying
Value		Level 1Level 2Level 3
Assets
Cash and cash equivalents$87.0 $87.0 $— $— 
Money market funds76.0 76.0 — — 
Pension assets:
Cash and cash equivalents(1.2)
(1)
(1.2)— — 
Equity securities8.1 8.1 — — 
Debt securities10.7 9.9 0.8 — 
Real estate funds3.1 — 3.1 — 
Alternative investments1.9 — 1.9 — 
Other0.5 — 0.5 — 
Equity securities1.7 1.7 — — 
Derivative instruments - cash flow hedges(2)
11.6 11.6 — — 
Derivative instruments - warrants1.0 1.0 — — 
Total assets$200.4 $194.1 $6.3 $— 
Liabilities
Derivative instruments - cash flow hedge$3.6 $3.6 $— $— 
Pension benefit obligation32.6 32.6 — — 
Total liabilities$36.2 $36.2 $— $— 
______________
(1)     Due to the timing of a cash transfer, there was a payable as of December 30, 2023, resulting in a negative allocation as of year end.
(2)    Includes accrued interest.
The following tables represent the Company’s financial assets, measured at fair value on a recurring basis at December 31, 2022:
Fair Value Measurement Hierarchy
(in millions)Total Carrying
Value		Level 1Level 2Level 3
Assets
Cash and cash equivalents$148.5 $148.5 $— $— 
U.S. treasuries— — — — 
Money market funds54.4 54.4 — — 
Pension assets:
      Cash and cash equivalents1.0 1.0 — — 
      Equity securities 6.6 6.6 — — 
      Debt securities8.0 7.2 0.8 — 
      Real estate funds3.5 — 3.5 — 
      Alternative investments1.9 — 1.9 — 
      Other1.2 — 1.2 — 
Derivative instruments - cash flow hedges19.7 — 19.7 — 
Total assets$244.8 $217.7 $27.1 $— 
Liabilities
Pension benefit obligation$32.3 $32.3 $— $— 
Total liabilities$32.3 $32.3 $— $— 
The Company invests in checking, savings and money market fund accounts, which are classified within Level 1 of the fair value hierarchy as they are valued using quoted market prices. These investments are classified as cash and cash equivalents within the Company’s accompanying consolidated balance sheets, in accordance with GAAP and its accounting policies.
The Company has certain strategic investments in privately-held companies (non-marketable equity securities) and companies that have completed initial public offerings (marketable equity securities). The Company’s marketable equity securities, whose price is based on quoted market price in an active market, are classified within Level 1 of the fair value hierarchy. Equity securities are classified as current, short-term investments, or non-current, recorded in other non-current assets, based on the nature of the securities and their availability for use in current operations. The changes in the fair value of those equity securities are measured at each reporting date and changes in the value of these investments between reporting dates are recorded within non-operating income (loss).
The Company’s pension assets consist of Level 1 and Level 2 investments. The fair values of Level 2 assets are based on observable inputs such as prices or quotes for similar assets, adjusted for any differences in terms or conditions that may affect the value of the instrument being valued. The valuation techniques used for Level 2 assets may include the use of models or other valuation techniques, but these methods are all based on observable market inputs.
The Company also has investments in certain derivative instruments, which are measured at fair value and classified within Level 3 of the fair value hierarchy.
Non-Recurring Fair Value Measurements
For certain other financial assets and liabilities, including restricted cash, accounts receivable, accounts payable and other current assets and liabilities, the carrying amounts approximate their fair value primarily due to the relatively short maturity of these balances. The Company also measures certain non-financial assets at fair value on a non-recurring basis, primarily goodwill, intangible assets and operating lease right-of-use assets, in connection with periodic evaluations for potential impairment.
Furthermore, the Company did not elect to apply the fair value option to specific assets or liabilities on a contract-by-contract basis. The Company did not have any transfers between Level 2 and Level 3 during the years ended December 30, 2023 and December 31, 2022.
Cash and Cash Equivalents
Cash and Cash Equivalents
The Company considers all highly liquid investments with an original maturity from the date of purchase of three months or less, or highly liquid investments that are readily convertible into known amounts of cash, to be cash equivalents. The Company carries cash and cash equivalents at cost, which approximates fair value, and they are Level 1 under the fair value hierarchy.
Accounts Receivable and Allowance for Credit Losses
Accounts Receivable and Allowance for Credit Losses
Accounts receivable consist of trade receivables recorded at the time of invoicing of product sales, reduced by reserves for estimated bad debts and returns. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Credit is extended based on an evaluation of the customer’s financial condition. Collateral is generally not required. The Company records an allowance for credit losses that it does not expect to collect based on relevant information, including historical experience, current conditions, and reasonable and supportable forecasts. Accounts are charged off against the allowance when the Company believes they are uncollectible. The allowance for credit losses is measured on a collective (pool) basis when similar risk characteristics exist. Based on the risk characteristics, the Company has identified U.S. and international customers as separate portfolios for both segments, and measures expected credit losses on such receivables using an aging methodology.
Inventories
Inventories
Inventories are stated at the lower of cost or net realizable value. Cost is determined using a standard cost method, which approximates the first in, first out method, and includes material, labor and overhead costs. Inventory valuation adjustments are recorded for inventory items that have become excess or obsolete or are no longer used in current production and for inventory items that have a market price less than the carrying value in inventory. The Company generally determines inventory valuation adjustments based on an evaluation of the expected future use of its inventory on an item by item basis and applies historical obsolescence rates to estimate the loss on inventory expected to have a recovery value below cost. The Company also records other specific inventory valuation adjustments when it becomes aware of unique events or circumstances that result in an expected recovery value below cost. For inventory items that have been written down, the reduced value becomes the new cost basis.
Property and Equipment
Property and Equipment
Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over estimated useful lives as follows:
Useful Lives
Buildings and building improvements
7 to 39 years
Computer equipment and software
2 to 12 years
Demonstration units
2 to 3 years
Furniture and office equipment
2 to 15 years
Leasehold improvementsLesser of useful life or term of lease
Machinery, equipment and tooling
3 to 20 years
Operating lease assetsLesser of useful life or term of lease
Transportation, vehicles and other
1 to 20 years
Land is not depreciated and construction-in-progress is not depreciated until placed in service. Normal repair and maintenance costs are expensed as incurred, whereas significant improvements that materially increase values or extend useful lives are capitalized and depreciated over the remaining estimated useful lives of the related assets. Upon sale or retirement of depreciable assets, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss on the sale or retirement is recognized in income.
Lessee Right-of-Use (ROU) Assets and Lease Liabilities
Lessee Right-of-Use (ROU) Assets and Lease Liabilities
The Company determines if an arrangement contains a lease at inception. ROU assets represent the Company’s right to use an asset underlying an operating lease for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from an operating lease. ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company generally estimates the applicable discount rate used to determine the net present value of lease payments based on available information at the lease commencement date. Many of the Company’s lessee agreements include options to extend the lease, which the Company does not include in its lease terms unless they are reasonably certain to be exercised. The Company utilizes a portfolio approach to account for the ROU assets and liabilities associated with certain equipment leases.
The Company has also made an accounting policy election not to separate lease and non-lease components for its real estate leases and to exclude short-term leases with a term of twelve months or less from its ROU assets and lease liabilities. Rental expense for lease payments related to operating leases is recognized on a straight-line basis over the lease term.
Intangible Assets
Intangible Assets
Intangible assets consist primarily of patents, trademarks, software development costs, customer relationships and acquired technology. Costs related to patents and trademarks, which include legal and application fees, are capitalized and amortized over the estimated useful lives using the straight-line method. Patent and trademark amortization commences once final approval of the patent or trademark has been obtained. Patent costs are amortized over the lesser of 10 years or the patent’s remaining legal life, which assumes renewals, and trademark costs are amortized over 17 years, and their associated amortization cost is included in selling, general and administrative expense in the accompanying consolidated statements of operations. For intangibles purchased in an asset acquisition or business combination, which mainly include patents, trademarks, customer relationships and acquired technologies, the useful life is determined largely by valuation estimates of remaining economic life.
The Company’s policy is to renew its patents and trademarks. Costs to renew patents and trademarks are capitalized and amortized over the remaining useful life of the intangible asset. The Company periodically evaluates the amortization period and carrying basis of patents and trademarks to determine whether any events or circumstances warrant a revised estimated useful life or reduction in value. Capitalized application costs are charged to operations when it is determined that the patent or trademark will not be obtained or is abandoned.
Software development costs are accounted for in accordance with ASC Topic 985-20, Software - Costs of Software to be Sold, Leased, or Marketed. Once technological feasibility has been established, qualifying costs incurred in development are capitalized until available for general release to customers, and subsequently reported at the lower of unamortized cost or net realizable value.
Intangibles purchased as part of an asset acquisition or business combination historically have included patents, trademarks, customer relationships, developed technologies and contractual licenses. In certain circumstances, the Company has also acquired non-compete agreements tied to certain employment relationships. The useful life for all of these is largely determined by valuation estimates of remaining economic life. In connection with the Sound United acquisition, the Company acquired certain trademarks/tradenames, which are intangible assets with indefinite useful lives. These brands are expected to maintain brand value for an indefinite period of time.
Impairment of Goodwill, Intangible Assets and Other Long-Lived Assets
Impairment of Goodwill, Intangible Assets and Other Long-Lived Assets
Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the acquired net tangible and intangible assets. Goodwill is not amortized, but instead is tested annually for impairment, or more frequently when events or changes in circumstances indicate that goodwill might be impaired. In assessing goodwill impairment, the Company has the option to first assess the qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. The Company has two reporting units, healthcare and non-healthcare. The Company’s qualitative assessment of the recoverability of goodwill considers various macro-economic, industry-specific and Company-specific factors, including: (i) severe adverse industry or economic trends; (ii) significant Company-specific actions; (iii) current, historical or projected deterioration of the Company’s financial performance; or (iv) a sustained decrease in the Company’s market capitalization below its net book value. If the qualitative assessment indicates that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying value, or if the Company elects to bypass the qualitative analysis, then the Company performs a quantitative analysis that compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, a goodwill impairment loss is recognized for the lesser of: (a) the amount that the carrying amount of such reporting unit exceeds its fair value; or (b) the amount of the goodwill allocated to such reporting unit. The annual impairment test is performed during the fourth fiscal quarter.
Similar to goodwill, indefinite-lived intangible assets are not amortized but instead are subject to annual impairment testing, unless circumstances dictate more frequent testing, if impairment indicators exist. Impairment for indefinite-lived assets exists if the carrying value of the indefinite-lived intangible asset exceeds its fair value. Determining whether impairment indicators exist and estimating the fair value of the Company’s indefinite-lived intangible assets if necessary for impairment testing require significant judgment. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors.
The Company reviews finite-lived intangible assets and long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.
Employee Defined Benefit Plans
Employee Defined Benefit Plans
The Company maintains noncontributory defined benefit plans that cover certain employees in certain international locations. The Company recognizes the funded status, or the difference between the fair value of plan assets and the projected benefit obligations of the pension plan on the consolidated balance sheet, with a corresponding adjustment to accumulated other comprehensive (loss) income. If the projected benefit obligation exceeds the fair value of plan assets, the difference or underfunded status represents the pension liability. The Company records a net periodic pension cost in the consolidated statement of operations. The liabilities and annual income or expense are determined using methodologies that involve several actuarial assumptions, the most significant of which are the discount rate and the expected long-term rate of asset return. The Company’s accounting policy includes an annual re-measurement of pension assets and obligations. In addition, the Company re-measures pension assets and obligations for significant events, as of the nearest month-end date on the calendar. The fair values of plan assets are determined based on prevailing market prices. See Note 21, “Employee Benefits”, for further details.
Income Taxes
Income Taxes
The Company accounts for income taxes using the asset and liability method, under which the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for net operating loss and tax credit carryforwards. Tax positions that meet a more-likely-than-not recognition threshold are recognized in the first reporting period that it becomes more-likely-than-not such tax position will be sustained upon examination. A tax position that meets this more-likely-than-not recognition threshold is recorded at the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Previously recognized income tax positions that fail to meet the recognition threshold in a subsequent period are derecognized in that period. Differences between actual results and the Company’s assumptions, or changes in the Company’s assumptions in future periods, are recorded in the period they become known. The Company records potential accrued interest and penalties related to unrecognized tax benefits in income tax expense.
As a multinational corporation, the Company is subject to complex tax laws and regulations in various jurisdictions. The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws themselves are subject to change as a result of changes in fiscal policy, changes in legislation, evolution of regulations and court rulings. Therefore, the actual liability for U.S. or foreign taxes may be materially different from the Company’s estimates, which could result in the need to record additional liabilities or potentially to reverse previously recorded tax liabilities.
Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance is recorded against any deferred tax assets when, in the judgment of management, it is more-likely-than-not that all or part of a deferred tax asset will not be realized. In assessing the need for a valuation allowance, the Company considers all positive and negative evidence, including recent financial performance, scheduled reversals of temporary differences, projected future taxable income, availability of taxable income in carryback periods and tax planning strategies.
Income taxes are highly susceptible to changes from period to period, requiring management to make assumptions about the Company’s future income over the lives of its deferred tax assets and the impact of changes in valuation allowances. Any difference in the assumptions, judgments and estimates mentioned above could result in changes to the Company’s results of operations.
Revenue Recognition, Deferred Revenue and Other Contract Liabilities
Revenue Recognition, Deferred Revenue and Other Contract Liabilities
The Company generally recognizes revenue following a single, principles-based five-step model to be applied to all contracts with customers and generally provides for the recognition of revenue in an amount that reflects the consideration to which the Company expects to be entitled, net of allowances for estimated returns, discounts or sales incentives, as well as taxes collected from customers that are remitted to government authorities when control over the promised goods or services are transferred to the customer.
Healthcare segment
While the majority of the Company’s healthcare segment revenue contracts and transactions contain standard business terms and conditions, there are some transactions that contain non-standard business terms and conditions. As a result, contract interpretation, judgment and analysis are required to determine the appropriate accounting, including: (i) the amount of the total consideration, as well as variable consideration, (ii) whether the arrangement contains an embedded lease, and if so, whether such embedded lease is a sales-type lease or an operating lease, (iii) the identification of the distinct performance obligations contained within the arrangement, (iv) how the arrangement consideration should be allocated to each performance obligation when multiple performance obligations exist, including the determination of standalone selling price, and (v) when to recognize revenue on the performance obligations. Changes in judgments on these assumptions and estimates could materially impact the timing of revenue recognition. Revenue from fixed lease payments related to equipment supplied under sales-type lease arrangements is recognized once control over the equipment is transferred to the customer, while revenue from fixed lease payments related to equipment supplied under operating-type lease arrangements is generally recognized on a straight-line basis over the term of the lease and variable lease payments are recognized as they occur.
The Company derives the majority of its healthcare segment revenue from four primary sources: (i) direct sales under deferred equipment agreements with end-user hospitals where the Company provides up-front monitoring equipment at no up-front charge in exchange for a multi-year sensor purchase commitment; (ii) other direct sales of noninvasive monitoring solutions to end-user hospitals, emergency medical response organizations and other direct customers; (iii) sales of noninvasive monitoring solutions to distributors who then typically resell to end-user hospitals, emergency medical response organizations and other customers; and (iv) sales of integrated circuit boards to OEM customers who incorporate the Company’s embedded software technology into their multiparameter monitoring devices. Subject to customer credit considerations, the majority of such sales are made on open accounts using industry standard payment terms based on the geography within which the specific customer is located.
The Company enters into agreements to sell its monitoring solutions and services, sometimes as a part of arrangements with multiple performance obligations that include various combinations of product sales, equipment leases, software and services. In the case of contracts with multiple performance obligations, the authoritative guidance provides that the total consideration be allocated to each performance obligation on the basis of relative standalone selling prices. When a standalone selling price is not readily observable, the Company estimates the standalone selling price by considering multiple factors including, but not limited to, features and functionality of the product, geographies, type of customer, contractual prices pursuant to Group Purchasing Organization (GPO) contracts, the Company’s pricing and discount practices, and other market conditions.
Sales under deferred equipment agreements are generally structured such that the Company agrees to provide certain monitoring-related equipment, software, installation, training and/or warranty support at no up-front charge in exchange for the customer’s commitment to purchase sensors over the term of the agreement, which generally ranges from three years to six years. The Company allocates contract consideration under deferred equipment agreements containing fixed annual sensor purchase commitments to the underlying lease and non-lease components at contract inception. In determining whether any underlying lease components are related to a sales-type lease or an operating lease, the Company evaluates the customer’s rights and ability to control the use of the underlying equipment throughout the contract term, including any equipment substitution rights retained by the Company, as well as the Company’s expectations surrounding potential contract/lease extensions or renewals and the customer’s likelihood to exercise any purchase options.
Beginning in 2022, for contracts that contain variable lease payments that are not dependent on an index or rate, the Company classifies as operating leases any lease components that would have otherwise been classified as sales-type leases that would result in a selling loss upon lease commencement. Revenue allocable to non-lease performance obligations is generally recognized as such non-lease performance obligations are satisfied. Revenue allocable to lease components under sales-type lease arrangements is generally recognized when control over the equipment is transferred to the customer. Revenue allocable to lease components under operating lease arrangements is generally recognized over the term of the operating lease. The Company generally does not expect to derive any significant value in excess of such asset’s unamortized book value from equipment underlying its operating lease arrangements after the end of the agreement.
Revenue from the sale of products and software, to end-user hospitals, emergency medical response organizations, other direct customers, distributors and OEM customers, is recognized by the Company when control of such performance obligations transfers to the customer based upon the terms of the contract or underlying purchase order.
Revenue related to OEM rainbow® parameter software licenses is recognized by the Company upon the OEM’s shipment of its product to its customer, as reported to the Company by the OEM.
The Company provides certain customers with various sales incentives that may take the form of discounts or rebates. The Company records estimates related to these programs as a reduction to revenue at the time of sale. In general, customers do not have a right of return for credit or refund. However, the Company allows returns under certain circumstances. At the end of each period, the Company estimates and accrues for these returns as a reduction to revenue. The Company estimates the revenue constraints related to these forms of variable consideration based on various factors, including expected purchasing volumes, prior sales and returns history, and specific contractual terms and limitations.
Non-healthcare segment
Non-healthcare segment revenue is related to hardware and embedded software that is integrated into final products that are manufactured and sold by the Company. Products and related software are accounted for as a single performance obligation and all intended functionality is available to the customer upon purchase. Non-healthcare segment revenue is recognized upon transfer of control of promised products or service to customers, which is either upon shipment or upon delivery to the customers, depending on delivery terms. The Company offers sales incentives and has customer programs consisting primarily of discounts and market development fund programs, and records them as contra revenue. Estimates for sales incentives are developed using the most likely amount and are included in the transaction price to the extent that a significant reversal of revenue would not result once the uncertainty is resolved. In developing these estimates, the Company also considers the susceptibility of the incentive to outside influences, the length of time until the uncertainty is resolved and the Company’s experience with similar contracts. Reductions in revenue related to discounts are allocated to products on a relative basis based on their respective standard selling price if there are undelivered products in a contract. Judgment is required to determine the timing and amount of recognition of marketing funds, which the Company estimates based on past practice of providing similar funds.
Payment terms and conditions vary among the Company’s distribution channels although terms generally include a requirement of payment within 30 to 60 days of product shipment. Sales made directly to customers from the Company’s website are paid at the time of product shipment. Prior to determining payment terms for each customer, an evaluation of such customer’s credit risk is performed. Contractual allowances are an offset to accounts receivable.
Shipping and Handling Costs and Fees
Shipping and Handling Costs and Fees
All shipping and handling costs are expensed as incurred and are recorded as a component of cost of goods sold in the accompanying consolidated statements of operations. Charges for shipping and handling billed to customers are included as a component of revenue.
Taxes Collected From Customers and Remitted to Governmental Authorities
Taxes Collected From Customers and Remitted to Governmental Authorities
The Company’s policy is to present revenue net of taxes collected from customers and remitted to governmental authorities.
Deferred Costs and Other Contract Assets
Deferred Costs and Other Contract Assets
The costs of monitoring-related equipment provided to customers under operating lease arrangements within the Company’s deferred equipment agreements are generally deferred and amortized to cost of goods sold over the life of the underlying contracts. Some of the Company’s deferred equipment agreements also contain provisions for certain allowances to be made directly to the end-user hospital customer at the inception of the arrangement. These allowances are generally allocated to the lease and non-lease components and recognized as a reduction to revenue as the underlying performance obligations are satisfied.
The Company generally invoices its customers under deferred equipment agreements as sensors are provided to the customer. However, the Company may recognize revenue for certain non-lease performance obligations under deferred equipment agreements with fixed annual commitments at the time such performance obligations are satisfied and prior to the customer being invoiced. When this occurs, the Company records an unbilled contract receivable related to such revenue until the customer has been invoiced pursuant to the terms of the underlying deferred equipment agreement.
The incremental costs of obtaining a contract with a customer are capitalized and deferred if the Company expects such costs to be recoverable over the life of the contract and the contract term is greater than one year. Such deferred costs generally relate to certain incentive sales commissions earned by the Company’s internal sales team in connection with the execution of deferred equipment agreements and are amortized to expense over the expected term of the underlying contract.
The Company recognizes non-healthcare royalty revenue associated with certain prepaid license arrangements. The Company recognizes non-healthcare revenue from the prepaid license arrangements based upon sales-based royalties when a subsequent sale occurs.
Warranty
Warranty
The Company generally provides a warranty against defects in material and workmanship for a period ranging from six months to forty-eight months, depending on the product type. In traditional sales activities, including direct and OEM sales, the Company establishes an accrued liability for the estimated warranty costs at the time of revenue recognition, with a corresponding provision to cost of goods sold. Customers may also purchase extended warranty coverage or service level upgrades separately or as part of a deferred equipment agreement. Revenue related to extended warranty coverage and service level upgrades is generally recognized over the life of the contract, which reasonably approximates the period over which such services will be provided. The related extended warranty and service level upgrade costs are expensed as incurred.
Changes in the product warranty accrual were as follows:
Year Ended
(in millions)December 30,
2023		December 31,
2022		January 1,
2022
Product warranty accrual, beginning of period$10.6 $2.5 $2.7 
Increase related to acquisition, net of reserve— 8.4 — 
Accrual for warranties issued7.8 1.8 2.2 
Changes in pre-existing warranties (including changes in estimates)(7.5)4.7 (1.4)
Settlements made(2.3)(6.8)(1.0)
Product warranty accrual, end of period$8.6 $10.6 $2.5 
Advertising Costs
Advertising Costs
Advertising costs are expensed as incurred. These costs are included in selling, general and administrative expense in the accompanying consolidated statements of operations. Advertising costs for the years ended December 30, 2023, December 31, 2022 and January 1, 2022, were $61.4 million, $49.3 million, and $9.0 million, respectively. Advertising costs for the year ended December 31, 2022 has been adjusted due to an immaterial correction of an error from the previously reported amount of $12.3 million.
Research and Development
Research and Development
Costs related to research and development activities are expensed as incurred. These costs include personnel costs, materials, depreciation and amortization on associated tangible and intangible assets and an allocation of facility costs, all of which are directly related to research and development activities.
Litigation Costs and Contingencies
Litigation Costs and Contingencies
The Company records a charge equal to at least the minimum estimated liability for a loss contingency or litigation settlement when both of the following conditions are met: (i) information available prior to issuance of the financial statements indicates that it is probable that a liability had been incurred at the date of the financial statements, and (ii) the range of loss can be reasonably estimated. The determination of whether a loss contingency or litigation settlement is probable or reasonably possible involves a significant amount of management judgment, as does the estimation of the range of loss given the nature of contingencies. Liabilities related to litigation settlements with multiple elements are recorded based on the fair value of each element. Legal and other litigation related expenses are recognized as the services are provided. The Company records insurance and other indemnity recoveries for litigation expenses when both of the following conditions are met: (a) the recovery is probable, and (b) collectability is reasonably assured. Insurance recoveries are only recorded to the extent the litigation costs to which they relate have been incurred and recognized in the financial statements.
Foreign Currency Translation
Foreign Currency Translation
The Company’s international headquarters is in Switzerland, and its functional currency is the U.S. Dollar. The Company has many other foreign subsidiaries, and the largest transactions in foreign currency translations occur in the Japanese Yen, the British Pound, the Chinese Yuan and the European Euro.
The Company records certain revenues and expenses in foreign currencies. These revenues and expenses are translated into U.S. Dollars based on the average exchange rate for the reporting period. Assets and liabilities denominated in foreign currencies are translated into U.S. Dollars at the exchange rate in effect as of the balance sheet date. Translation gains and losses related to foreign currency assets and liabilities of a subsidiary that are denominated in the functional currency of such subsidiary are included as a component of accumulated other comprehensive (loss) income within the accompanying consolidated balance sheets. Realized and unrealized foreign currency gains and losses related to foreign currency assets and liabilities of the Company, or a subsidiary that are not denominated in the underlying functional currency are included as a component of non-operating income (loss) within the accompanying consolidated statements of operations.
Derivatives Instruments and Hedging Activities
Derivatives Instruments and Hedging Activities
The Company addresses market risk from changes in interest rates risks through risk management programs, which include the use of derivative instruments. The Company’s exposure to a counterparty’s credit risk is generally limited to the amounts of the net obligation to the counterparty. The Company established policies to enter into contracts only with major investment-grade financial institutions to mitigate such counterparty credit risk. The Company also established a policy to further monitor the counterparty risks throughout the life of the instruments. None of the derivative instruments currently held by the Company were entered into for speculative trading purposes.
All derivative financial instruments are recognized as either assets or liabilities at fair value in the consolidated balance sheets and are classified as short-term or long-term based on the tenor of the instrument. The Company has elected not to separate a derivative instrument into current and long-term portions. A derivative instrument whose fair value is a net liability is classified as current in total. A derivative instrument whose fair value is a net asset and whose current portion is an asset is classified as non-current in total. For a derivative instrument that meets the criteria to qualify for hedge accounting, the Company marks the fair value of the derivative instrument to market periodically through other comprehensive (loss) income. When the hedged items are recorded to income (loss), the associated deferred gains (losses) of the derivatives in accumulated other comprehensive (loss) income will be reclassified into earnings. Any fluctuation in the fair value of a derivative instrument that does not meet the criteria for hedge accounting is recorded to earnings (expense) in the period it occurs.
Comprehensive (Loss) Income
Comprehensive (Loss) Income
Comprehensive (loss) income includes foreign currency translation adjustments, changes to pension benefits, unrealized gains (losses) on cash flow hedges and any related tax benefits (expenses) that have been excluded from net income and reflected in stockholders’ equity.
Net Income Per Share
Net Income Per Share
A computation of basic and diluted net income per share is as follows:
Year Ended
(in millions, except per share amounts)December 30,
2023		December 31,
2022		January 1,
2022
Net income$81.5 $143.5 $229.6 
Basic net income per share:
Weighted-average shares outstanding - basic52.8 53.6 55.2 
Net income per basic share$1.54 $2.68 $4.16 
Diluted net income per share:
Weighted-average shares outstanding - basic52.8 53.6 55.2 
Diluted share equivalents: stock options, RSUs and PSUs1.3 1.6 2.5 
Weighted-average shares outstanding - diluted54.1 55.2 57.7 
Net income per diluted share$1.51 $2.60 $3.98 
Basic net income per share is computed by dividing net income by the weighted-average number of shares outstanding during the period. Net income per diluted share is computed by dividing the net income by the weighted-average number of shares and potential shares outstanding during the period, if the effect of potential shares is dilutive. Potential shares include incremental shares of stock issuable upon the exercise of stock options and the vesting of both restricted share units (RSUs) and performance stock units (PSUs). For the years ended December 30, 2023, December 31, 2022 and January 1, 2022, weighted options to purchase 1.2 million, 0.8 million and 0.2 million shares of common stock, respectively, were outstanding but not included in the computation of diluted net income per share because the effect of including such shares would have been antidilutive in the applicable period. Certain RSUs were considered contingently issuable shares as their vesting is contingent upon the occurrence of certain future events. Since such events had not occurred and were not considered probable of occurring as of December 30, 2023, December 31, 2022 and January 1, 2022, 2.7 million weighted-average shares related to such RSUs have been excluded from the calculation of potential shares. For additional information with respect to these RSUs, please see “Employment and Severance Agreements” in Note 24, “Commitments and Contingencies”.
Recently Adopted and Recently Announced Accounting Pronouncements
Recently Adopted Accounting Pronouncements
There were no recently adopted accounting pronouncements during for the fiscal year ended December 30, 2023.
Recently Announced Accounting Pronouncements
In July 2023, the Financial Accounting Standard Board (FASB) issued Accounting Standard Update (ASU) No. 2023-03, Presentation of Financial Statements (Topic 205), Income Statement—Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation—Stock Compensation (Topic 718): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 120, SEC Staff Announcement at the March 24, 2022 EITF Meeting, and Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280—General Revision of Regulation S-X: Income or Loss Applicable to Common Stock. The new standard amends the FASB Codification for SEC paragraphs to SEC SAB 120, 2022 EITF Meeting and SAB Topic 6B. ASU No. 2023-03 is effective upon addition to the FASB Codification. ASU No. 2023-03 does not provide new guidance, and the Company does not expect it to have a material impact on its consolidated financial statements upon adoption.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The new standard is intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. ASU No. 2023-07 is effective for annual reporting periods beginning after December 15, 2023 and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted with retrospective application to all prior periods presented. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company is currently evaluating the expected impact of this standard on its consolidated financial statements upon adoption.
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The new standard requires companies to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate). ASU No. 2023-09 is effective for annual reporting periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the expected impact of this standard, but does not expect it to have a material impact on its consolidated financial statements upon adoption.
v3.24.0.1
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 30, 2023
Accounting Policies [Abstract]  
Schedule of Fair Value, Assets Measured on Recurring Basis
The following tables represent the Company’s financial assets, measured at fair value on a recurring basis at December 30, 2023:
Fair Value Measurement Hierarchy
(in millions)Total Carrying
Value		Level 1Level 2Level 3
Assets
Cash and cash equivalents$87.0 $87.0 $— $— 
Money market funds76.0 76.0 — — 
Pension assets:
Cash and cash equivalents(1.2)
(1)
(1.2)— — 
Equity securities8.1 8.1 — — 
Debt securities10.7 9.9 0.8 — 
Real estate funds3.1 — 3.1 — 
Alternative investments1.9 — 1.9 — 
Other0.5 — 0.5 — 
Equity securities1.7 1.7 — — 
Derivative instruments - cash flow hedges(2)
11.6 11.6 — — 
Derivative instruments - warrants1.0 1.0 — — 
Total assets$200.4 $194.1 $6.3 $— 
Liabilities
Derivative instruments - cash flow hedge$3.6 $3.6 $— $— 
Pension benefit obligation32.6 32.6 — — 
Total liabilities$36.2 $36.2 $— $— 
______________
(1)     Due to the timing of a cash transfer, there was a payable as of December 30, 2023, resulting in a negative allocation as of year end.
(2)    Includes accrued interest.
The following tables represent the Company’s financial assets, measured at fair value on a recurring basis at December 31, 2022:
Fair Value Measurement Hierarchy
(in millions)Total Carrying
Value		Level 1Level 2Level 3
Assets
Cash and cash equivalents$148.5 $148.5 $— $— 
U.S. treasuries— — — — 
Money market funds54.4 54.4 — — 
Pension assets:
      Cash and cash equivalents1.0 1.0 — — 
      Equity securities 6.6 6.6 — — 
      Debt securities8.0 7.2 0.8 — 
      Real estate funds3.5 — 3.5 — 
      Alternative investments1.9 — 1.9 — 
      Other1.2 — 1.2 — 
Derivative instruments - cash flow hedges19.7 — 19.7 — 
Total assets$244.8 $217.7 $27.1 $— 
Liabilities
Pension benefit obligation$32.3 $32.3 $— $— 
Total liabilities$32.3 $32.3 $— $— 
Schedule of Property and Equipment
Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over estimated useful lives as follows:
Useful Lives
Buildings and building improvements
7 to 39 years
Computer equipment and software
2 to 12 years
Demonstration units
2 to 3 years
Furniture and office equipment
2 to 15 years
Leasehold improvementsLesser of useful life or term of lease
Machinery, equipment and tooling
3 to 20 years
Operating lease assetsLesser of useful life or term of lease
Transportation, vehicles and other
1 to 20 years
Property and equipment, net, consists of the following:
(in millions)December 30,
2023		December 31,
2022
Building and building improvements$151.0 $151.0 
Machinery, equipment and tooling169.7 149.4 
Operating lease assets92.2 50.2 
Land66.2 65.1 
Computer equipment and software45.5 42.1 
Leasehold improvements37.5 32.3 
Transportation, vehicles and other34.0 32.7 
Furniture and office equipment20.4 19.4 
Demonstration units11.1 11.2 
Construction-in-progress (CIP)59.2 50.6 
Total property and equipment
686.8 604.0 
Accumulated depreciation(262.4)(201.5)
Property and equipment, net
$424.4 $402.5 
Schedule of Changes in Product Warranty Accrual
Changes in the product warranty accrual were as follows:
Year Ended
(in millions)December 30,
2023		December 31,
2022		January 1,
2022
Product warranty accrual, beginning of period$10.6 $2.5 $2.7 
Increase related to acquisition, net of reserve— 8.4 — 
Accrual for warranties issued7.8 1.8 2.2 
Changes in pre-existing warranties (including changes in estimates)(7.5)4.7 (1.4)
Settlements made(2.3)(6.8)(1.0)
Product warranty accrual, end of period$8.6 $10.6 $2.5 
Schedule of Reconciliation of Basic and Diluted Net Income Per Share
A computation of basic and diluted net income per share is as follows:
Year Ended
(in millions, except per share amounts)December 30,
2023		December 31,
2022		January 1,
2022
Net income$81.5 $143.5 $229.6 
Basic net income per share:
Weighted-average shares outstanding - basic52.8 53.6 55.2 
Net income per basic share$1.54 $2.68 $4.16 
Diluted net income per share:
Weighted-average shares outstanding - basic52.8 53.6 55.2 
Diluted share equivalents: stock options, RSUs and PSUs1.3 1.6 2.5 
Weighted-average shares outstanding - diluted54.1 55.2 57.7 
Net income per diluted share$1.51 $2.60 $3.98 
Schedule of Supplemental Cash Flow Information
Supplemental Cash Flow Information
Supplemental cash flow information includes the following:
Year Ended
(in millions)December 30,
2023		December 31,
2022		January 1,
2022
Cash paid during the year for:
Interest expense
$51.0 $23.0 $0.3 
Income taxes
54.4 87.3 43.9 
Operating lease liabilities
22.4 17.2 7.3 
Non-cash operating activities:
ROU assets obtained in exchange for lease liabilities$16.3 $— $6.0 
Non-cash investing activities:
Unpaid purchases of property and equipment$0.2 $3.8 $— 
Non-cash financing activities:
       Unsettled common stock proceeds from option exercises$— $— $0.7 
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents
$163.0 $202.9 $745.3 
Restricted cash
5.2 6.7 3.1 
Total cash, cash equivalents and restricted cash shown in the statement of cash flows
$168.2 $209.6 $748.4 
v3.24.0.1
Inventories (Tables)
 12 Months Ended
Dec. 30, 2023
Inventory Disclosure [Abstract]  
Schedule of Components of Inventory
Inventories consist of the following:
(in millions)December 30,
2023		December 31,
2022
Raw materials$229.7 $209.9 
Work-in-process30.0 30.4 
Finished goods285.3 260.7 
Total inventories$545.0 $501.0 
v3.24.0.1
Other Current Assets - (Tables)
 12 Months Ended
Dec. 30, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Other Non-Current Assets
Other current assets consist of the following:
(in millions)December 30,
2023		December 31,
2022
Prepaid expenses$58.3 $77.5 
Lease receivable, current30.2 28.5 
Prepaid income taxes29.3 12.4 
Indirect taxes receivable28.6 26.8 
Contract assets, current6.7 3.9 
Prepaid rebates and royalties4.8 3.7 
Restricted cash(1)
3.0 2.4 
Other current assets7.5 3.6 
Total other current assets
$168.4 $158.8 
______________
(1)     Restricted cash includes funds received from the Bill and Melinda Gates Foundation. As the Company incurs costs associated with research and development related to this project, on a quarterly basis, the Company reclasses amounts from the grant to offset costs incurred.
Other non-current assets consist of the following:
(in millions)December 30,
2023		December 31,
2022
Lessee ROU assets, net$59.1 $69.6 
Derivative assets - non-current(1)
11.4 19.3 
Prepaid deposits and other6.4 5.8 
Strategic investments7.2 13.8 
Equity investments - fair value2.7 — 
Restricted cash(2)
2.2 5.2 
Other non-current assets0.3 0.3 
Total non-current assets$89.3 $114.0 
______________
(1)    Excludes accrued interest.
(2)    Restricted cash includes cash held in certain subsidiaries such as China, that may be subject to transfer restrictions depending on jurisdictions.
v3.24.0.1
Lease Receivable (Tables)
 12 Months Ended
Dec. 30, 2023
Leases [Abstract]  
Schedule of Sale-Type Lease Receivable
Lease receivable from sales-type leases consists of the following:
(in millions)December 30,
2023		December 31,
2022
Lease receivable$101.9 $101.8 
Allowance for credit loss(0.3)(0.2)
     Lease receivable, net101.6 101.6 
Less: current portion of lease receivable(30.2)(28.5)
     Lease receivable, non-current$71.4 $73.1 
Schedule of Sales-type Lease, Lease Receivable, Maturity
As of December 30, 2023, estimated future maturities of customer sales-type lease receivables and operating lease payments for each of the following fiscal years are as follows:
Future Lease Receivables/Payments
(in millions)
Fiscal year
Sales-Type LeasesOperating Leases
2024$30.2 $10.4 
202525.0 9.3 
202618.9 8.5 
202713.6 6.9 
20287.0 5.4 
Thereafter6.9 6.0 
     Total$101.6 $46.5 
Less: imputed interest(1)
— 
     Present value of total lease payments$101.6 
______________
(1) The calculation of the rates implicit in the leases resulted in negative discount rates. Therefore, the Company as a lessor used a 0% discount rate to measure the net investment in the lease.
v3.24.0.1
Deferred Costs and Other Contract Assets - (Tables)
 12 Months Ended
Dec. 30, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Deferred Costs and Other Contract Assets
Deferred costs and other contract assets consist of the following:
(in millions)December 30,
2023		December 31,
2022
Deferred commissions$21.8 $17.1 
Prepaid contract allowances17.0 13.7 
Unbilled contract receivables17.0 9.4 
Deferred equipment agreements, net1.5 1.7 
     Deferred costs and other contract assets$57.3 $41.9 
For the years ended December 30, 2023, December 31, 2022 and January 1, 2022, deferred commission amortization expense was $5.8 million, $4.3 million and $3.2 million, respectively.
v3.24.0.1
Property and Equipment, net (Tables)
 12 Months Ended
Dec. 30, 2023
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over estimated useful lives as follows:
Useful Lives
Buildings and building improvements
7 to 39 years
Computer equipment and software
2 to 12 years
Demonstration units
2 to 3 years
Furniture and office equipment
2 to 15 years
Leasehold improvementsLesser of useful life or term of lease
Machinery, equipment and tooling
3 to 20 years
Operating lease assetsLesser of useful life or term of lease
Transportation, vehicles and other
1 to 20 years
Property and equipment, net, consists of the following:
(in millions)December 30,
2023		December 31,
2022
Building and building improvements$151.0 $151.0 
Machinery, equipment and tooling169.7 149.4 
Operating lease assets92.2 50.2 
Land66.2 65.1 
Computer equipment and software45.5 42.1 
Leasehold improvements37.5 32.3 
Transportation, vehicles and other34.0 32.7 
Furniture and office equipment20.4 19.4 
Demonstration units11.1 11.2 
Construction-in-progress (CIP)59.2 50.6 
Total property and equipment
686.8 604.0 
Accumulated depreciation(262.4)(201.5)
Property and equipment, net
$424.4 $402.5 
v3.24.0.1
Intangible Assets, net (Tables)
 12 Months Ended
Dec. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
Intangible assets, net, consist of the following:
December 30,
2023
As Adjusted,
December 31,
2022(1)
(in millions)Gross Carrying
Amount		Accumulated
Amortization		Net Carrying
Amount		Gross Carrying
Amount		Accumulated
Amortization		Net Carrying
Amount
Intangible assets subject to amortization:
Customer relationships$209.2 $(31.5)$177.7 $220.9 $(19.3)$201.6 
Acquired technologies174.7 (45.3)129.4 185.3 (25.2)160.1 
Capitalized software development costs53.9 (15.2)38.7 25.0 (2.9)22.1 
Licenses39.7 (7.4)32.3 39.0 (4.4)34.6 
Patents39.2 (15.2)24.0 35.2 (13.9)21.3 
Trademarks20.1 (7.4)12.7 19.8 (5.8)14.0 
Licenses-related party7.5 (6.7)0.8 7.5 (6.3)1.2 
Non-compete agreements6.3 (2.6)3.7 6.3 (1.1)5.2 
Other1.7 (1.1)0.6 1.6 (1.1)0.5 
     Total intangible assets subject to amortization, net$552.3 $(132.4)$419.9 $540.6 $(80.0)$460.6 
Intangible assets not subject to amortization:
Trademarks$242.4 $262.0 
Impairment charge(10.0)— 
     Total trademarks232.4 262.0 
     Intangible assets, net$652.3 $722.6 
The following intangible assets reclassification adjustments were made as of September 30, 2023(1):
As Adjusted,
 December 31,
2022
As Previously Filed,
 December 31,
2022
(in millions)Gross Carrying
Amount		Accumulated
Amortization		Net Carrying
Amount		Gross Carrying
Amount		Accumulated
Amortization		Net Carrying
Amount
Intangible assets subject to amortization:
Capitalized software development costs$25.0 $(2.9)$22.1 $5.5 $(2.9)$2.6 
Trademarks19.8 (5.8)14.0 39.3 (5.8)33.5 
__________________
(1)    The Company recorded an immaterial reclassification adjustment between the intangible assets balances in Trademarks and Capitalized Software Development Costs in the amount of $19.5 million, for the year ended December 31, 2022. There was no impact on total intangible assets, net as for December 30, 2022. The adjusted balances were reflected in the Form 10-Q for the quarter ended September 30, 2023, filed with the SEC November 8, 2023.
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
Estimated amortization expense for each of the next fiscal years is as follows:
Fiscal year
Amount
(in millions)
2024$53.7 
202551.0 
202640.1 
202739.2 
202839.0 
Thereafter196.9 
Total$419.9 
v3.24.0.1
Goodwill - (Tables)
 12 Months Ended
Dec. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Changes in Goodwill
Changes in goodwill were as follows:
December 30,
2023
(in millions)HealthcareNon-healthcareTotal
Goodwill, beginning of period$97.6 $347.8 $445.4 
Adjustments to goodwill from purchase price allocation(1)
— (18.2)(18.2)
Foreign currency translation adjustment1.0 (20.5)(19.5)
Goodwill, end of period$98.6 $309.1 $407.7 
December 31,
2022
(in millions)HealthcareNon-healthcareTotal
Goodwill, beginning of period$100.3 $— $100.3 
Increase from business combinations— 347.8 347.8 
Foreign currency translation adjustment(2.7)— (2.7)
Goodwill, end of period$97.6 $347.8 $445.4 
______________
(1)     Includes an immaterial correction of an error to the final purchase price allocation from the Sound United acquisition, which resulted in a reduction of goodwill of $7.8 million. See Note 18 “Business Combinations” for further details.
v3.24.0.1
Lessee ROU Assets and Lease Liabilities (Tables)
 12 Months Ended
Dec. 30, 2023
Leases [Abstract]  
Schedule of Lessee Operating Lease Balance Sheet Classification The balance sheet classifications for amounts related to the Company’s operating leases for which it is the lessee are as follows:
(in millions)Balance Sheet ClassificationDecember 30,
2023		December 31,
2022
Lessee ROU assetsOther non-current assets$59.1 $69.6 
Lessee current lease liabilitiesOther current liabilities18.2 18.7 
Lessee non-current lease liabilitiesOther non-current liabilities45.8 53.4 
     Total operating lease liabilities$64.0 $72.1 
Schedule of Lessee, Operating Lease, Liability, Maturity
As of December 30, 2023, estimated future operating lease payments for each of the following fiscal years were as follows:
Fiscal year
Amount
(in millions)
2024$19.2 
202515.3 
202610.9 
20276.6 
20285.7 
Thereafter(1)
17.8 
Total75.5 
Imputed interest(11.5)
Present value$64.0 
______________
(1)     Includes optional renewal period for certain leases.
v3.24.0.1
Other Non-Current Assets (Tables)
 12 Months Ended
Dec. 30, 2023
Other Assets, Noncurrent [Abstract]  
Schedule of Other Non-Current Assets
Other current assets consist of the following:
(in millions)December 30,
2023		December 31,
2022
Prepaid expenses$58.3 $77.5 
Lease receivable, current30.2 28.5 
Prepaid income taxes29.3 12.4 
Indirect taxes receivable28.6 26.8 
Contract assets, current6.7 3.9 
Prepaid rebates and royalties4.8 3.7 
Restricted cash(1)
3.0 2.4 
Other current assets7.5 3.6 
Total other current assets
$168.4 $158.8 
______________
(1)     Restricted cash includes funds received from the Bill and Melinda Gates Foundation. As the Company incurs costs associated with research and development related to this project, on a quarterly basis, the Company reclasses amounts from the grant to offset costs incurred.
Other non-current assets consist of the following:
(in millions)December 30,
2023		December 31,
2022
Lessee ROU assets, net$59.1 $69.6 
Derivative assets - non-current(1)
11.4 19.3 
Prepaid deposits and other6.4 5.8 
Strategic investments7.2 13.8 
Equity investments - fair value2.7 — 
Restricted cash(2)
2.2 5.2 
Other non-current assets0.3 0.3 
Total non-current assets$89.3 $114.0 
______________
(1)    Excludes accrued interest.
(2)    Restricted cash includes cash held in certain subsidiaries such as China, that may be subject to transfer restrictions depending on jurisdictions.
v3.24.0.1
Deferred Revenue and Other Contract Liabilities, Current (Tables)
 12 Months Ended
Dec. 30, 2023
Revenue Recognition and Deferred Revenue [Abstract]  
Schedule of Contract with Customer, Asset and Liability
Deferred revenue and other contract liabilities consist of the following:
(in millions)December 30,
2023		December 31,
2022
Deferred revenue$63.8 $61.0 
Accrued rebates and allowances37.5 38.5 
Accrued customer reimbursements12.4 6.1 
     Total deferred revenue and other contract liabilities113.7 105.6 
Less: Non-current portion of deferred revenue(26.4)(25.0)
     Deferred revenue and other contract liabilities, current$87.3 $80.6 
Schedule of Deferred Revenue
Changes in deferred revenue for the year ended December 30, 2023 were as follows:
(in millions)December 30,
2023
Deferred revenue, beginning of the period$61.0 
  Revenue deferred during the period28.3 
  Recognition of revenue deferred in prior periods(25.5)
     Deferred revenue, end of the period$63.8 
v3.24.0.1
Other Current Liabilities - (Tables)
 12 Months Ended
Dec. 30, 2023
Other Liabilities Disclosure [Abstract]  
Schedule of Other Current Liabilities
Other current liabilities consist of the following:
(in millions)December 30,
2023		December 31,
2022
Current portion of long-term debt$34.3 $15.1 
Accrued expenses26.3 39.9 
Accrued indirect taxes payable23.9 28.2 
Lessee lease liabilities, current18.2 18.7 
Income tax payable16.1 32.1 
Accrued property taxes10.2 12.1 
Accrued legal fees9.9 11.4 
Accrued warranty8.6 10.6 
Other current liabilities6.7 6.1 
Related party payables4.2 4.0 
Accrued donations4.0 5.1 
Total other current liabilities
$162.4 $183.3 
v3.24.0.1
Debt (Tables)
 12 Months Ended
Dec. 30, 2023
Debt Disclosure [Abstract]  
Schedule of Debt
(in millions)December 30,
2023		December 31,
2022
Japanese loans - current portion$23.0 $7.6 
Term loan - current portion11.3 7.5 
Short-term debt34.3 15.1 
Revolver - long-term591.5 651.0 
Term loan - long-term271.4 278.9 
Japanese loans - long-term8.8 11.7 
Long-term debt871.7 941.6 
Total debt$906.0 $956.7 
Schedule of Maturities of Long-term Debt
As of December 30, 2023, the aggregate maturities of principal on all debt for each of the next five years and thereafter are as follows:
Fiscal year
Amount
(in millions)
2024$34.3 
202516.7
202616.7
2027834.6
20281.1 
Thereafter2.6
Total$906.0 
v3.24.0.1
Other Non-Current Liabilities - (Tables)
 12 Months Ended
Dec. 30, 2023
Other Liabilities Disclosure [Abstract]  
Components of Other Non-Current Liabilities
Other non-current liabilities consist of the following:
(in millions)December 30,
2023		December 31,
2022
Lessee non-current lease liabilities$45.8 $53.4 
Deferred revenue, non-current26.4 25.0 
Unrecognized tax benefits24.4 18.0 
Projected benefit obligation9.5 10.1 
Indirect tax payable, non-current8.4 8.2 
Income tax payable, non-current7.1 12.7 
Other7.9 9.1 
Total other non-current liabilities
$129.5 $136.5 
v3.24.0.1
Derivative Instruments and Hedging Activities (Tables)
 12 Months Ended
Dec. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value The following table summarizes the fair value of the hedging instruments, presented on a gross basis, as of December 30, 2023 and December 31, 2022.
Consolidated
Balance Sheets
(in millions)Balance Sheet ClassificationDecember 30,
2023		December 31,
2022
Interest rate contracts, inclusive of accrued interestOther non-current assets$11.6 $19.7 
Interest rate contracts, inclusive of accrued interest
Other non-current liabilities
(3.6)— 
Total$8.0 $19.7 
Reclassification out of Accumulated Other Comprehensive Income
The following table summarizes the gains (losses) reclassified from accumulated other comprehensive (loss) income to the consolidated financial statements for the year ended December 30, 2023.
Consolidated
Statement of Operations
(in millions)Location of Gain (Loss) December 30,
2023		December 31,
2022		January 1,
2022
Cash flow hedges - interest rate contracts
Non-operating (loss) income
$14.9 $0.7 $— 
Total$14.9 $0.7 $— 
Schedule of Accumulated Other Comprehensive Income (Loss)
The following tables summarize the changes in accumulated other comprehensive (loss) income related to the hedging instruments:
(in millions)December 30,
2023		December 31,
2022
Beginning balance$19.3 $— 
Amount recognized in other comprehensive income3.4 20.0 
Amount reclassified into earnings(14.9)(0.7)
Ending balance$7.8 $19.3 
v3.24.0.1
Business Combinations (Tables)
 12 Months Ended
Dec. 30, 2023
Business Combination and Asset Acquisition [Abstract]  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The table below summarizes the final allocation of fair value of assets acquired and liabilities assumed.
(in millions)Sound United
Cash consideration
$1,057.5 
Purchase price$1,057.5 
Assets acquired:
Cash and cash equivalents$82.6 
Accounts receivables108.5 
Inventories238.6 
Prepaid expenses and other current assets30.0 
Property, plant and equipment113.2 
Intangible assets
649.0 
Goodwill(1)
318.0 
Long-term other assets7.4 
Total assets acquired$1,547.3 
Liabilities assumed:
Accounts payable$(118.8)
Accrued liabilities and other current liabilities(148.9)
Deferred tax liabilities(1)
(145.1)
Other long-term liabilities(77.0)
Total liabilities assumed$(489.8)
______________
(1)    Includes an immaterial correction of an error to the final purchase price allocation from the Sound United acquisition, which resulted in a reduction to both goodwill and deferred tax liabilities of $7.8 million.
The following table sets forth the components of identifiable intangible assets acquired and the weighted average amortization period as of the acquisition date:
Weighted average
amortization period
(in years)
April 11,
 2022
(in millions)
Trademarks/tradenames10$6.0 
Customer relationships17196.0 
Developed technology8156.0 
Contractual license agreements1529.0 
Subtotal14 years$387.0 
Indefinite trademarks/tradenamesN/A262.0 
Total$649.0 
Business Acquisition, Pro Forma Information
There are no other material non-recurring pro forma adjustments directly attributable to the Sound United Acquisition included in the reported pro forma revenue and pro forma net income.
Twelve Months Ended
December 30,
2023		December 31,
2022		January 1,
2022
(in millions)ActualPro formaPro forma
Net revenue$2,048.1 $2,293.4 $2,187.4 
Net income $81.5 $181.8 $126.2 
v3.24.0.1
Equity (Tables)
 12 Months Ended
Dec. 30, 2023
Equity [Abstract]  
Schedule of Stock Repurchase Activities
The following table provides a summary of the Company’s stock repurchase activities during the years ended December 30, 2023, December 31, 2022 and January 1, 2022:
Years Ended
(in millions, except per share amounts)December 30,
2023		December 31,
2022		January 1,
2022
Shares repurchased
— (1)3.0 (1)0.5 (1)
Average cost per share$— $133.82 $235.88 
Value of shares repurchased$— $401.5 $129.0 
______________
(1)     Excludes shares withheld from the shares of its common stock actually issued in connection with the vesting of PSU or RSU awards to satisfy certain U.S. federal and state tax withholding obligations.
v3.24.0.1
Stock-Based Compensation - (Tables)
 12 Months Ended
Dec. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Number and Weighted Average Exercise Price of Options Issued and Outstanding under All Stock Option Plans
The number and weighted-average exercise price of options issued and outstanding under all of the Company’s equity plans are as follows:
Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
(in millions, except for weighted-average exercise prices)SharesWeighted-Average
Exercise
Price		SharesWeighted-Average
Exercise
Price		SharesWeighted-Average
Exercise
Price
Options outstanding, beginning of period2.8 $83.85 2.9 $81.38 3.4 $77.44 
Granted0.1 177.29 0.1 150.91 0.1 250.15 
Canceled— 45.96 (0.1)162.77 (0.2)149.11 
Exercised(0.2)43.22 (0.1)54.53 (0.4)53.55 
Options outstanding, end of period2.7 $87.79 2.8 $83.85 2.9 $81.38 
Options exercisable, end of period2.4 $73.79 2.4 $65.83 2.2 $57.09 
Number and Weighted Average Exercise Price of Outstanding and Exercisable Options
The number and weighted-average exercise price of outstanding and exercisable stock options segregated by exercise price ranges were as follows:
Year Ended
December 30,
2023
Year Ended
December 31,
2022
(in millions, except range of exercise prices and average remaining contractual life)
Options OutstandingOptions
Exercisable		Options OutstandingOptions
Exercisable
Range of Exercise PricesNumber of
Options		Average
Remaining
Contractual
Life		Number of
Options		Number of
Options		Average
Remaining
Contractual
Life
Number of
Options
$15.00 to $50.00
1.2 1.51.2 1.3 2.41.3 
$50.01 to $80.00
— 2.5— 0.1 3.70.1 
$80.01 to $120.00
0.7 3.70.7 0.8 4.80.7 
$120.01 to $160.00
0.4 6.00.3 0.4 7.10.2 
$160.01 to $200.00
0.3 7.00.1 0.2 7.20.1 
$200.01 to $230.00
— 6.5— — 7.2— 
$230.01 to $280.00
0.1 7.00.1 — 8.0— 
Total
2.7 4.92.4 2.8 4.32.4 
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity
The number of RSUs issued and outstanding under all of the Company’s equity plans are as follows:
Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
(in millions, except for weighted-average grant date fair value)
UnitsWeighted-Average
Grant Date
Fair Value		UnitsWeighted-Average
Grant Date
Fair Value		UnitsWeighted-Average
Grant Date
Fair Value
RSUs outstanding, beginning of period3.2 $105.65 3.0 $104.13 2.9 $99.66 
Granted
0.5 125.44 0.3 148.52 0.1 257.43 
Canceled(0.1)172.19 (0.1)168.90 — 204.33 
Vested(0.1)173.18 — 184.04 — 163.71 
RSUs outstanding, end of period3.5 $105.87 3.2 $105.65 3.0 $104.13 
Schedule of Nonvested Performance-based Units Activity
The number of PSUs outstanding under all of the Company’s equity plans are as follows:
Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
(in millions, except for weighted-average grant date fair value)
UnitsWeighted-Average
Grant Date
Fair Value		UnitsWeighted-Average
Grant Date
Fair Value		UnitsWeighted-Average
Grant Date
Fair Value
PSUs outstanding, beginning of period0.3 $180.04 0.3 $168.68 0.4 $120.28 
Granted(1)
0.1 
(1)
204.67 0.3 
(1)
145.49 0.2 250.73 
Canceled— 155.98 (0.1)139.73 — 166.84 
Vested(0.1)179.42 (0.2)127.46 (0.3)86.95 
PSUs outstanding, end of period0.3 $190.04 0.3 $180.04 0.3 $168.68 
(1) On February 27, 2023, the Audit Committee approved the weighted payout percentage for the 2019 PSU awards (three-year performance period), which were based upon the Company’s actual fiscal year 2022 performance against pre-established performance objectives. Included in the granted amount are those additional PSUs earned based on actual performance achieved. These PSUs were originally awarded at target.
Range of Assumptions Used and Resulting Weighted-Average Fair Value of Options Granted at Date of Grant The range of assumptions used and the resulting weighted-average fair value of options granted at the date of grant were as follows:
Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
Risk-free interest rate
3.6% to 4.2%
1.0% to 1.9%
0.3% to 0.9%
Expected term (in years)
5.1 years to 5.9 years
5.1 years to 5.7 years
5.1 years to 5.6 years
Estimated volatility
31.6% to 36.7%
31.2% to 38.9%
30.9% to 34.7%
Expected dividends0%0%0%
Weighted-average fair value of options granted$75.08 per share$49.69 per share$75.72 per share
Share-Based Compensation Expense Included in Consolidated Statements of Operations
The following table presents the total stock-based compensation expense that is included in each functional line item of the consolidated statements of operations:
(in millions)
Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
Cost of goods sold$1.1 $1.0 $0.8 
Selling, general and administrative(1.5)32.9 31.3 
Research and development7.4 13.8 12.5 
Total
$7.0 $47.7 $44.6 
v3.24.0.1
Employee Benefits (Tables)
 12 Months Ended
Dec. 30, 2023
Postemployment Benefits [Abstract]  
Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets
The following table sets forth the funded status and amounts recognized in the consolidated balance sheet for the Company’s defined benefit plans.
(in millions)December 30,
2023		December 31,
2022
Plan Assets
Fair value of plan assets at beginning of year$22.2 $21.7 
Realized net gains (losses) on plan assets1.1 (2.5)
Employer contributions0.4 1.5 
Participant contributions0.6 0.5 
Benefits paid0.8 2.8 
Foreign currency revaluation and translation gains and (losses)
(2.0)(1.8)
Fair value of plan assets at end of year$23.1 $22.2 
Projected Benefit Obligation
Projected benefit obligation at beginning of year$32.3 $32.3 
Service cost1.2 1.1 
Interest cost0.5 0.1 
Participant contributions0.6 0.5 
Actuarial gains (losses)2.3 (1.9)
Benefits paid(0.5)
(1)
2.0 
Foreign currency revaluation and translation gains and (losses)
(3.8)(1.8)
Projected benefit obligation at end of year$32.6 $32.3 
Funded status$(9.5)$(10.1)
______________
(1)     Due to the timing of a cash transfer, there was a payable as of December 30, 2023, resulting in a negative allocation as of year end.
International defined benefit plans with accumulated benefit obligations in excess of fair value of plan assets consist of the following:
(in millions)December 30,
2023		December 31,
2022
Projected benefit obligation$32.6 $32.3 
Accumulated benefit obligation28.3 31.0 
Fair value of plan assets$23.1 $22.2 
Schedule of Net Benefit Costs
The Company’s consolidated statement of operations reflect the following components of net periodic defined benefit costs:
(in millions)Year Ended
December 30,
2023		Year Ended
December 31,
2022
Components of net periodic benefit cost $— $— 
Service cost1.2 1.1 
Interest cost0.5 0.1 
Expected (gains) on plan assets(0.7)(0.6)
Amortization of net losses— 0.1 
Recognized net actuarial loss— 0.3 
Net periodic defined benefit plan cost$1.0 $1.0
On a weighted-average basis, the following assumptions were used to determine benefit obligations and to determine net periodic benefit cost:
Year Ended
December 30,
2023		Year Ended
December 31,
2022
Assumptions - benefit obligations:
Discount rate1.35 %1.61 %
Rate of compensation increase1.04 0.96 
Assumptions - net periodic benefit costs:
Discount rate 1.91 %0.49 %
Rate of compensation increase1.43 0.09 
Expected long-term return on plan assets(1)
3.53 1.70 
Interest credit rate1.98 2.34 
______________
(1)     The pension expected return on assets assumption is derived primarily from underlying investment allocations and historical risk premiums per each plan, adjusted for current and future expectations, such as easing of global inflationary pressure.
Schedule of Amounts Recognized in Other Comprehensive Income (Loss)
Classification of amounts recognized in the consolidated balance sheets are as follows:
(in millions)December 30,
2023		December 31,
2022
Non-current assets$— $— 
Current liability— — 
Non-current liability9.5 10.1 
Schedule of Allocation of Plan Assets
The weighted-average asset allocations at year end by asset category were as follows:
Actual Allocation
Asset category
December 30,
2023		December 31,
2022
Cash and cash equivalents(5.0)%
(1)
3.0 %
Equity securities35.0 30.0 
Debt securities47.0 36.0 
Other24.0 31.0 
______________
(1)     Due to the timing of a cash transfer , there was a payable as of December 30, 2023, resulting in a negative allocation as of year end.
Schedule of Expected Benefit Payments
The estimated future benefit payments, based upon the same assumptions used to measure the benefit obligations and expected future employee service, were as follows:
(in millions)Year Ended
December 30,
2023
2024$0.4 
20252.5 
20262.4 
20272.5 
2028
2.2 
Thereafter
4.2 
Total $14.2 
v3.24.0.1
Non-operating Loss - (Tables)
 12 Months Ended
Dec. 30, 2023
Nonoperating Income (Expense) [Abstract]  
Schedule of Non-operating Income (Expense)
Non-operating loss consists of the following:
(in millions)
Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
Interest income$3.0 $1.8 $0.9 
Realized and unrealized foreign currency (loss) gain(1.1)7.3 (2.0)
Interest expense(50.3)(25.7)(0.3)
Total non-operating loss$(48.4)$(16.6)$(1.4)
v3.24.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 30, 2023
Income Tax Disclosure [Abstract]  
Schedule of components of Income Before Provision for Income Taxes
The components of income before provision for income taxes are as follows:
(in millions)
Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
United States$9.1 $77.6 $221.2 
Foreign79.0 115.8 53.2 
Total
$88.1 $193.4 $274.4 
Schedule of current and deferred provision (benefit) for income taxes
The following table presents the current and deferred provision (benefit) for income taxes:
(in millions)Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
Current:
Federal$15.0 $48.7 $38.1 
State3.5 6.1 7.1 
Foreign23.7 34.4 14.7 
Subtotal$42.2 $89.2 $59.9 
Deferred:
Federal$(12.5)$(20.5)$(4.9)
State(9.0)(8.7)(6.1)
Foreign(14.1)(10.1)(4.1)
Subtotal
(35.6)(39.3)(15.1)
Total
$6.6 $49.9 $44.8 
Schedule of reconciliation of U.S. federal statutory tax rate to company's effective tax rate
The reconciliation of the U.S. federal statutory tax rate to the Company’s effective tax rate is as follows:
Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
Statutory regular federal income tax rate21.0 %21.0 %21.0 %
U.S. tax on foreign income, net10.0 4.8 0.9 
Foreign income taxed at different rates1.1 — (0.3)
Transaction-related costs— 0.9 — 
Nondeductible executive compensation(1.6)2.9 2.1 
Derecognition of uncertain tax position(2.3)(0.8)(1.0)
State provision, net of federal benefit(4.9)(1.0)0.3 
Excess stock-based compensation(3.2)(1.2)(5.5)
Research and development tax credits(5.1)(1.7)(1.8)
Tax Credit(9.2)— — 
Other1.6 0.9 0.6 
Total
7.4 %25.8 %16.3 %
Schedule of components of deferred tax assets
The components of the deferred tax assets are as follows:
(in millions)December 30,
2023		December 31,
2022
Deferred tax assets:
Net operating losses$53.7 $34.7 
Tax credits33.2 18.0 
Capitalized R&D33.0 18.5 
Deferred revenue28.0 27.8 
Accrued liabilities24.6 32.1 
Interest15.6 22.4 
Stock-based compensation12.3 10.9 
Operating lease liabilities9.7 8.7 
Other7.3 5.8 
Total217.4 178.9 
Valuation allowance(18.9)(7.3)
Total deferred tax assets$198.5 $171.6 
Deferred tax liabilities:
Inventory$(0.8)$(4.0)
Interest rate hedge(1.9)(4.1)
Withholding taxes on undistributed foreign earnings(3.1)(2.8)
State taxes and other(10.4)(7.5)
Operating lease liabilities(11.8)(8.6)
Property and equipment(14.4)(18.2)
Intangible assets(160.5)(186.7)
Other(0.2)(0.9)
Total deferred tax liabilities(203.1)(232.8)
Net deferred tax assets$(4.6)$(61.2)
Schedule of reconciliation of total amounts of unrecognized tax benefits
The following is a tabular reconciliation of the total amounts of unrecognized tax benefits:
(in millions)Year Ended
December 30,
2023		Year Ended
December 31,
2022
Unrecognized tax benefits (gross), beginning of period$26.1 $21.6 
Increase from tax positions in current period7.9 6.0 
Increase from tax positions in prior period1.3 0.7 
Decrease from tax position in prior period— (0.6)
Lapse of statute of limitations(2.3)(1.6)
Unrecognized tax benefits (gross), end of period$33.0 $26.1 
v3.24.0.1
Segment and Enterprise Reporting - (Tables)
 12 Months Ended
Dec. 30, 2023
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
Selected information by reportable segment is presented below for the years ended December 30, 2023, December 31, 2022 and January 1, 2022:
(in millions)Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
Revenues by segment:
Healthcare$1,275.5 $1,340.3 $1,239.2 
Non-healthcare772.6 695.5 — 
Total revenue by segment$2,048.1 $2,035.8 $1,239.2 
Gross profit:
Healthcare$777.1 $870.2 $808.4 
Non-healthcare258.0 252.5 — 
Other(1)
(31.6)(63.9)— 
Gross profit$1,003.5 $1,058.8 $808.4 
__________________
(1)     Management excludes certain corporate expenses from segment gross profit. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment gross profit because management evaluates the operating results of the segments excluding such items.
The Company’s depreciation and amortization by segment are as follows:
(in millions)Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
Total depreciation and amortization by segment:
Healthcare$38.1 $36.0 $35.6 
Non-healthcare60.1 100.1 — 
Total depreciation and amortization by segment
$98.2 $136.1 $35.6 
The Company’s total assets by segment are as follows:
(in millions)December 30,
2023		December 31,
2022
Total assets by segment:
Healthcare$1,631.8 $1,594.1 
Non-healthcare1,390.6 1,597.5 
Corporate overhead19.1 19.0 
Total assets by segment$3,041.5 $3,210.6 
The Company’s consolidated long-lived assets (tangible non-current assets) by geographic area are as follows:
(in millions, except percentages)
Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
Total long-lived assets by geographic area:
United States$317.9 74.6 %$319.7 79.1 %$239.4 86.9 %
International108.0 25.4 84.5 20.9 36.0 13.1 
Total long-lived assets by geographic area$425.9 100.0 %$404.2 100.0 %$275.4 100.0 %
The following schedule presents an analysis of the Company’s revenues based upon the geographic area:
(in millions, except percentages)
Year Ended
December 30,
2023		Year Ended
December 31,
2022		Year Ended
January 1,
2022
Total revenue by geographic area:
United States (U.S.)$1,058.8 51.7 %$1,141.7 56.1 %$822.4 66.4 %
Europe, Middle East and Africa571.9 27.9 523.6 25.7 251.8 20.3 
Asia and Australia351.0 17.1 326.8 16.1 123.6 10.0 
North and South America (excluding U.S.)66.4 3.3 43.7 2.1 41.4 3.3 
     Total revenue by geographic area$2,048.1 100.0 %$2,035.8 100.0 %$1,239.2 100.0 %
v3.24.0.1
Summary of Significant Accounting Policies - Schedule of Financial Assets Measured at Fair Value on a Recurring Basis (Detail) - Recurring - USD ($)
$ in Millions
Dec. 30, 2023
Dec. 31, 2022
Assets    
Cash and cash equivalents $ 87.0 $ 148.5
U.S. treasuries   0.0
Money market funds 76.0 54.4
Pension assets:    
Cash and cash equivalents (1.2) 1.0
Equity securities 8.1 6.6
Debt securities 10.7 8.0
Real estate funds 3.1 3.5
Alternative investments 1.9 1.9
Other 0.5 1.2
Equity securities 1.7  
Total assets 200.4 244.8
Liabilities    
Pension benefit obligation 32.6 32.3
Total liabilities 36.2 32.3
Cash Flow Hedging    
Pension assets:    
Derivative instruments   19.7
Cash Flow Hedging    
Pension assets:    
Derivative instruments 11.6  
Liabilities    
Derivative instruments - cash flow hedge 3.6  
Warrant    
Pension assets:    
Derivative instruments 1.0  
Level 1    
Assets    
Cash and cash equivalents 87.0 148.5
U.S. treasuries   0.0
Money market funds 76.0 54.4
Pension assets:    
Cash and cash equivalents (1.2) 1.0
Equity securities 8.1 6.6
Debt securities 9.9 7.2
Real estate funds 0.0 0.0
Alternative investments 0.0 0.0
Other 0.0 0.0
Equity securities 1.7  
Total assets 194.1 217.7
Liabilities    
Pension benefit obligation 32.6 32.3
Total liabilities 36.2 32.3
Level 1 | Cash Flow Hedging    
Pension assets:    
Derivative instruments   0.0
Level 1 | Cash Flow Hedging    
Pension assets:    
Derivative instruments 11.6  
Liabilities    
Derivative instruments - cash flow hedge 3.6  
Level 1 | Warrant    
Pension assets:    
Derivative instruments 1.0  
Level 2    
Assets    
Cash and cash equivalents 0.0 0.0
U.S. treasuries   0.0
Money market funds 0.0 0.0
Pension assets:    
Cash and cash equivalents 0.0 0.0
Equity securities 0.0 0.0
Debt securities 0.8 0.8
Real estate funds 3.1 3.5
Alternative investments 1.9 1.9
Other 0.5 1.2
Equity securities 0.0  
Total assets 6.3 27.1
Liabilities    
Pension benefit obligation 0.0 0.0
Total liabilities 0.0 0.0
Level 2 | Cash Flow Hedging    
Pension assets:    
Derivative instruments   19.7
Level 2 | Cash Flow Hedging    
Pension assets:    
Derivative instruments 0.0  
Liabilities    
Derivative instruments - cash flow hedge 0.0  
Level 2 | Warrant    
Pension assets:    
Derivative instruments 0.0  
Level 3    
Assets    
Cash and cash equivalents 0.0 0.0
U.S. treasuries   0.0
Money market funds 0.0 0.0
Pension assets:    
Cash and cash equivalents 0.0 0.0
Equity securities 0.0 0.0
Debt securities 0.0 0.0
Real estate funds 0.0 0.0
Alternative investments 0.0 0.0
Other 0.0 0.0
Equity securities 0.0  
Total assets 0.0 0.0
Liabilities    
Pension benefit obligation 0.0 0.0
Total liabilities 0.0 0.0
Level 3 | Cash Flow Hedging    
Pension assets:    
Derivative instruments   $ 0.0
Level 3 | Cash Flow Hedging    
Pension assets:    
Derivative instruments 0.0  
Liabilities    
Derivative instruments - cash flow hedge 0.0  
Level 3 | Warrant    
Pension assets:    
Derivative instruments $ 0.0  
v3.24.0.1
Summary of Significant Accounting Policies - Useful Life (Details)
Dec. 30, 2023
Building and building improvements | Minimum  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 7 years
Building and building improvements | Maximum  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 39 years
Computer equipment and software | Minimum  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 2 years
Computer equipment and software | Maximum  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 12 years
Demonstration units | Minimum  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 2 years
Demonstration units | Maximum  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 3 years
Furniture and office equipment | Minimum  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 2 years
Furniture and office equipment | Maximum  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 15 years
Machinery, equipment and tooling | Minimum  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 3 years
Machinery, equipment and tooling | Maximum  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 20 years
Transportation, vehicles and other | Minimum  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 1 year
Transportation, vehicles and other | Maximum  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 20 years
v3.24.0.1
Summary of Significant Accounting Policies - Additional Information (Detail)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 30, 2023
USD ($)
segment
shares
Dec. 31, 2022
USD ($)
shares
Jan. 01, 2022
USD ($)
shares
Summary Of Significant Accounting Policies [Line Items]      
Number of Sources of Product Revenue | segment 4    
Advertising costs | $ $ 61.4 $ 49.3 $ 9.0
Options to purchase of shares of common stock (in shares)   0.8 0.2
Non-Healthcare Segment | As Previously Reported      
Summary Of Significant Accounting Policies [Line Items]      
Advertising costs | $   $ 12.3  
Restricted Stock Units (RSUs)      
Summary Of Significant Accounting Policies [Line Items]      
Weighted average shares contingently issuable (in shares) 0.5 0.3 0.1
Chief Executive Officer | Restricted Stock Units (RSUs)      
Summary Of Significant Accounting Policies [Line Items]      
Weighted average shares contingently issuable (in shares) 2.7 2.7 2.7
Minimum      
Summary Of Significant Accounting Policies [Line Items]      
Revenue, remaining performance obligation, expected timing of satisfaction, period 3 years    
Warranty period for defects in material and workmanship 6 months    
Maximum      
Summary Of Significant Accounting Policies [Line Items]      
Revenue, remaining performance obligation, expected timing of satisfaction, period 6 years    
Warranty period for defects in material and workmanship 48 months    
Patents      
Summary Of Significant Accounting Policies [Line Items]      
Estimated life maximum 10 years    
Trademarks      
Summary Of Significant Accounting Policies [Line Items]      
Estimated life maximum 17 years    
v3.24.0.1
Summary of Significant Accounting Policies - Changes in Product Warranty Accrual (Detail) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Movement in Standard Product Warranty Accrual [Roll Forward]      
Product warranty accrual, beginning of period $ 10.6 $ 2.5 $ 2.7
Increase related to acquisition, net of reserve 0.0 8.4 0.0
Accrual for warranties issued 7.8 1.8 2.2
Changes in pre-existing warranties (including changes in estimates) (7.5) 4.7 (1.4)
Settlements made (2.3) (6.8) (1.0)
Product warranty accrual, end of period $ 8.6 $ 10.6 $ 2.5
v3.24.0.1
Summary of Significant Accounting Policies - Computation of Basic and Diluted Net Income Per Share (Detail) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Net income      
Net income $ 81.5 $ 143.5 $ 229.6
Basic net income per share:      
Weighted-average shares outstanding - basic (in shares) 52.8 53.6 55.2
Net income per basic share (in dollars per share) $ 1.54 $ 2.68 $ 4.16
Diluted net income per share:      
Weighted-average shares outstanding - basic (in shares) 52.8 53.6 55.2
Diluted share equivalents: stock options and RSUs (in shares) 1.3 1.6 2.5
Weighted-average shares outstanding - diluted (in shares) 54.1 55.2 57.7
Net income per diluted share (in dollars per share) $ 1.51 $ 2.60 $ 3.98
v3.24.0.1
Summary of Significant Accounting Policies-Cash Flow Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Jan. 02, 2021
Cash paid during the year for:        
Interest expense $ 51.0 $ 23.0 $ 0.3  
Income taxes 54.4 87.3 43.9  
Operating lease liabilities 22.4 17.2 7.3  
Non-cash operating activities:        
ROU assets obtained in exchange for lease liabilities 16.3 0.0 6.0  
Non-cash investing activities:        
Unpaid purchases of property and equipment 0.2 3.8 0.0  
Unsettled common stock proceeds from option exercises 0.0 0.0 0.7  
Reconciliation of cash, cash equivalents and restricted cash:        
Cash and cash equivalents 163.0 202.9 745.3  
Restricted cash 5.2 6.7 3.1  
Total cash, cash equivalents and restricted cash shown in the statement of cash flows $ 168.2 $ 209.6 $ 748.4 $ 645.0
v3.24.0.1
Related Party Transactions (Detail)
 1 Months Ended 12 Months Ended
Jul. 31, 2021
USD ($)
Dec. 30, 2023
USD ($)
ft²
Dec. 31, 2022
USD ($)
Jan. 01, 2022
USD ($)
Jul. 03, 2021
USD ($)
Related Party Transaction [Line Items]          
Proceeds from Royalties Received   $ 100,000 $ 200,000 $ 100,000  
Revenue   2,048,100,000 2,035,800,000 1,239,200,000  
Related Party          
Related Party Transaction [Line Items]          
Other current liabilities   4,200,000 4,000,000.0    
Minimum | Related Party          
Related Party Transaction [Line Items]          
Minimum aggregate royalty payments   5,000,000      
Willow Laboratories, Inc.          
Related Party Transaction [Line Items]          
Payment for administrative fees   500,000 400,000 300,000  
Sublease Income   1,200,000 1,200,000 1,200,000  
Willow Laboratories, Inc. | Related Party          
Related Party Transaction [Line Items]          
Minimum aggregate royalty payments   19,200,000 16,900,000 13,500,000  
Other current liabilities   $ 4,100,000 3,800,000    
Leased Property          
Related Party Transaction [Line Items]          
Square feet of office | ft²   34,000      
Not for Profit Organization          
Related Party Transaction [Line Items]          
Cash contributions   $ 1,000,000 1,000,000 0  
Like Minded Entertainment          
Related Party Transaction [Line Items]          
Cash contributions   1,500,000 1,400,000 0  
Like Minded Entertainment | Related Party          
Related Party Transaction [Line Items]          
Other current liabilities   0 0    
Like Minded Labs          
Related Party Transaction [Line Items]          
License fee         $ 3,000,000
Vantrix Corp | Purchase Commitment          
Related Party Transaction [Line Items]          
Purchases from related party $ 500,000        
Vantrix Corp | Options Held          
Related Party Transaction [Line Items]          
Purchases from related party $ 1,100,000        
Reimbursement Fee | Chief Executive Officer          
Related Party Transaction [Line Items]          
Cash contributions   $ 100,000 $ 100,000 $ 100,000  
v3.24.0.1
Inventories - Components of Inventory (Detail) - USD ($)
$ in Millions
Dec. 30, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Raw materials $ 229.7 $ 209.9
Work-in-process 30.0 30.4
Finished goods 285.3 260.7
Total inventories $ 545.0 $ 501.0
v3.24.0.1
Other Current Assets - (Details) - USD ($)
$ in Millions
Dec. 30, 2023
Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Prepaid expenses $ 58.3 $ 77.5
Lease receivable, current 30.2 28.5
Prepaid income taxes 29.3 12.4
Indirect taxes receivable 28.6 26.8
Contract assets, current 6.7 3.9
Prepaid rebates and royalties 4.8 3.7
Restricted cash 3.0 2.4
Other current assets 7.5 3.6
Total other current assets $ 168.4 $ 158.8
v3.24.0.1
Lease Receivable (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Lessee, Lease, Description [Line Items]    
Lease revenue $ 58.0 $ 52.0
As Previously Reported    
Lessee, Lease, Description [Line Items]    
Lease revenue   $ 57.0
v3.24.0.1
Lease Receivable - Sales-Type (Details) - USD ($)
$ in Millions
Dec. 30, 2023
Dec. 31, 2022
Leases [Abstract]    
Lease receivable $ 101.9 $ 101.8
Allowance for credit loss (0.3) (0.2)
Lease receivable, net 101.6 101.6
Less: current portion of lease receivable (30.2) (28.5)
Lease receivable, non-current $ 71.4 $ 73.1
v3.24.0.1
Lease Receivable - Sales-Type Lease, Maturity (Details) - USD ($)
$ in Millions
Dec. 30, 2023
Dec. 31, 2022
Sales-Type Leases    
2024 $ 30.2  
2025 25.0  
2026 18.9  
2027 13.6  
2028 7.0  
Thereafter 6.9  
Lease receivable, net 101.6 $ 101.6
Less: imputed interest 0.0  
Present value of total lease payments 101.6  
Operating Leases    
2024 10.4  
2025 9.3  
2026 8.5  
2027 6.9  
2028 5.4  
Thereafter 6.0  
Total $ 46.5  
Discount rate used to measure the net investment in lease 0.00%  
v3.24.0.1
Deferred Costs and Other Contract Assets - (Details) - USD ($)
$ in Millions
Dec. 30, 2023
Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Deferred commissions $ 21.8 $ 17.1
Prepaid contract allowances 17.0 13.7
Unbilled contract receivables 17.0 9.4
Deferred equipment agreements, net 1.5 1.7
Deferred costs and other contract assets $ 57.3 $ 41.9
v3.24.0.1
Property and Equipment, net - Components of Property and Equipment (Detail) - USD ($)
$ in Millions
Dec. 30, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 686.8 $ 604.0
Accumulated depreciation (262.4) (201.5)
Property and equipment, net 424.4 402.5
Building and building improvements    
Property, Plant and Equipment [Line Items]    
Total property and equipment 151.0 151.0
Machinery, equipment and tooling    
Property, Plant and Equipment [Line Items]    
Total property and equipment 169.7 149.4
Operating lease assets    
Property, Plant and Equipment [Line Items]    
Total property and equipment 92.2 50.2
Land    
Property, Plant and Equipment [Line Items]    
Total property and equipment 66.2 65.1
Computer equipment and software    
Property, Plant and Equipment [Line Items]    
Total property and equipment 45.5 42.1
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Total property and equipment 37.5 32.3
Transportation, vehicles and other    
Property, Plant and Equipment [Line Items]    
Total property and equipment 34.0 32.7
Furniture and office equipment    
Property, Plant and Equipment [Line Items]    
Total property and equipment 20.4 19.4
Demonstration units    
Property, Plant and Equipment [Line Items]    
Total property and equipment 11.1 11.2
Construction-in-progress (CIP)    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 59.2 $ 50.6
v3.24.0.1
Property and Equipment, net - Additional Information (Detail)
$ in Millions, $ in Millions
 12 Months Ended
Feb. 14, 2022
CAD ($)
Dec. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Jan. 01, 2022
USD ($)
Property, Plant and Equipment [Line Items]        
Depreciation   $ 43.9 $ 43.0 $ 25.3
Amortization of deferred cost of goods sold   19.3 4.3  
Accumulated amortization of deferred cost of goods sold   1.5 2.1  
Property, plant and equipment, additions $ 123.0      
Escrow deposit $ 21.0      
Operating lease assets        
Property, Plant and Equipment [Line Items]        
Depreciation   $ 19.3 $ 4.4 $ 0.5
v3.24.0.1
Intangible Assets, net - Schedule of Finite-Lived Intangible Assets (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 30, 2023
Sep. 30, 2023
Dec. 30, 2023
Dec. 31, 2022
Intangible assets subject to amortization:        
Gross Carrying Amount $ 552.3   $ 552.3 $ 540.6
Accumulated Amortization (132.4)   (132.4) (80.0)
Net Carrying Amount 419.9   $ 419.9 $ 460.6
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]     Impairment charge Impairment charge
Intangible assets not subject to amortization:        
Trademarks 232.4   $ 232.4 $ 262.0
Intangible Assets, Net (Excluding Goodwill) [Abstract]        
Intangible assets, net 652.3   652.3 722.6
Trademarks        
Intangible assets not subject to amortization:        
Trademarks 242.4   242.4 262.0
Impairment charge (3.0) $ (7.0) (10.0) 0.0
Total trademarks 232.4   232.4 262.0
Customer relationships        
Intangible assets subject to amortization:        
Gross Carrying Amount 209.2   209.2 220.9
Accumulated Amortization (31.5)   (31.5) (19.3)
Net Carrying Amount 177.7   177.7 201.6
Acquired technologies        
Intangible assets subject to amortization:        
Gross Carrying Amount 174.7   174.7 185.3
Accumulated Amortization (45.3)   (45.3) (25.2)
Net Carrying Amount 129.4   129.4 160.1
Capitalized software development costs        
Intangible assets subject to amortization:        
Gross Carrying Amount 53.9   53.9 25.0
Accumulated Amortization (15.2)   (15.2) (2.9)
Net Carrying Amount 38.7   38.7 22.1
Capitalized software development costs | As Previously Reported        
Intangible assets subject to amortization:        
Gross Carrying Amount       5.5
Accumulated Amortization       (2.9)
Net Carrying Amount       2.6
Licenses        
Intangible assets subject to amortization:        
Gross Carrying Amount 39.7   39.7 39.0
Accumulated Amortization (7.4)   (7.4) (4.4)
Net Carrying Amount 32.3   32.3 34.6
Licenses | Willow Laboratories, Inc.        
Intangible assets subject to amortization:        
Gross Carrying Amount 7.5   7.5 7.5
Accumulated Amortization (6.7)   (6.7) (6.3)
Net Carrying Amount 0.8   0.8 1.2
Patents        
Intangible assets subject to amortization:        
Gross Carrying Amount 39.2   39.2 35.2
Accumulated Amortization (15.2)   (15.2) (13.9)
Net Carrying Amount 24.0   24.0 21.3
Trademarks        
Intangible assets subject to amortization:        
Gross Carrying Amount 20.1   20.1 19.8
Accumulated Amortization (7.4)   (7.4) (5.8)
Net Carrying Amount 12.7   12.7 14.0
Trademarks | As Previously Reported        
Intangible assets subject to amortization:        
Gross Carrying Amount       39.3
Accumulated Amortization       (5.8)
Net Carrying Amount       33.5
Non-compete agreements        
Intangible assets subject to amortization:        
Gross Carrying Amount 6.3   6.3 6.3
Accumulated Amortization (2.6)   (2.6) (1.1)
Net Carrying Amount 3.7   3.7 5.2
Other        
Intangible assets subject to amortization:        
Gross Carrying Amount 1.7   1.7 1.6
Accumulated Amortization (1.1)   (1.1) (1.1)
Net Carrying Amount $ 0.6   $ 0.6 0.5
Trademarks and Capitalized Software Development Costs | Revision of Prior Period, Reclassification, Adjustment        
Intangible assets subject to amortization:        
Net Carrying Amount       $ 19.5
v3.24.0.1
Intangible Assets, net - Additional Information (Detail) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 30, 2023
Sep. 30, 2023
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Finite-Lived Intangible Assets [Line Items]          
Accumulated Amortization $ 132.4   $ 132.4 $ 80.0  
Cost of patents, gross 12.1   12.1 10.6  
Cost of trademarks, gross 1.0   1.0 1.1  
Trademarks          
Finite-Lived Intangible Assets [Line Items]          
Impairment charge 3.0 $ 7.0 $ 10.0 0.0  
Minimum          
Finite-Lived Intangible Assets [Line Items]          
Acquired finite-lived intangible assets, weighted average useful life     12 years    
Maximum          
Finite-Lived Intangible Assets [Line Items]          
Acquired finite-lived intangible assets, weighted average useful life     14 years    
Patents And Trademarks          
Finite-Lived Intangible Assets [Line Items]          
Accumulated Amortization 54.4   $ 54.4 39.8 $ 10.3
Total renewal costs capitalized     1.0 1.2  
Patents          
Finite-Lived Intangible Assets [Line Items]          
Accumulated Amortization 15.2   $ 15.2 13.9  
Weighted average number of years until the next renewal     2 years    
Trademarks          
Finite-Lived Intangible Assets [Line Items]          
Accumulated Amortization $ 7.4   $ 7.4 $ 5.8  
Weighted average number of years until the next renewal     6 years    
v3.24.0.1
Intangible Assets, net - Estimated Amortization Expense (Detail) - USD ($)
$ in Millions
Dec. 30, 2023
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]    
2024 $ 53.7  
2025 51.0  
2026 40.1  
2027 39.2  
2028 39.0  
Thereafter 196.9  
Net Carrying Amount $ 419.9 $ 460.6
v3.24.0.1
Goodwill - Changes in Goodwill - (Detail) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Goodwill [Roll Forward]    
Goodwill, beginning of period $ 445.4 $ 100.3
Adjustments to goodwill from purchase price allocation (18.2) 347.8
Foreign currency translation adjustment (19.5) (2.7)
Goodwill, end of period 407.7 445.4
Sound United Acquisition    
Goodwill [Roll Forward]    
Adjustments to goodwill from purchase price allocation (7.8)  
Healthcare    
Goodwill [Roll Forward]    
Goodwill, beginning of period 97.6 100.3
Adjustments to goodwill from purchase price allocation 0.0 0.0
Foreign currency translation adjustment 1.0 (2.7)
Goodwill, end of period 98.6 97.6
Non-healthcare    
Goodwill [Roll Forward]    
Goodwill, beginning of period 347.8 0.0
Adjustments to goodwill from purchase price allocation (18.2) 347.8
Foreign currency translation adjustment (20.5) 0.0
Goodwill, end of period $ 309.1 $ 347.8
v3.24.0.1
Lessee ROU Assets and Lease Liabilities - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Leases [Abstract]      
Operating lease renewal term 5 years    
Weighted average discount rate 4.10%    
Accumulated amortization for operating leases $ 48.9 $ 36.6  
Weighted average remaining lease term 5 years 7 months 6 days    
Operating lease costs $ 22.7 $ 18.0 $ 8.2
v3.24.0.1
Lessee ROU Assets and Lease Liabilities Lessee - Operating Lease Balance Sheet Classification (Details) - USD ($)
$ in Millions
Dec. 30, 2023
Dec. 31, 2022
Leases [Abstract]    
Lessee ROU assets, net $ 59.1 $ 69.6
Lessee current lease liabilities 18.2 18.7
Lessee non-current lease liabilities 45.8 53.4
Total operating lease liabilities $ 64.0 $ 72.1
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other non-current assets Other non-current assets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Other current liabilities Other current liabilities
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Other non-current liabilities Other non-current liabilities
v3.24.0.1
Lessee ROU Assets and Lease Liabilities - Future Maturities Operating Lease Payments (Details) - USD ($)
$ in Millions
Dec. 30, 2023
Dec. 31, 2022
Leases [Abstract]    
2024 $ 19.2  
2025 15.3  
2026 10.9  
2027 6.6  
2028 5.7  
Thereafter 17.8  
Total 75.5  
Imputed interest (11.5)  
Present value $ 64.0 $ 72.1
v3.24.0.1
Other Non-Current Assets - (Details) - USD ($)
$ in Millions
Dec. 30, 2023
Dec. 31, 2022
Product Information [Line Items]    
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Total non-current assets Total non-current assets
Lessee ROU assets, net $ 59.1 $ 69.6
Prepaid deposits and other 6.4 5.8
Strategic investments 7.2 13.8
Equity investments - fair value 2.7 0.0
Restricted cash 2.2 5.2
Other non-current assets 0.3 0.3
Total non-current assets 89.3 114.0
Cash Flow Hedging    
Product Information [Line Items]    
Derivative assets - non-current $ 11.4 $ 19.3
v3.24.0.1
Deferred Revenue and Other Contract Liabilities, Current - Schedule of Deferred Revenue and Other Contract Liabilities, Current (Details) - USD ($)
$ in Millions
Dec. 30, 2023
Dec. 31, 2022
Revenue Recognition and Deferred Revenue [Abstract]    
Deferred revenue $ 63.8 $ 61.0
Accrued rebates and allowances 37.5 38.5
Accrued customer reimbursements 12.4 6.1
Total deferred revenue and other contract liabilities 113.7 105.6
Less: Non-current portion of deferred revenue (26.4) (25.0)
Deferred revenue and other contract-related liabilities, current $ 87.3 $ 80.6
v3.24.0.1
Deferred Revenue and Other Contract Liabilities, Current - Narrative (Details) - USD ($)
$ in Millions
Dec. 30, 2023
Dec. 31, 2022
Oct. 31, 2020
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Unrecognized contract revenue $ 1,497.2    
Deferred revenue 63.8 $ 61.0  
Bowers and Wilkins      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Royalty prepayment     $ 20.0
Deferred revenue 15.3   $ 35.0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-12-31      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Unrecognized contract revenue $ 380.9    
Revenue, remaining performance obligation, expected timing of satisfaction, period 1 year    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-12-31 | Twelve Months and Thereafter      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Revenue, remaining performance obligation, expected timing of satisfaction, period 12 months    
v3.24.0.1
Deferred Revenue and Other Contract Liabilities, Current - Changes in Deferred Revenue (Details)
$ in Millions
 12 Months Ended
Dec. 30, 2023
USD ($)
Movement in Deferred Revenue [Roll Forward]  
Deferred revenue, beginning of the period $ 61.0
Revenue deferred during the period 28.3
Recognition of revenue deferred in prior periods (25.5)
Deferred revenue, end of the period $ 63.8
v3.24.0.1
Other Current Liabilities - (Details) - USD ($)
$ in Millions
Dec. 30, 2023
Dec. 31, 2022
Other Current Liabilities [Line Items]    
Current portion of long-term debt $ 34.3 $ 15.1
Accrued expenses 26.3 39.9
Accrued indirect taxes payable 23.9 28.2
Lessee lease liabilities, current 18.2 18.7
Income tax payable 16.1 32.1
Accrued property taxes 10.2 12.1
Accrued legal fees 9.9 11.4
Accrued warranty 8.6 10.6
Accrued donations 4.0 5.1
Total other current liabilities 162.4 183.3
Nonrelated Party    
Other Current Liabilities [Line Items]    
Other current liabilities 6.7 6.1
Related Party    
Other Current Liabilities [Line Items]    
Other current liabilities $ 4.2 $ 4.0
v3.24.0.1
Debt - Schedule of Debt (Details) - USD ($)
$ in Millions
Dec. 30, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
Short-term debt $ 34.3 $ 15.1
Long-term debt 871.7 941.6
Total debt 906.0 956.7
Japanese Loans    
Debt Instrument [Line Items]    
Short-term debt 23.0 7.6
Long-term debt 8.8 11.7
Term Loan    
Debt Instrument [Line Items]    
Short-term debt 11.3 7.5
Long-term debt 271.4 278.9
Revolver    
Debt Instrument [Line Items]    
Long-term debt $ 591.5 $ 651.0
v3.24.0.1
Debt - Narrative (Details)
 1 Months Ended 12 Months Ended
Feb. 28, 2023
USD ($)
Apr. 11, 2022
USD ($)
Mar. 31, 2020
USD ($)
Dec. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Jan. 01, 2022
USD ($)
Feb. 28, 2023
JPY (¥)
May 16, 2022
USD ($)
May 31, 2021
USD ($)
May 31, 2021
JPY (¥)
Apr. 30, 2021
USD ($)
Apr. 30, 2021
JPY (¥)
Jun. 30, 2020
USD ($)
Jun. 30, 2020
JPY (¥)
Mar. 31, 2020
JPY (¥)
Prior Credit Facility                              
Debt Instrument [Line Items]                              
Line of credit facility, maximum borrowing capacity   $ 550,000,000                          
New Credit Facility Agreement                              
Debt Instrument [Line Items]                              
Accordion feature, increase limit   $ 400,000,000                          
New Credit Facility Agreement | Adjusted Secured Overnight Financing Rate (SOFR)                              
Debt Instrument [Line Items]                              
Basis spread on variable rate   1.00%                          
New Credit Facility Agreement | Federal Funds Effective Swap Rate                              
Debt Instrument [Line Items]                              
Basis spread on variable rate   0.50%                          
New Credit Facility Agreement | Adjusted Secured Overnight Financing Rate (SOFR), One-Month Interest Period                              
Debt Instrument [Line Items]                              
Basis spread on variable rate   0.10%                          
New Credit Facility Agreement | Adjusted Secured Overnight Financing Rate (SOFR), Three-Month Interest Period                              
Debt Instrument [Line Items]                              
Basis spread on variable rate   0.15%                          
New Credit Facility Agreement | Adjusted Secured Overnight Financing Rate (SOFR), Six-Month Interest Period                              
Debt Instrument [Line Items]                              
Basis spread on variable rate   0.25%                          
New Credit Facility Agreement | Minimum                              
Debt Instrument [Line Items]                              
Commitment fee percentage   0.15%                          
New Credit Facility Agreement | Minimum | Alternate Base Rate                              
Debt Instrument [Line Items]                              
Basis spread on variable rate   0.00%                          
New Credit Facility Agreement | Minimum | Adjusted Secured Overnight Financing Rate (SOFR)                              
Debt Instrument [Line Items]                              
Basis spread on variable rate   1.00%                          
New Credit Facility Agreement | Maximum                              
Debt Instrument [Line Items]                              
Commitment fee percentage   0.275%                          
New Credit Facility Agreement | Maximum | Alternate Base Rate                              
Debt Instrument [Line Items]                              
Basis spread on variable rate   0.75%                          
New Credit Facility Agreement | Maximum | Adjusted Secured Overnight Financing Rate (SOFR)                              
Debt Instrument [Line Items]                              
Basis spread on variable rate   1.75%                          
Japanese Government Loans                              
Debt Instrument [Line Items]                              
Debt instrument face amount                         $ 10,500,000 ¥ 1,480,000,000  
Average interest rate                         1.33% 1.33%  
Japanese Equipment Loans                              
Debt Instrument [Line Items]                              
Debt instrument face amount                 $ 600,000 ¥ 80,000,000 $ 1,100,000 ¥ 150,000,000      
Average interest rate                 1.20% 1.20% 0.58% 0.58%      
Revolving Credit Facility                              
Debt Instrument [Line Items]                              
Interest expense       $ 47,000,000 $ 23,700,000 $ 0                  
Revolving Credit Facility | New Credit Facility Agreement                              
Debt Instrument [Line Items]                              
Accordion feature, increase limit               $ 205,000,000              
Line of credit facility, maximum borrowing capacity   $ 500,000,000           $ 705,000,000              
Revolving Credit Facility | Line of Credit | Japanese Revolving Loan                              
Debt Instrument [Line Items]                              
Line of credit facility, maximum borrowing capacity $ 21,300,000   $ 5,700,000       ¥ 3,000,000,000               ¥ 800,000,000
Collateralized assets     11,400,000                        
Debt issuance costs $ 200,000   $ 100,000       ¥ 22,000,000               ¥ 7,200,000
Basis spread on variable rate 0.75%   0.50%                        
Revolving Credit Facility | Line of Credit | Initial Lenders                              
Debt Instrument [Line Items]                              
Debt issuance costs   8,400,000                          
Unsecured Debt | Prior Credit Facility                              
Debt Instrument [Line Items]                              
Accordion feature, increase limit   150,000,000                          
Debt issuance costs   100,000                          
Unsecured Debt | New Credit Facility Agreement                              
Debt Instrument [Line Items]                              
Line of credit facility, maximum borrowing capacity   300,000,000                          
Letter of Credit | Prior Credit Facility                              
Debt Instrument [Line Items]                              
Line of credit facility, maximum borrowing capacity   25,000,000                          
Letter of Credit | New Credit Facility Agreement                              
Debt Instrument [Line Items]                              
Line of credit facility, maximum borrowing capacity   50,000,000                          
Credit Line In Foreign Currency | Prior Credit Facility                              
Debt Instrument [Line Items]                              
Line of credit facility, maximum borrowing capacity   $ 75,000,000                          
v3.24.0.1
Debt - Maturity Debt Schedule (Details)
$ in Millions
Dec. 30, 2023
USD ($)
Debt Disclosure [Abstract]  
2024 $ 34.3
2025 16.7
2026 16.7
2027 834.6
2028 1.1
Thereafter 2.6
Total $ 906.0
v3.24.0.1
Other Non-Current Liabilities - (Detail) - USD ($)
$ in Millions
Dec. 30, 2023
Dec. 31, 2022
Other Liabilities Disclosure [Abstract]    
Lessee non-current lease liabilities $ 45.8 $ 53.4
Deferred revenue, non-current 26.4 25.0
Unrecognized tax benefits 24.4 18.0
Projected benefit obligation 9.5 10.1
Indirect tax payable, non-current 8.4 8.2
Income tax payable, non-current 7.1 12.7
Other 7.9 9.1
Deferred tax liabilities 111.7 163.6
Other non-current liabilities $ 129.5 $ 136.5
v3.24.0.1
Derivative Instruments and Hedging Activities - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 28, 2024
Dec. 30, 2023
Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Net of tax gain (Loss) on derivatives   $ (8.8) $ 14.7
Forecast | Interest Expense      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Net of tax gain (Loss) on derivatives $ 10.6    
Designated as Hedging Instrument | Interest rate contracts, inclusive of accrued interest      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Average fixed interest rate related to derivative contracts   3.14%  
Maturities of derivative contracts   3 years  
v3.24.0.1
Derivative Instruments and Hedging Activities - Schedule of Fair Value of Hedging Instruments (Details) - Designated as Hedging Instrument - USD ($)
$ in Millions
Dec. 30, 2023
Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Fair value of hedging instruments $ 8.0 $ 19.7
Interest rate contracts, inclusive of accrued interest | Other non-current assets    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Fair value of hedging instruments $ 11.6 $ 19.7
v3.24.0.1
Derivative Instruments and Hedging Activities - Schedule of Gain (Losses) Reclassified from AOCI (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Gains (losses) reclassified from accumulated other comprehensive income $ 14.9 $ 0.7 $ 0.0
Designated as Hedging Instrument      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Fair value of hedging instruments 8.0 19.7  
Designated as Hedging Instrument | Interest rate contracts, inclusive of accrued interest | Non-current liability      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Fair value of hedging instruments (3.6) 0.0  
Designated as Hedging Instrument | Interest rate contracts, inclusive of accrued interest | Non-operating loss (income) | Cash Flow Hedging      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Gains (losses) reclassified from accumulated other comprehensive income $ 14.9 $ 0.7 $ 0.0
v3.24.0.1
Derivative Instruments and Hedging Activities - Schedule of Accumulated Other Comprehensive Income Related to Hedging Instruments (Details) - Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Beginning balance $ 19.3 $ 0.0
Amount recognized in other comprehensive income 3.4 20.0
Amount reclassified into earnings (14.9) (0.7)
Ending balance $ 7.8 $ 19.3
v3.24.0.1
Business Combinations - Narrative (Details) - Sound United - USD ($)
$ in Millions
 6 Months Ended 12 Months Ended
Apr. 11, 2022
Oct. 01, 2022
Dec. 30, 2023
Dec. 31, 2022
Business Acquisition [Line Items]        
Percentage of voting interests acquired 100.00%      
Cash consideration $ 1,057.5      
Revenue   $ 694.9 $ 771.1  
Net loss   $ 38.6 20.9  
Masimo        
Business Acquisition [Line Items]        
Acquisition related costs       $ 22.4
Sound United        
Business Acquisition [Line Items]        
Acquisition related costs       41.1
Selling, General and Administrative Expenses        
Business Acquisition [Line Items]        
Transaction costs     $ 0.0 $ 16.6
v3.24.0.1
Business Combinations - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Millions
 12 Months Ended
Apr. 11, 2022
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Assets acquired:        
Goodwill   $ 407.7 $ 445.4 $ 100.3
Liabilities assumed:        
Adjustments to goodwill from purchase price allocation   18.2 $ (347.8)  
Sound United        
Business Acquisition [Line Items]        
Cash consideration $ 1,057.5      
Purchase price 1,057.5      
Assets acquired:        
Cash and cash equivalents 82.6      
Accounts receivables 108.5      
Inventories 238.6      
Prepaid expenses and other current assets 30.0      
Property, plant and equipment 113.2      
Intangible assets 649.0 387.0    
Goodwill 318.0      
Long-term other assets 7.4      
Total assets acquired 1,547.3      
Liabilities assumed:        
Accounts payable (118.8)      
Accrued liabilities and other current liabilities (148.9)      
Deferred tax liabilities (145.1)      
Other long-term liabilities (77.0)      
Total liabilities assumed $ (489.8)      
Sound United Acquisition        
Liabilities assumed:        
Adjustments to goodwill from purchase price allocation   $ 7.8    
v3.24.0.1
Business Combinations - Schedule of Acquired Intangible Assets (Details) - Sound United - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2023
Apr. 11, 2022
Business Acquisition [Line Items]    
Acquired finite-lived intangible assets, weighted average useful life 14 years  
Intangible assets $ 387.0 $ 649.0
Indefinite trademarks/tradenames 262.0  
Total $ 649.0  
Trademarks/tradenames    
Business Acquisition [Line Items]    
Acquired finite-lived intangible assets, weighted average useful life 10 years  
Intangible assets $ 6.0  
Customer relationships    
Business Acquisition [Line Items]    
Acquired finite-lived intangible assets, weighted average useful life 17 years  
Intangible assets $ 196.0  
Developed technology    
Business Acquisition [Line Items]    
Acquired finite-lived intangible assets, weighted average useful life 8 years  
Intangible assets $ 156.0  
Contractual license agreements    
Business Acquisition [Line Items]    
Acquired finite-lived intangible assets, weighted average useful life 15 years  
Intangible assets $ 29.0  
v3.24.0.1
Business Combinations - Pro Forma Information (Details) - Sound United - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]      
Net revenue $ 2,048.1 $ 2,293.4 $ 2,187.4
Net income $ 81.5 $ 181.8 $ 126.2
v3.24.0.1
Equity - Additional Information (Detail) - $ / shares
 1 Months Ended 12 Months Ended
Oct. 31, 2021
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Sep. 20, 2022
Jun. 30, 2022
Class of Stock [Line Items]            
Preferred stock, par value (in dollars per share)   $ 1.000 $ 1.000      
Shares repurchased (in shares)   0 3,000,000.0 500,000    
Rights to Purchase Series A Junior Participating Preferred Stock            
Class of Stock [Line Items]            
Preferred stock purchase right declared for each share of common stock (in shares)         1  
Preferred stock, par value (in dollars per share)         $ 0.001  
Purchase price per each right (in dollars per share)         $ 1,000  
Rights to Purchase Series A Junior Participating Preferred Stock | Minimum            
Class of Stock [Line Items]            
Threshold percentage to exercise purchase right         10.00%  
Rights to Purchase Series A Junior Participating Preferred Stock | Maximum            
Class of Stock [Line Items]            
Threshold percentage to exercise purchase right         20.00%  
2021 Repurchase Program | Common Stock            
Class of Stock [Line Items]            
Stock repurchase program, number of shares authorized to be repurchased (in shares) 3,000,000          
Stock repurchase program period in force 3 years          
2022 Repurchase Program | Common Stock            
Class of Stock [Line Items]            
Stock repurchase program, number of shares authorized to be repurchased (in shares)   5,000,000       5,000,000
v3.24.0.1
Equity - Schedule of Stock Repurchase Activities (Detail) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Equity [Abstract]      
Shares repurchased (in shares) 0 3,000,000.0 500,000
Average cost per share (in dollars per share) $ 0 $ 133.82 $ 235.88
Value of shares repurchased $ 0.0 $ 401.5 $ 129.0
v3.24.0.1
Stock-Based Compensation - Narrative (Detail) - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
May 31, 2020
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Jun. 01, 2017
Schedule Of Share Based Compensation Arrangements [Line Items]          
Stock-based compensation expense   $ 7.0 $ 47.7 $ 44.6  
Share-based compensation arrangement, weighted average remaining contractual term (in years)   4 years 10 months 24 days 4 years 3 months 18 days    
Weighted average remaining contractual term of options exercisable, years   2 years 10 months 24 days 3 years 7 months 6 days    
Award vesting rights   three years three years three  
Total fair market value of all vesting options   $ 9.5 $ 12.4 $ 15.2  
Aggregated intrinsic value of options outstanding   123.3      
Aggregated intrinsic value of options exercisable   123.3      
Aggregated intrinsic value of options exercised   19.0 14.6 84.7  
Total income tax benefit recognized for share-based compensation expense   2.9 $ 2.5 $ 16.4  
2021 PSU Grant          
Schedule Of Share Based Compensation Arrangements [Line Items]          
Weighted average shares contingently issuable (in shares)     325,124 138,000  
Employee Stock Option          
Schedule Of Share Based Compensation Arrangements [Line Items]          
Stock-based compensation expense   8.8 $ 11.4 $ 13.0  
Unrecognized compensation cost   $ 15.2      
Unrecognized share-based compensation related to unvested options granted, term   2 years 3 months 18 days      
Restricted Stock Units (RSUs)          
Schedule Of Share Based Compensation Arrangements [Line Items]          
Stock-based compensation expense   $ 20.1 $ 14.4 $ 9.0  
Unrecognized share-based compensation related to unvested options granted   $ 90.7      
Weighted average period   4 years      
Weighted average shares contingently issuable (in shares)   500,000 300,000 100,000  
Performance Shares          
Schedule Of Share Based Compensation Arrangements [Line Items]          
Stock-based compensation expense   $ (21.9) $ 21.9 $ 22.6  
Unrecognized share-based compensation related to unvested options granted   $ 7.2      
Weighted average period   1 year 3 months 18 days      
Weighted average shares contingently issuable (in shares)   100,000 300,000 200,000  
2017 Equity Incentive Plan          
Schedule Of Share Based Compensation Arrangements [Line Items]          
Increase in number of shares authorized (in shares) 2,500,000        
Maximum | Performance Shares | 2021 PSU Grant          
Schedule Of Share Based Compensation Arrangements [Line Items]          
Weighted average shares contingently issuable (in shares)   103,000 162,562 69,000  
Share-based compensation arrangement by share-based payment award, range of percentage payout   200.00% 200.00% 200.00%  
Maximum | 2007 Stock Incentive Plan          
Schedule Of Share Based Compensation Arrangements [Line Items]          
Number of shares available for grant (in shares)   5,000,000      
Maximum | 2017 Equity Incentive Plan          
Schedule Of Share Based Compensation Arrangements [Line Items]          
Number of shares available for grant (in shares) 7,500,000        
Minimum | Performance Shares | 2021 PSU Grant          
Schedule Of Share Based Compensation Arrangements [Line Items]          
Weighted average shares contingently issuable (in shares)     162,562 69,000  
Share-based compensation arrangement by share-based payment award, range of percentage payout   0.00% 0.00% 0.00%  
Minimum | 2017 Equity Incentive Plan          
Schedule Of Share Based Compensation Arrangements [Line Items]          
Number of shares available for grant (in shares)         5,000,000
v3.24.0.1
Stock-Based Compensation - Number and Weighted Average Exercise Price of Options Issued and Outstanding under All Stock Option Plans (Detail) - $ / shares
shares in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Shares      
Options outstanding, beginning of period (in shares) 2.8 2.9 3.4
Granted (in shares) 0.1 0.1 0.1
Canceled/Forfeited (in shares) 0.0 (0.1) (0.2)
Exercised (in shares) (0.2) (0.1) (0.4)
Options outstanding, end of period (in shares) 2.7 2.8 2.9
Options exercisable, end of period (in shares) 2.4 2.4 2.2
Weighted-Average Exercise Price      
Options outstanding, beginning of period, average exercise price (in dollars per share) $ 83.85 $ 81.38 $ 77.44
Granted (in dollars per share) 177.29 150.91 250.15
Canceled/Forfeited (in dollars per share) 45.96 162.77 149.11
Exercised (in dollars per share) 43.22 54.53 53.55
Options outstanding, end of period, average exercise price (in dollars per share) 87.79 83.85 81.38
Options exercisable, end of period (in dollars per share) $ 73.79 $ 65.83 $ 57.09
v3.24.0.1
Stock-Based Compensation - Number and Weighted Average Exercise Price of Outstanding and Exercisable Options (Detail) - $ / shares
shares in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Jan. 02, 2021
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]        
Number of options, options outstanding (in shares) 2.7 2.8 2.9 3.4
Average Remaining Contractual Life 4 years 10 months 24 days 4 years 3 months 18 days    
Number of options, options exercisable (in shares) 2.4 2.4 2.2  
$15.00 to $50.00        
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]        
Range of exercise prices, lower (in dollars per share) $ 15.00      
Range of Exercise Prices, upper (in dollars per share) $ 50.00      
Number of options, options outstanding (in shares) 1.2 1.3    
Average Remaining Contractual Life 1 year 6 months 2 years 4 months 24 days    
Number of options, options exercisable (in shares) 1.2 1.3    
$50.01 to $80.00        
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]        
Range of exercise prices, lower (in dollars per share) $ 50.01      
Range of Exercise Prices, upper (in dollars per share) $ 80.00      
Number of options, options outstanding (in shares) 0.0 0.1    
Average Remaining Contractual Life 2 years 6 months 3 years 8 months 12 days    
Number of options, options exercisable (in shares) 0.0 0.1    
$80.01 to $120.00        
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]        
Range of exercise prices, lower (in dollars per share) $ 80.01      
Range of Exercise Prices, upper (in dollars per share) $ 120.00      
Number of options, options outstanding (in shares) 0.7 0.8    
Average Remaining Contractual Life 3 years 8 months 12 days 4 years 9 months 18 days    
Number of options, options exercisable (in shares) 0.7 0.7    
$120.01 to $160.00        
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]        
Range of exercise prices, lower (in dollars per share) $ 120.01      
Range of Exercise Prices, upper (in dollars per share) $ 160.00      
Number of options, options outstanding (in shares) 0.4 0.4    
Average Remaining Contractual Life 6 years 7 years 1 month 6 days    
Number of options, options exercisable (in shares) 0.3 0.2    
$160.01 to $200.00        
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]        
Range of exercise prices, lower (in dollars per share) $ 160.01      
Range of Exercise Prices, upper (in dollars per share) $ 200.00      
Number of options, options outstanding (in shares) 0.3 0.2    
Average Remaining Contractual Life 7 years 7 years 2 months 12 days    
Number of options, options exercisable (in shares) 0.1 0.1    
$200.01 to $230.00        
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]        
Range of exercise prices, lower (in dollars per share) $ 200.01      
Range of Exercise Prices, upper (in dollars per share) $ 230.00      
Number of options, options outstanding (in shares) 0.0 0.0    
Average Remaining Contractual Life 6 years 6 months 7 years 2 months 12 days    
Number of options, options exercisable (in shares) 0.0 0.0    
$230.01 to $280.00        
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]        
Range of exercise prices, lower (in dollars per share) $ 230.01      
Range of Exercise Prices, upper (in dollars per share) $ 280.00      
Number of options, options outstanding (in shares) 0.1 0.0    
Average Remaining Contractual Life 7 years 8 years    
Number of options, options exercisable (in shares) 0.1 0.0    
v3.24.0.1
Stock-Based Compensation - Summary of Unvested RSU and PSU Award Activity (Details) - $ / shares
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Restricted Stock Units (RSUs)      
Units      
Beginning of period (in shares) 3,200,000 3,000,000.0 2,900,000
Granted (in shares) 500,000 300,000 100,000
Canceled/Forfeited (in shares) (100,000) (100,000) 0
Vested (in shares) (100,000) 0 0
End of period (in shares) 3,500,000 3,200,000 3,000,000.0
Weighted-Average Grant Date Fair Value      
Beginning of period (in dollars per share) $ 105.65 $ 104.13 $ 99.66
Granted (in dollars per share) 125.44 148.52 257.43
Canceled (in dollars per share) 172.19 168.90 204.33
Vested (in dollars per share) 173.18 184.04 163.71
End of period, fair value (in dollars per share) $ 105.87 $ 105.65 $ 104.13
Performance Shares      
Units      
Beginning of period (in shares) 300,000 300,000 400,000
Granted (in shares) 100,000 300,000 200,000
Canceled/Forfeited (in shares) 0 (100,000) 0
Vested (in shares) (100,000) (200,000) (300,000)
End of period (in shares) 300,000 300,000 300,000
Weighted-Average Grant Date Fair Value      
Beginning of period (in dollars per share) $ 180.04 $ 168.68 $ 120.28
Granted (in dollars per share) 204.67 145.49 250.73
Canceled (in dollars per share) 155.98 139.73 166.84
Vested (in dollars per share) 179.42 127.46 86.95
End of period, fair value (in dollars per share) $ 190.04 $ 180.04 $ 168.68
Award vesting period 3 years    
v3.24.0.1
Stock-Based Compensation - Range of Assumptions Used and Resulting Weighted-Average Fair Value of Options Granted at Date of Grant (Detail) - $ / shares
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Range of assumptions used and resulting weighted-average fair value of options granted at the date of grant      
Risk-free interest rate, minimum 3.60% 1.00% 0.30%
Risk-free interest rate, maximum 4.20% 1.90% 0.90%
Estimated volatility, minimum 31.60% 31.20% 30.90%
Estimated volatility, maximum 36.70% 38.90% 34.70%
Expected dividends 0.00% 0.00% 0.00%
Weighted-average fair value of options granted (in dollars per share) $ 75.08 $ 49.69 $ 75.72
Minimum      
Range of assumptions used and resulting weighted-average fair value of options granted at the date of grant      
Expected term, years 5 years 1 month 6 days 5 years 1 month 6 days 5 years 1 month 6 days
Maximum      
Range of assumptions used and resulting weighted-average fair value of options granted at the date of grant      
Expected term, years 5 years 10 months 24 days 5 years 8 months 12 days 5 years 7 months 6 days
v3.24.0.1
Stock-Based Compensation - Total Share-Based Compensation Expense Included in Consolidated Statements of Comprehensive Income (Detail) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Schedule Of Share Based Compensation Arrangements [Line Items]      
Stock-based compensation $ 7.0 $ 47.7 $ 44.6
Cost of goods sold      
Schedule Of Share Based Compensation Arrangements [Line Items]      
Stock-based compensation 1.1 1.0 0.8
Selling, general and administrative      
Schedule Of Share Based Compensation Arrangements [Line Items]      
Stock-based compensation (1.5) 32.9 31.3
Research and development      
Schedule Of Share Based Compensation Arrangements [Line Items]      
Stock-based compensation $ 7.4 $ 13.8 $ 12.5
v3.24.0.1
Employee Benefits - Narrative (Details)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 30, 2023
USD ($)
plan
Dec. 31, 2022
USD ($)
Dec. 30, 2023
USD ($)
plan
Dec. 31, 2022
USD ($)
Jan. 01, 2022
USD ($)
Defined Contribution Plan Disclosure [Line Items]          
Defined contribution plan, number of plans | plan 1   1    
Expected long-term return on plan assets     3.53% 1.70%  
Other     $ 2.0 $ 1.8  
Defined benefit plan, plan assets, foreign currency revaluation     4.3    
Actual net gain on plan assets     1.1 (2.5)  
Benefits paid     0.8 2.8  
Other, includes translation     3.8 1.8  
Defined benefit plan, benefit obligation, foreign currency revaluation     6.1    
Actuarial gain     (2.3) (1.9)  
Unfunded balance $ (9.5) $ (10.1) (9.5) (10.1)  
Employer contributions     0.4 1.5  
Expected contributions for next fiscal year 1.8   $ 1.8    
Masimo Retirement Savings Plan          
Defined Contribution Plan Disclosure [Line Items]          
Percent of employees pay     100.00%    
Percent of match     3.00%    
Company's contribution to employee retirement savings plan $ 4.9 $ 4.5     $ 3.4
Masimo Retirement Savings Plan | Foreign Plan          
Defined Contribution Plan Disclosure [Line Items]          
Company's contribution to employee retirement savings plan     $ 5.5 $ 4.3 $ 0.0
v3.24.0.1
Employee Benefits - Defined Benefit Plans (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Plan Assets    
Fair value of plan assets at beginning of year $ 22.2 $ 21.7
Realized net gains (losses) on plan assets 1.1 (2.5)
Employer contributions 0.4 1.5
Participant contributions 0.6 0.5
Benefits paid 0.8 2.8
Other (2.0) (1.8)
Fair value of plan assets at end of year 23.1 22.2
Projected Benefit Obligation    
Projected benefit obligation at beginning of year 32.3 32.3
Service cost 1.2 1.1
Interest cost 0.5 0.1
Participant contributions 0.6 0.5
Actuarial gains (losses) 2.3 1.9
Benefits paid (0.5) 2.0
Other (3.8) (1.8)
Projected benefit obligation at end of year   32.3
Funded status $ (9.5) $ (10.1)
v3.24.0.1
Employee Benefits - Net Periodic Costs (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Postemployment Benefits [Abstract]    
Components of net periodic benefit cost $ 0.0 $ 0.0
Service cost 1.2 1.1
Interest cost 0.5 0.1
Expected (gains) on plan assets (0.7) (0.6)
Amortization of net losses 0.0 0.1
Recognized net actuarial loss 0.0 0.3
Net periodic defined benefit plan cost $ 1.0 $ 1.0
v3.24.0.1
Employee Benefits - Classification of Amounts Recognized in the Consolidated Balance Sheet (Details) - USD ($)
$ in Millions
Dec. 30, 2023
Dec. 31, 2022
Defined Contribution Plan Disclosure [Line Items]    
Unfunded balance $ 9.5 $ 10.1
Non-current assets    
Defined Contribution Plan Disclosure [Line Items]    
Unfunded balance 0.0 0.0
Current liability    
Defined Contribution Plan Disclosure [Line Items]    
Unfunded balance 0.0 0.0
Non-current liability    
Defined Contribution Plan Disclosure [Line Items]    
Unfunded balance $ 9.5 $ 10.1
v3.24.0.1
Employee Benefits - International Define Benefit Plans (Details) - USD ($)
$ in Millions
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Defined Contribution Plan Disclosure [Line Items]      
Projected benefit obligation   $ 32.3 $ 32.3
Defined Benefit Plan, Plan Assets, Amount $ 23.1 22.2 $ 21.7
Foreign Plan      
Defined Contribution Plan Disclosure [Line Items]      
Projected benefit obligation 32.6 32.3  
Defined Benefit Plan, Accumulated Benefit Obligation 28.3 31.0  
Defined Benefit Plan, Plan Assets, Amount $ 23.1 $ 22.2  
v3.24.0.1
Employee Benefits - Plan Assumptions (Details)
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Assumptions - benefit obligations:    
Discount rate 1.35% 1.61%
Rate of compensation increase 1.04% 0.96%
Assumptions - net periodic benefit costs:    
Discount rate 1.91% 0.49%
Rate of compensation increase 1.43% 0.09%
Expected long-term return on plan assets 3.53% 1.70%
Interest credit rate 1.98% 2.34%
v3.24.0.1
Employee Benefits - Plan Assets (Details)
Dec. 30, 2023
Dec. 31, 2022
Cash and cash equivalents    
Defined Contribution Plan Disclosure [Line Items]    
Defined Benefit Plan, Plan Assets, Actual Allocation, Including Adjustments, Percentage (5.00%) 3.00%
Equity securities    
Defined Contribution Plan Disclosure [Line Items]    
Weighted-average asset allocation 35.00% 30.00%
Debt securities    
Defined Contribution Plan Disclosure [Line Items]    
Weighted-average asset allocation 47.00% 36.00%
Other    
Defined Contribution Plan Disclosure [Line Items]    
Weighted-average asset allocation 24.00% 31.00%
v3.24.0.1
Employee Benefits - Estimated Future Benefit Payments (Details)
$ in Millions
Dec. 30, 2023
USD ($)
Postemployment Benefits [Abstract]  
2024 $ 0.4
2025 2.5
2026 2.4
2027 2.5
2028 2.2
Thereafter 4.2
Total $ 14.2
v3.24.0.1
Non-operating Loss - (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Nonoperating Income (Expense) [Abstract]      
Interest income $ 3.0 $ 1.8 $ 0.9
Realized and unrealized foreign currency (loss) gain (1.1) 7.3 (2.0)
Interest expense (50.3) (25.7) (0.3)
Non-operating loss $ (48.4) $ (16.6) $ (1.4)
v3.24.0.1
Income Taxes - Components of Income Before Provision for Income Taxes (Detail) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Income Tax Disclosure [Abstract]      
United States $ 9.1 $ 77.6 $ 221.2
Foreign 79.0 115.8 53.2
Income before provision for income taxes $ 88.1 $ 193.4 $ 274.4
v3.24.0.1
Income Taxes - Current and Deferred Provision (Benefit) for Income Taxes (Detail) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Current:      
Federal $ 15.0 $ 48.7 $ 38.1
State 3.5 6.1 7.1
Foreign 23.7 34.4 14.7
Subtotal 42.2 89.2 59.9
Deferred:      
Federal (12.5) (20.5) (4.9)
State (9.0) (8.7) (6.1)
Foreign (14.1) (10.1) (4.1)
Subtotal (35.6) (39.3) (15.1)
Total $ 6.6 $ 49.9 $ 44.8
v3.24.0.1
Income Taxes - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Income Taxes [Line Items]      
Increase (decrease) to tax and accrued interest related to uncertain tax positions $ 7.4 $ 4.5 $ 3.6
Undistributed earnings of foreign subsidiaries 875.5    
Accumulated undistributed earnings 86.5    
Foreign tax credits 1.9    
Reinvested earnings 789.0    
Additional income tax expense 23.1    
Indefinitely carryforward research and development credits 29.5    
Investment tax credit 2.3    
Increase in valuation allowance 11.6    
Estimated income tax benefit $ 1.4   $ 1.7
Earnings per share, diluted, effect of foreign tax benefit relating to business and employment actions (in dollars per share) $ 0.03 $ 0.03  
Amount of unrecognized benefits affecting future tax rate $ 30.6 $ 24.0  
Income tax expense related to unrecognized tax benefits 1.0 (0.3)  
Penalties and interest related to unrecognized tax benefits 2.1 $ 1.1  
Research Tax Credit Carryforward      
Income Taxes [Line Items]      
Tax credit 2.8    
General Business Tax Credit Carryforward      
Income Taxes [Line Items]      
Tax credit 8.2    
Domestic Tax Authority      
Income Taxes [Line Items]      
Operating loss carryforwards, gross 39.0    
State and Local Jurisdiction      
Income Taxes [Line Items]      
Operating loss carryforwards, gross 208.1    
Foreign Tax Authority      
Income Taxes [Line Items]      
Operating loss carryforwards, gross $ 114.7    
v3.24.0.1
Income Taxes - Reconciliation of U.S. Federal Statutory Tax Rate to Company's Effective Tax Rate (Detail)
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Income Tax Disclosure [Abstract]      
Statutory regular federal income tax rate 21.00% 21.00% 21.00%
U.S. tax on foreign income, net 10.00% 4.80% 0.90%
Foreign income taxed at different rates 1.10% 0.00% (0.30%)
Transaction-related costs 0.00% 0.90% 0.00%
Nondeductible executive compensation (1.60%) 2.90% 2.10%
Derecognition of uncertain tax position (2.30%) (0.80%) (1.00%)
State provision, net of federal benefit (4.90%) (1.00%) 0.30%
Excess stock-based compensation (3.20%) (1.20%) (5.50%)
Research and development tax credits (5.10%) (1.70%) (1.80%)
Tax Credit (9.20%) 0.00% 0.00%
Other 1.60% 0.90% 0.60%
Total 7.40% 25.80% 16.30%
v3.24.0.1
Income Taxes - Components of Deferred Tax Assets (Detail) - USD ($)
$ in Millions
Dec. 30, 2023
Dec. 31, 2022
Deferred tax assets:    
Net operating losses $ 53.7 $ 34.7
Tax credits 33.2 18.0
Capitalized R&D 33.0 18.5
Deferred revenue 28.0 27.8
Accrued liabilities 24.6 32.1
Interest 15.6 22.4
Stock-based compensation 12.3 10.9
Operating lease liabilities 9.7 8.7
Other 7.3 5.8
Total 217.4 178.9
Valuation allowance (18.9) (7.3)
Total deferred tax assets 198.5 171.6
Deferred tax liabilities:    
Inventory (0.8) (4.0)
Interest rate hedge (1.9) (4.1)
Withholding taxes on undistributed foreign earnings (3.1) (2.8)
State taxes and other (10.4) (7.5)
Operating lease liabilities (11.8) (8.6)
Property and equipment (14.4) (18.2)
Intangible assets (160.5) (186.7)
Other (0.2) (0.9)
Total deferred tax liabilities (203.1) (232.8)
Net deferred tax liabilities $ (4.6) $ (61.2)
v3.24.0.1
Income Taxes - Reconciliation of Total Amounts of Unrecognized Tax Benefits (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]    
Unrecognized tax benefits (gross), beginning of period $ 26,100 $ 21,600
Increase from tax positions in current period 7,900 6,000
Increase from tax positions in prior period 1,300 700
Decrease from tax position in prior period 0 (600)
Lapse of statute of limitations (2,300) (1,600)
Unrecognized tax benefits (gross), end of period $ 33,000 $ 26,100
v3.24.0.1
Commitments and Contingencies - Additional Information - (Detail)
$ in Millions
 1 Months Ended 12 Months Ended
Sep. 07, 2023
USD ($)
Jan. 30, 2023
patent
Apr. 21, 2021
patent
Feb. 28, 2023
patent
Jul. 31, 2017
Dec. 30, 2023
USD ($)
customer
agreement
distributor
Dec. 31, 2022
customer
distributor
Jan. 01, 2022
distributor
Oct. 20, 2022
complaint
Contingencies And Commitments [Line Items]                  
Severance plan participation agreements | agreement           6      
Period for notice of resignation           6 months      
Current annual minimum royalty obligation           $ 5.0      
License fee           2.5      
Royalty guarantees, commitments, change in control           15.0      
Royalty guarantees, commitments, additional, change in control           2.0      
Remaining amount committed           274.5      
Other commitment           4.3      
Bank balances           163.0      
Bank balance covered by Federal Deposit Insurance Corporation limit           $ 7.6      
Masimo Vs. Apple Inc                  
Contingencies And Commitments [Line Items]                  
Number of patents found infringed | patent   2   2          
Masimo Vs. Apple Inc | Pending Litigation                  
Contingencies And Commitments [Line Items]                  
Patents found infringed upon | patent     3            
Patents found not infringed upon | patent     9            
Apple, Inc. Patent Infringement | Pending Litigation                  
Contingencies And Commitments [Line Items]                  
Number of complaints | complaint                 2
Masimo Vs. Politan Capital Management LP and Politan Capital NY LLC | Pending Litigation                  
Contingencies And Commitments [Line Items]                  
Attorney fees $ 18.0                
Sales                  
Contingencies And Commitments [Line Items]                  
Number of just-in-time distributors | distributor           1 1 1  
Accounts Receivable                  
Contingencies And Commitments [Line Items]                  
Concentration risk accounts receivable customer | customer           1 1    
GPO Members | Revenue Benchmark | Customer Concentration Risk                  
Contingencies And Commitments [Line Items]                  
Concentration risk, percentage           53.20% 53.80% 51.90%  
Just in time distributor one | Revenue Benchmark | Customer Concentration Risk                  
Contingencies And Commitments [Line Items]                  
Concentration risk, percentage           18.10% 10.10%    
Just in time distributor two | Revenue Benchmark | Customer Concentration Risk                  
Contingencies And Commitments [Line Items]                  
Concentration risk, percentage               14.60%  
Customer One | Accounts Receivable | Customer Concentration Risk                  
Contingencies And Commitments [Line Items]                  
Percentage of accounts receivable balance           6.40% 9.10%    
Chief Executive Officer                  
Contingencies And Commitments [Line Items]                  
Qualifying termination           $ 479.7      
Chief Executive Officer | Cash Distribution                  
Contingencies And Commitments [Line Items]                  
Severance terms         50.00%        
Chief Executive Officer | Restricted Stock Units (RSUs)                  
Contingencies And Commitments [Line Items]                  
Severance terms         50.00%        
v3.24.0.1
Segment and Enterprise Reporting - Narrative (Details)
$ in Millions
 12 Months Ended
Dec. 30, 2023
USD ($)
segment
Dec. 31, 2022
USD ($)
Jan. 01, 2022
USD ($)
Segment Reporting [Abstract]      
Number of reportable segments 2    
Number of operating segments 2    
Revenue | $ $ 2,048.1 $ 2,035.8 $ 1,239.2
v3.24.0.1
Segment and Enterprise Reporting - Segment Information (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Segment Reporting Information [Line Items]      
Total revenue by segment $ 2,048,100 $ 2,035,800 $ 1,239,200
Gross profit 1,003,500 1,058,800 808,400
Depreciation and amortization 98,200 136,100 35,600
Total long-lived assets 425,900 404,200 275,400
Total assets 3,041,500 3,210,600  
Operating Segments      
Segment Reporting Information [Line Items]      
Total revenue by segment 2,048,100 2,035,800 1,239,200
Corporate overhead      
Segment Reporting Information [Line Items]      
Total assets 19,100 19,000  
Segment Reconciling Items      
Segment Reporting Information [Line Items]      
Gross profit (31,600) (63,900) 0
Intersegment Eliminations      
Segment Reporting Information [Line Items]      
Total revenue by segment 7,700 0  
Healthcare      
Segment Reporting Information [Line Items]      
Depreciation and amortization 38,100 36,000 35,600
Healthcare | Operating Segments      
Segment Reporting Information [Line Items]      
Total revenue by segment 1,275,500 1,340,300 1,239,200
Gross profit 777,100 870,200 808,400
Total assets 1,631,800 1,594,100  
Non-healthcare      
Segment Reporting Information [Line Items]      
Depreciation and amortization 60,100 100,100 0
Non-healthcare | Operating Segments      
Segment Reporting Information [Line Items]      
Total revenue by segment 772,600 695,500 0
Gross profit 258,000 252,500 $ 0
Total assets $ 1,390,600 $ 1,597,500  
v3.24.0.1
Segment and Enterprise Reporting - Revenue and Long-Lived Assets (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 01, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]      
Total long-lived assets $ 425,900 $ 404,200 $ 275,400
Total long-lived assets, percentage 100.00% 100.00% 100.00%
Total revenue $ 2,048,100 $ 2,035,800 $ 1,239,200
Total revenue, percentage 100.00% 100.00% 100.00%
United States (U.S.)      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Total long-lived assets $ 317,900 $ 319,700 $ 239,400
Total long-lived assets, percentage 74.60% 79.10% 86.90%
Total revenue $ 1,058,800 $ 1,141,700 $ 822,400
Total revenue, percentage 51.70% 56.10% 66.40%
Europe, Middle East and Africa      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Total revenue $ 571,900 $ 523,600 $ 251,800
Total revenue, percentage 27.90% 25.70% 20.30%
Asia and Australia      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Total revenue $ 351,000 $ 326,800 $ 123,600
Total revenue, percentage 17.10% 16.10% 10.00%
North and South America (excluding U.S.)      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Total revenue $ 66,400 $ 43,700 $ 41,400
Total revenue, percentage 3.30% 2.10% 3.30%
International      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Total long-lived assets $ 108,000 $ 84,500 $ 36,000
Total long-lived assets, percentage 25.40% 20.90% 13.10%
v3.24.0.1
Schedule II - Valuation and Qualifying Accounts (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Jan. 02, 2021
Allowance for credit losses      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at Beginning of Period $ 7.9 $ 2.5  
Additions Charged to Expense and Other Accounts (2.7) 5.6 $ 0.7
Amounts Charged Against Reserve (0.2) (0.2) 0.0
Balance at End of Period 5.0 7.9 1.8
Allowance for sales returns      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at Beginning of Period 5.3 1.5  
Additions Charged to Expense and Other Accounts 3.8 11.1 (0.6)
Amounts Charged Against Reserve (0.4) (7.3) (0.1)
Balance at End of Period $ 8.7 $ 5.3 $ 2.2